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Gregory H. Norris 
University of Connecticut, 2018 
Metabolic dysfunction directly links of obesity and metabolic disorders. Although poor 
diet and lack of exercise are known factors for the development of metabolic disorders, there is a 
clear need to identify dietary components that may be effective for preventing metabolic 
dysfunction. Therefore, this dissertation aimed to define the effects of dietary sphingomyelin (SM) 
on diet-induced metabolic dysfunction. In Aim 1, we explored the short-term effects of dietary 
milk and egg SM on lipid homeostasis in C57BL/6J mice fed a high-fat diet. Milk SM reduced 
both hepatic lipid accumulation and serum cholesterol, which correlates well with the existing 
literature. Conversely, egg SM increased both hepatic and serum lipids. Having demonstrated 
differences between two sources of SM, the study progressed to Aim 2, where we investigated the 
effects of both egg and milk SM on preventing metabolic dysfunction in C57BL/6J mice on an 
obesogenic diet. Egg SM reduced hypercholesterolemia and fasting hyperglycemia. Both SM 
treatments reduced hepatic steatosis and adipose inflammation, however, egg SM was more 
effective than milk SM. When designing Aim 3, we focused on defining possible anti-
inflammatory effects of milk SM. We observed that feeding milk SM reduced circulating cytokine 
concentrations in mice fed an obesogenic diet. We also tested the effects of milk SM and its 
hydrolytic products, ceramide and sphingosine, on LPS-stimulation of RAW264.7 macrophages. 
We observed all three compounds to be effective inhibitors of the LPS-induced inflammatory 
response. Additionally, SM hydrolysis was required for SM effectiveness. In a normal diet, the 
consumption of dietary SM found in foods will be accompanied by other dietary phospholipids. 
Therefore, we also tested the effects of milk phospholipids supplied by beta-serum, a dairy  
Gregory H. Norris 
University of Connecticut, 2018 
byproduct, on diet-induced metabolic dysfunction and inflammation in hypercholesterolemic 
LDL-receptor knockout mice. We found that the highest dose of milk phospholipids markedly 
reduced cholesterol in both serum and liver, with more modest effects on reducing inflammation 
markers in liver and adipose tissues.  Overall, this work demonstrates a clear potential for dietary 
SM to be useful for the prevention of obesity-associated metabolic dysfunction. More research is 
warranted to translate this work into human clinical trials.
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Obesity is a public health crisis. More than 1 out of every 3 Americans are obese and over two-
thirds are considered overweight [1]. Nutritional scientists have set forth to address this crisis 
through multiple methods. Epidemiological and community-based nutrition researchers examine 
populations’ eating habits, behaviors, and how those are interrelated with the public’s obesity rates. 
Clinical researchers are interested in dietary interventions and how they may alter a patient’s 
metabolic phenotype. Meanwhile, molecular nutrition researchers focus on preclinical trials, 
finding new potential nutraceuticals to help improve obesity-related outcomes. Many molecular 
researchers have focused on phytochemicals, plant-based chemicals, as potential nutraceuticals. 
This is in part because the epidemiological studies indicate positive health outcomes associated 
with an increase intake of plant-based foods [2]. This may have suggested animal-based foods to 
be unhealthy. On the contrary, animal-based foods have many potentially beneficial components 
including: high-quality protein [3], micronutrients [4], and carotenoids [5]. In fact, the field of 
zoochemicals, animal-based chemicals, is continuing to produce potential nutraceuticals. One such 
nutraceutical is sphingomyelin (SM), a sphingolipid commonly found in dairy, meat, and eggs [6]. 
1.2. Obesity and Metabolic Dysfunction 
Obesity raises the risk of all-cause mortality by 21-79% [7, 8]. To combat this, the US spends $200 
billion annually, in response to obesity-related health issues [9]. Cardiovascular disease (CVD), 
type II diabetes (T2D), non-alcoholic fatty liver disease (NAFLD), and cancer all have strong ties 
to obesity [10]. Thus, curbing obesity would be an effective measure to reduce the prevalence of 
these life-threatening diseases and the economic burden. Both epidemiological and clinical trials 
have reported calorie restriction combined with exercise to be an effective means to reduce obesity 
for most individuals [11-13]. However, according to the Centers for Disease Control (CDC), only 
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25% of Americans meet weekly goals for both strength and aerobic exercise [14]. Meanwhile, 
according to the Food and Agriculture Organization, the average American is consuming over 
3,000 kilocalories per day [15]. Therefore, despite the knowledge of preventing obesity through 
calorie restriction and exercise, obesity is projected to increase to 42% of the adult US population 
by the year 2030 [16]. 
The increased risk of health complications is not due to merely obesity. It is the underlying 
metabolic consequences that come from overtaxing the adipose tissues’ energy buffering capacity. 
This results in metabolic dysfunction, which manifests itself as dyslipidemia, insulin resistance, 
and endotoxemia or elevated lipopolysaccharide (LPS) activity [10]. These symptoms of metabolic 
dysfunction are the defining difference between metabolically-healthy and unhealthy individuals. 
Compared to the typically obese population, the metabolically-healthy population has a reduced 
relative risk of all-cause mortality [8]. Therefore, improving metabolic health could improve the 
health and economic burdens on the United States. Rodents fed calorically-dense Western-type 
diets are a common preclinical model of obesity. Western-type diet is an umbrella term 
encompassing several diets rich in saturated fat, simple sugars, and sometimes added cholesterol. 
Rodents fed Western-type diets have increased weight gain, dyslipidemia, insulin resistance, 
inflammation, and steatotic livers, which is similar to humans [17, 18].  
Briefly, the pathogenesis of metabolic syndrome and insulin resistance (IR) stems from 
overwhelming the lipid buffering capacity of the adipose tissue [19]. The increase in lipids 
originates both from the diet and an increase in de novo lipogenesis. As adipose tissue enlarges, 
the adipocytes become stressed, insulin resistant, and secrete inflammatory cytokines and non-
esterified fatty acids (NEFA) into circulation [20]. These excessive lipids will accumulate 
ectopically in the liver and skeletal muscle causing IR in these tissues [21]. This will impair the 
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handling of lipids and glucose, consequentially elevating the risk of the chronic metabolic-related 
diseases such as CVD, T2D, NAFLD, and cancer. 
1.2.1. Inhibition of Lipid Absorption Can Improve Metabolic Dysfunction 
As the field of molecular nutrition has grown, the search for potential therapeutic targets to slow 
down obesity has increased. The ability to prevent metabolic dysfunction is the underlying goal. 
Reducing intestinal lipid absorption has been a mechanistic target that has shown some success. 
First, inhibiting cholesterol absorption through use of the drug ezetimibe has shown benefits. 
Ezetimibe inhibits the Niemann-Pick C1-Like 1 (NPC1L1) protein, which is the major importer of 
luminal free cholesterol into the enterocyte [22]. Luminal cholesterol is sourced from both dietary 
and biliary cholesterol. When inhibiting cholesterol absorption, the net result is a lowering of 
circulating cholesterol [23], and this can reduce hepatic and adipose inflammation associated with 
a Western-type diet [24-26]. Additionally, ezetimibe has been shown to reduce visceral fat mass, 
consequently improving metabolic dysfunction [27]. Another commonly prescribed drug is 
orlistat. Orlistat inhibits intestinal lipases which slows the absorption of lipids by inhibiting their 
breakdown. This is an effective treatment to reduce body weight [28]. However, pharmacological 
agents can be costly. Additionally, ezetimibe and orlistat are not without their side effects [29, 30]. 
Therefore, the inhibition of lipid absorption is a viable target for improving metabolic dysfunction 
but, there is a need for novel therapies.  
1.3. Dietary Sphingolipids as a Part of the Western Diet  
On average, 2-8 g/day of a typical American’s diet are phospholipids [31]. Within those 2-8 g, 
sphingolipids constitute 200-400 mg/day [32]. Animal-derived sphingolipids are by far the most 
abundant and the most common of them is SM [33]. Therefore, the majority of dietary 
sphingolipids are SM. The average American adult consumes 200-400 mg of cholesterol per day 
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[34]. Despite the relative abundances of these lipids, dietary cholesterol has dominated the 
literature (>9,000 papers available on PubMed as of January 2018) in comparison to dietary 
sphingolipids (<100 papers). This discrepancy exists in spite of the potential bioactive effects of 
sphingolipids [32]. Therefore, there is a clear lack of research into the effects of dietary 
sphingolipids.  
Once dietary SM reaches the small intestine its hydrolysis is initiated by bile salt-dependent 
alkaline sphingomyelinase (alk-SMase), located on the brush border membrane in mammals and 
additionally found in human bile [35]. Sphingomyelinase activity is low in the duodenum and 
peaks in the mid-jejunum [36]. The delay in activity is due in part to the inhibition of alk-SMase 
by common luminal lipids [37]. Hydrolysis of SM produces a phosphocholine and ceramide. 
Subsequently, the ceramide will be digested by neutral ceramidase to produce sphingosine and a 
fatty acid [35]. The sphingosine backbone will be readily absorbed by the enterocyte through a 
passive diffusion mechanism [38]. Once absorbed, most of the sphingosine will enter the 
sphingosine-1-phosphate lyase pathway to recover a fatty acid while, some can be used to 
resynthesize complex sphingolipids [35].  
Different food sources of SM contain structurally distinct SM profiles. Egg-derived SM 
contains predominantly C16:0 N-linked acyl chains and d18:1 as the sphingoid backbone [39]. 
Comparatively, milk-derived SM contains N-linked acyl chains ranging from C16:0-C24:0 and 
sphingoid backbones ranging from 16-19 carbons with and without a double bond [40]. The longer 
saturated chains could increase hydrophobic interactions with cholesterol [41]. The SM species 
with a saturated backbone in milk-derived SM are classified as dihydrosphingomyelin. 
Dihydrosphingomyelin has been shown to slow cholesterol’s desorption from a model membrane 
to cyclodextrin more strongly than sphingomyelin [42]. Dihydroceramides have been shown to be 
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inert in terms of apoptosis when compared to ceramide [43]. However, new insights into the 
potential biological role of dihydroceramide metabolism are surfacing. While exogenous 
dihydroceramides seem biologically inert [44], a build-up of dihydroceramide has been shown to 
induce autophagy and coincides with both oxidative stress and hypoxia [45]. However, due to the 
interconnected nature of sphingolipid metabolism, it is hard to discern whether these effects are 
associated with increases in dihydroceramide or depletion of ceramide. Regardless, there is 
increasing data suggesting that subtle differences between ceramide species can have distinct 
biological effects [46]. Therefore, structurally-distinct dietary SM could have differing biological 
effects.  
1.4. Dietary Sphingomyelin for the Prevention of Metabolic Disease 
Exogenous SM and its metabolites have been shown in cell culture models to modulate cholesterol 
absorption [47-49], in part by decreasing the release of cholesterol from the micelles [50]. 
Furthermore, in animal models, reductions in both triglyceride and cholesterol absorption were 
observed [41, 50-52]. In lymph duct-cannulated rats, milk-derived SM was more potent than egg-
derived SM when inhibiting cholesterol and triglycerides during duodenal infusion [41]. This 
suggests that SM from different sources will have differential effects on lipid absorption. Since 
then, studies conducted in rodents have observed reductions in serum and hepatic cholesterol 
during chronic feeding of SM on a high-fat diet [52-54]. In humans, intervention studies with 
purified dietary SM are scarce, but the consumption of dietary milk-derived SM for 14 days has 
been shown to raise high-density lipoprotein cholesterol (HDL-C) in healthy adult men and women 
[55]. There are consistently observed reductions in serum and hepatic lipids with feeding of SM. 
However, comparing distinct SMs could elucidate further understanding of the mechanism. 
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Dietary SM has also been investigated for its role in chemically-induced colitis and 
inflammation. Two separate research groups found that dietary SM mixed into the diet reduced 
inflammation induced by dextran sodium sulfate (DSS) treatment of mice [56, 57]. However, when 
mice were gavaged with similar quantities of egg-derived SM, both DSS-induced and IL-10-/--
induced forms of colitis were exacerbated [58]. This could be due to differences in the timing of 
the dose, as the studies inhibiting inflammation gave SM over the course of the day as opposed to 
a single dose. This observation is consistent with large doses of exogenous SM and ceramide 
having been shown to be pro-inflammatory in cell culture [59], while lower doses of exogenous 
sphingolipids are anti-inflammatory [60]. This suggests a delicate balance in sphingolipids 
regulates their role in inflammation.  
1.5 Objective and Central Hypothesis 
The main objective of this work is to further clarify the role of dietary SM as a therapeutic food 
component in preventing diet-induced metabolic dysfunction and inflammation utilizing both 
animal and cell models. We hypothesize that dietary SM will be beneficial in attenuating the 
progression of dyslipidemia, metabolic dysfunction, and inflammation in mice fed Western-type 
diets. These effects will likely be related to the ability of dietary SM to inhibit the absorption of 
other dietary, biliary, and possibly microbial lipids. Metabolic dysfunction is also associated with 
systemic inflammation. Therefore, we expect to see a reduction in systemic inflammation with 
dietary SM. Dietary SM has shown potential in alleviating chemically-induced colitis through a 
poorly understood mechanism. Logically, there is potential for SM to reduce systemic 
inflammation in a manner independent from its effects on lipid homeostasis. Thus, we will test an 
in vitro model of inflammation to examine potential anti-inflammatory effects of SM. Purified SM 
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is currently prohibitively expensive and therefore we will test a less expensive alternative, beta-
serum, a dairy byproduct that is rich in phospholipids, like SM, for reducing hypercholesterolemia. 
Question 1: Are there differences in the effects of structurally-distinct dietary SM derived from 
egg and milk on metabolic dysfunction when fed a short-term Western-type diet?  
Hypothesis 1: We hypothesize that both SM sources will improve Western-type diet-induced 
metabolic dysfunction and endotoxemia, but milk-derived SM will be more potent compared to 
egg-derived SM. This difference will be due to milk-derived SM’s more potent inhibitory effect 
on lipid absorption compared to egg-derived SM. 
Question 2: Will either milk or egg SM slow the progression of diet-induced obesity and the onset 
of metabolic dysfunction in mice fed a Western-type diet? 
Hypothesis 2: Both SM treatment groups will reduce the metabolic dysfunction phenotype, due 
to SM’s effects on both lipid absorption and inflammation compared to a high-fat control. 
However, milk-derived SM will be more effective than egg-derived SM because of the stronger 
inhibitory effect on lipid absorption. 
Question 3: Will exogenous SM inhibit the LPS-stimulation of macrophages, and will this effect 
be dependent on SM hydrolysis? 
Hypothesis 3: We hypothesize exogenous SM treatment will inhibit LPS-stimulation of 
RAW264.7 macrophages. Due to the fact that SM metabolites have been shown to have inhibitory 
properties, blocking hydrolysis of SM will reduce SM’s effectiveness for inhibiting LPS-
stimulation. Consequently, the addition of the hydrolytic products of SM will also inhibit LPS-
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stimulation. Furthermore, dihydroceramide and ceramide with have differential effects on 
inflammatory response, as they have previously shown different bioactivities.  
Question 4: Does phospholipid supplementation confer hypolipidemic benefits and improve 
metabolic dysfunction in genetically hypercholesterolemic LDLr-/- mice?  
Hypothesis 4: Phospholipid supplementation will reduce dyslipidemia and insulin resistance in 
Western-type diet-fed LDLr-/- mice. This will result in an improved hepatic phenotype and 
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In 2014, 36.5% of the US adult population was considered obese with a body mass index (BMI) 
≥30 [1]. Obesity is estimated to cost the US $200 billion annually due to complications associated 
with increased body weight [2]. Obesity increases the relative risk of all-cause mortality by 21-
79% [3, 4] due to metabolic dysfunction. Metabolic dysfunction is characterized by dyslipidemia, 
insulin resistance (IR), and endotoxemia [5]. These symptoms are driving factors in the 
development of type II diabetes, cardiovascular disease (CVD), and non-alcoholic fatty liver 
disease (NAFLD) [5]. This is conceptually supported by metabolically healthy obese individuals, 
that have a reduced relative risk of all-cause mortality compared to metabolically unhealthy 
patients [4]. The metabolically healthy obese population lacks some of the critical symptoms of 
metabolic dysfunction. Although proper diet and exercise can reduce BMI and lessen metabolic 
dysfunction [6], the number of obese US adults is expected to increase to 42% of the total adult 
population by the year 2030 [7].  
One cause of increased BMI is the overconsumption of nutrients. Chronic consumption of 
a high-fat diet (HFD) may provide the greatest risk of over-nutrition, due to high energy density 
in concert with a lesser impact on satiety and satiation per calorie compared to other macronutrients 
[8]. Several epidemiological studies show when dietary fat increases, so does the prevalence of 
obesity [9-11]. High-fat diets are used in rodent models to induce characteristics similar to human 
obesity, such as increased weight gain, dyslipidemia, IR, inflammation, and steatotic livers [12, 
13]. Thus, HFD-fed rodents are commonly used in preclinical trials to study obesity. The strong 
association of these comorbidities with metabolic disease warrants the identification of dietary 
interventions to prevent or slow their progression. The overall goal of these interventions is to 
reduce the incidence of obesity-related disease.  
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2.2. Pathogenesis of Metabolic Dysfunction and Insulin Resistance 
2.2.1. Adipose Tissue Dysfunction 
Historically, obesity’s role in metabolic dysfunction was attributed to adipose tissue inflammation 
and IR. More recently, the gut microbiota and intestinal inflammation are being recognized as 
potential initiators of metabolic dysfunction that may compound the effects of adipose tissue 
dysfunction [14]. Gut microbiota and intestinal inflammation will be discussed later in this review.  
When adults gain fat mass, they enlarge existing adipocytes via hypertrophy to deal with 
the increased fat load, to a much greater extent than creating more adipocytes via hyperplasia [15]. 
When adipocytes approach their maximum size/capacity, which depends heavily on genetic factors 
and fat depot, they can begin to malfunction; setting off the cascade of events associated with 
metabolic dysfunction. This malfunction originates from many related pathways. For example, as 
the size of adipocytes increase, adipocyte stress may increase in part due to hypoxia. Larger 
adipocytes are typically >100 μm in diameter [16]. Some larger adipocytes may not receive a full 
supply of oxygen from blood vessels due to oxygen’s limited diffusion distance in tissues (100-
200 μm) [17]. Diet-induced obese mice have been found to have <50% of the oxygenation of 
adipose tissue of lean mice [18]. Hypoxia will induce several inflammatory pathways and inhibit 
insulin signaling [18, 19]. This inflammation will contribute to the IR and lipolysis seen in 
dysfunctional adipose tissue.  
Endoplasmic reticulum (ER) stress is another insult to hypertrophic adipocytes. High-fat 
fed and genetically obese ob/ob mice both show increased adipose tissue ER stress compared to 
lean controls [20, 21]. ER stress is characterized by the unfolded protein response (UPR). The 
UPR occurs when the demand for protein synthesis produces more protein than cellular chaperone 
folding proteins can manage or when there is damage to the ER, such as disruption of the ER 
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membrane. One inducer of ER stress is high cellular concentration of long-chain free fatty acids. 
Saturated fatty acids seem to be more cytotoxic and may disrupt the fluidity of the ER membrane 
[22]. This has been shown by using chemical chaperones to increase protein folding to alleviate 
ER stress in mice [23]. ER stress will induce apoptosis [24], and in the adipose tissue this will 
release fatty acids into the interstitial space and circulation.   
Systemic oxidative stress is another contributor to adipose tissue dysfunction. 
Unsurprisingly, obesity and systemic oxidative stress correlate well [25]. Oxidative stress is 
increased by a myriad of causes, including hyperleptinemia [26], hyperglycemia [27], and 
mitochondrial dysfunction [28]. Several of these have direct links to obesity and adipose 
hypertrophy. Serum leptin concentrations are positively correlated with adipose tissue mass [29]. 
Hyperleptinemia increases oxidative stress and adipose dysfunction in mice and differentiated 
mouse pre-adipocytes (3T3-L1) [30] Hyperglycemia can drive metabolic production of reactive 
oxygen species (ROS) from oxidative phosphorylation in the mitochondria [31]. Insulin resistance 
reduces glucose transporter 4 (GLUT4)-dependent glucose uptake and subsequently increases 
hyperglycemia [32, 33]. Hyperlipidemia is associated with ectopic lipid accumulation. Ectopic 
lipid accumulation will progress to lipotoxicity contributing to IR in non-adipose tissues [34]. It 
has also been shown that excessive storage of lipids leads to an increase in lipid peroxidation 
within the adipose tissue itself [35]. Oxidative stress, in general, will lead to inflammation 
signaling and vice versa, which will drive IR in adipose tissue.  
2.2.2. The Role of the Gut in Metabolic Dysfunction  
The gut microbiota may contribute to metabolic dysfunction by extracting more energy from 
undigested food which contributes to weight gain, and by activating the immune system. Germ-
free mice are resistant to diet-induced metabolic dysfunction and obesity [36, 37]. However, it is 
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still unclear if gut microbiota from obese mice promote weight gain more than from lean mice, 
although they do differentially affect IR [38]. High-fat diet has been shown to induce ileal 
inflammation compared to low-fat diet in conventionally raised mice in as little as 2 weeks. This 
effect was absent in germ-free mice [39]. Indeed, consumption of HFD can result in inflammation 
that acutely increases gut permeability [40]. This would lead to a “leaky gut” which allows for 
more bacterial byproducts to translocate into the intestinal tissue. Chronic consumption of HFD 
can disrupt the balance of the gut microbiota [41], potentially reducing commensal bacteria, 
allowing for more pathogens to grow. Gut-derived bacterial byproducts can also contribute to 
adipose tissue inflammation. The most well studied of these byproducts is lipopolysaccharide 
(LPS). Lipopolysaccharide activates Toll-like receptor 4 (TLR4), and in adipocytes increases 
tumor necrosis factor α (TNF-α) production [42]. Lipopolysaccharide is also taken up by the 
enterocyte likely via TLR4 and localizes to the Golgi, the site of chylomicron maturation [43]. 
Large amounts of dietary fat have been shown to increase the concentration of LPS-rich 
chylomicrons in the lymph of mice in acute experimental conditions [44]. This effect was 
facilitated by chylomicron production, as pluronic L-81, which inhibits chylomicron secretion, 
reduced the appearance of LPS in the lymph [44]. Additionally, Gram-negative bacteria are taken 
up by enterocytes in a manner similar to phagocytosis, through a TLR4-dependent mechanism 
[45]. Although the mechanisms have not been fully elucidated, HFD can increase intestinal 
inflammation and LPS translocation; both of which would increase systemic inflammation and 
contribute to metabolic dysfunction.  
2.2.3. Systemic Consequences of Metabolic Dysfunction 
Dysfunction of the adipose has major consequences for other metabolic tissues, such as the liver 
and skeletal muscle. Local inflammation of the adipose tissue will contribute to the circulating 
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pool of cytokines, including TNF-α, C-C motif chemokine ligand 2/4 (CCL2 and CCL4), 
interleukin 6 (IL-6), IL-1β, and interferon-γ (IFN-γ) [46]. Adipose tissue inflammation and IR will 
also increase the rate of lipolysis, or release of FAs [47]. These circulating fatty acids can be stored 
in other tissues if they are not oxidized and their accumulation contributes to systemic IR. This 
typically can occur with diacylglycerol (DAG) buildup, which is a well-known activator of protein 
kinase C [48]. Protein kinase C can phosphorylate the insulin receptor, subsequently disrupting its 
signaling [48]. Insulin resistance in the adipose tissue will also increase lipolysis further increasing 
the amount of FA efflux.  
Adiponectin is an adipokine, known for its anti-inflammatory effects. Serum adiponectin 
is reduced in obese patients compared to healthy controls [49]; furthermore, adiponectin is 
inversely associated with non-alcoholic steatohepatitis (NASH), the inflammatory progression of 
NAFLD [50, 51]. Mice pretreated with adiponectin were resistant to chemically-induced acute 
liver failure, which was dependent on the protective effects of IL-10 [52]. High molecular weight 
(HMW) adiponectin is thought to be the more bioactive form and is also found to be decreased in 
obesity [53]. Adiponectin can upregulate RAW 264.7 macrophage IL-10 production, by initially 
increasing nuclear factor kappa-B (NFκB)-dependent TNF-α production [54]. This mechanism can 
dampen LPS sensitivity in macrophages [54]. Treating primary human macrophages with 
adiponectin inhibited LPS- and TNF-α-induced inflammation independent of IL-10 [55]. 
Adiponectin also inhibits TNF-α and IL-6 production by LPS-stimulated human macrophages 
[56]. Thus, adiponectin, which is reduced in obesity, has anti-inflammatory effects which may be 
useful in preventing metabolic dysfunction.  
21 
 
2.2.3.1 Effects of Metabolic Dysfunction on the Liver 
The liver functions as a hub for lipoprotein transport, bile production, and detoxification. Adipose 
dysfunction and IR manifests itself as hepatic lipid accumulation which precedes NAFLD and 
NASH. One of the oldest hypotheses surrounding NAFLD/NASH is the “two-hit hypothesis” [57]. 
The “first hit” is hepatic triglyceride (TG) accumulation. The “first hit” is present in 60-90% of 
obese individuals [58]. During the fed and fasted states, about 60-90% of plasma NEFAs are from 
the adipose tissue in patients with both NAFLD and IR [59]. Insulin signaling inhibits lipolysis in 
a healthy individual [60, 61]. Additionally, when insulin sensitivity is impaired, lipoprotein lipase 
(LPL) activity in insulin-sensitive tissue is reduced [32, 33]. Delayed metabolism of chylomicrons 
by the systemic tissues can increase the hepatic uptake of diet-derived TGs [62]. Lastly, if 
circulating free NEFAs and glucose exceed the metabolic needs of the body, they can accumulate 
and drive ectopic lipid droplet formation [63]. The excess glucose will be converted to lipid 
through de novo lipogenesis. Although the classical de novo lipogenesis pathways through sterol 
response element binding protein (SREBP) are insulin responsive [64]. The mechanistic target of 
rapamycin (mTOR) is required for insulin-SREBP-1c signaling [65]. However, SREBP-1c 
expression is increased despite IR, this has been hypothesized as a result of mTOR’s 
responsiveness to nutrients [66]. Namely, the glucose signaling pathways including carbohydrate 
response element binding protein (ChREBP) also contributes to de novo synthesis of lipids 
independent of SREBP [67]. These accumulating lipid droplets and plasma free NEFAs exacerbate 
hepatic IR through diacylglycerol activating protein kinase ε/θ [68] and saturated fatty acids 
activating TLR4 [69], worsening the metabolic conditions of the liver. Although simple hepatic 
steatosis is thought to be relatively benign, it sensitizes the liver to the “second hit.” 
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The “second hit” exploits the heightened sensitivity of the liver to oxidative damage. 
Oxidative stress is typically the initial insult stemming from the production of ROS in response to 
metabolic dysfunction or inflammation. Healthy hepatocytes will produce metabolic ROS and 
reactive nitrogen species that will be sufficiently neutralized/quenched with cellular antioxidant 
defense systems [70]. However, in mitochondrial dysfunction the normal metabolic reactions are 
perturbed or overwhelmed, leading to an increase in ROS-mediated cellular damage. It has been 
shown that diet-induced mitochondrial dysfunction precedes NAFLD in fatty rats [71]. Takamura 
et al. suggested obesity contributes to the leakage of electrons from electron transport chain, which 
increases metabolic ROS production [72]. Reactive oxygen species drive lipid peroxidation, 
especially in polyunsaturated fatty acids (PUFAs). Lipid peroxidation also occurs enzymatically 
by lipoxygenases and cyclooxygenases [73]. Oxidized PUFAs will fragment, producing several 
oxidized products which create a more pro-oxidative environment [74]. This can contribute to the 
UPR causing hepatocyte death and liver damage [75]. Lipid peroxides can induce cell death by 
either disruption of the membrane or by oxidizing protein and DNA [76]. DNA damage can induce 
apoptosis through activation of the caspase mechanism [77]. 
 Although the two-hit hypothesis appears to explain the increased prevalence of NASH in 
obese populations (37%) [78] compared to the general population (13%) [79], only an estimated 
3-20% of steatosis cases progress to NASH [80]. Therefore, there must be other underlying factors 
that drive the progression of steatosis to NASH. Some of these factors are likely associated with 
metabolic dysfunction associated with obesity. Supporting this viewpoint, there is a population of 
lean NASH patients, whom are seemingly opposite of the metabolically healthy obese population, 
in that despite their healthy BMI, they have central obesity and metabolic dysfunction. This 
population presents with hallmarks of metabolic dysfunction, such as increased visceral adiposity, 
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dyslipidemia, and IR [81]. Additionally, adipocyte size is an independent predictor of hepatic 
steatosis from obesity [82], suggesting obesity may drive the “first hit” through dysregulation of 
adipocyte metabolism more so than obesity itself. 
Lipotoxicity is the accumulation of toxic lipid species, such as DAG and free cholesterol, 
both of which are a likely contributor to NAFLD progression. Overexpression of DAG 
acyltransferase 1 and 2 (DGAT1/2) in mice fed HFD, which led to a decrease hepatic DAG, 
demonstrated that hepatic TG accumulation alone was insufficient to induce inflammation and IR 
in this model [83]. Triglyceride production may actually be preventative in mouse models of 
NASH because TGs are biologically inert compared to DAG. Deleting stearoyl-CoA desaturase 1 
(Scd1) protected mice from hepatic steatosis, by inhibiting TG synthesis. However, these mice had 
exacerbated apoptosis and inflammation in liver when they were fed a methionine choline-
deficient diet [84]. A high-sucrose, low-fat diet fed to Scd1-/- mice doubled hepatic free cholesterol 
and increased serum hepatic enzymes compared to wild-type (WT) mice [85]. High dietary 
cholesterol is a common tool to induce NASH in animal models [86]. Genetically 
hypercholesteremic mice fed Western-type diets (high-fat, high-cholesterol) are also commonly 
used as animal models of NASH [87]. These models may develop NASH, in part, via elevations 
in hepatic free cholesterol, which is known to activate inflammasomes [88] and induce ER stress 
[89]. There are several other factors that may contribute to NASH progression, including decreased 
adiponectin, increased leptin, and genetic predisposition.  
2.2.3.2. Effects on Skeletal Muscle 
In addition to playing an essential role in mobility, skeletal muscle also functions as both an 
endocrine organ and a major site for macronutrient disposal [90]. Adipose tissue dysfunction 
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drastically affects skeletal muscle metabolism due to its insulin-sensitive nature, albeit typically to 
a lesser extent than in the liver. The causes of skeletal muscle dysfunction are similar to liver 
dysfunction in that they share the accumulation of ectopic lipid [91] and mitochondrial dysfunction 
[92]. The accumulation of lipids in the muscle is associated with IR in this tissue [93, 94]. Insulin 
resistance within the muscle will decrease glucose uptake, contributing to hyperglycemia. 
Mitochondrial dysfunction is associated with increased ROS production [95]. This can lead to 
damage of the mitochondria that, if not repaired, could lead to decreased mitochondrial density 
through autophagy [96]. The most well-studied myokine is IL-6. While IL-6 is classically thought 
to be proinflammatory, IL-6 can improve skeletal muscle glucose uptake and improve whole body 
insulin sensitivity [97]. Obesity’s effects on IL-6 production in the skeletal muscle remain 
controversial, as some studies report increases [98] and others decreases [99]; although, this could 
be due to differences in the study populations used for tissue biopsies. Decreased myocyte IL-6 
was found in diabetics, while increases were found in healthy individuals in response to 
conditioned medium intended to mimic obese conditions. Skeletal muscle can also secrete pro-
inflammatory cytokines such as TNF-α and CCL2 [99, 100] which, similar to adipose tissue and 
liver, will contribute to IR. TNF-α and CCL2 are increased in the skeletal muscle with the 
occurrence of obesity and diabetes [99, 100]. Ultimately, obesity disrupts the skeletal muscle’s 
capacity to catabolize nutrients, leaving more for the non-adipose tissues to handle, and increasing 
IR. The inflammatory cytokines secreted by skeletal muscle may also contribute to systemic IR. 




Figure 2.1. Schematic summary of metabolic dysfunction 
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2.3. Molecular Mechanisms Governing Lipid Metabolism 
2.3.1. Insulin 
Insulin is known for its role in modulating blood glucose levels. However, it also controls several 
factors crucial for lipid synthesis and storage. As reviewed above, insulin alters skeletal muscle 
and adipose tissue metabolism. Several tissues are insulin sensitive, such as liver, skeletal muscle, 
and adipose tissue [101]. Insulin signaling in the liver has major implications for both carbohydrate 
and lipid homeostasis. In terms of carbohydrate metabolism, insulin induces GLUT4 translocation 
to the plasma membranes of skeletal muscle and adipose tissue. This allows for maximal glucose 
uptake in these tissues [102]. Insulin will also inhibit the production of glucose in the liver, derived 
from both gluconeogenesis and glycogenolysis. This is substantial because the liver is the major 
site of gluconeogenesis in the body [103]. Insulin signaling will inhibit gluconeogenesis through 
forkhead transcription factor 1 (FoxO1) [104], which is a major regulator of gluconeogenic gene 
expression. Hepatic insulin signaling also stimulates glycogen synthesis [105]. In terms of lipid 
metabolism, insulin stimulates many of the de novo lipogenesis genes including fatty acid synthase 
(Fas) and acetyl-CoA carboxylase (Acc) [106]. Fatty acid synthesis in healthy individuals usually 
accounts for about 5% of FAs in the serum but can climb to 24% in the post-absorptive state [107]. 
In a healthy liver, insulin affects lipid metabolism in two ways: it will 1) upregulate de novo 
lipogenesis and TG synthesis; and 2) inhibit very low-density lipoprotein (VLDL) secretion [108]. 
This will increase the temporary storage of hepatic TGs that will be released after the post-prandial 
state.  
Factors outside of local insulin signaling will have effects on local insulin responsive 
pathways. For example, hyperglycemia and hyperinsulinemia can suppress gluconeogenesis and 
glycogenolysis independent of hepatic insulin signaling [109].  Glucagon is known to upregulate 
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both hepatic gluconeogenesis and glycogenolysis [110]. Insulin signaling in pancreatic α-cells will 
suppress glucagon production [111]. Another consideration is insulin’s effects on gluconeogenic 
substrate availability. Triglyceride hydrolysis from adipose tissue and skeletal muscle proteolysis 
can supply glycerol and amino acids, respectively. Insulin will inhibit both of these actions, and 
thus limits the availability of these substrates critical for gluconeogenesis [112]. It is important to 
note that when examining mice with a liver-specific insulin receptor knockout, insulin was unable 
to suppress gluconeogenesis during a euglycemic clamp [113].  Thus, direct liver insulin signaling 
must remain intact to suppress gluconeogenesis. This highlights the importance of considering a 
whole-body system when examining insulin’s effects.  
2.3.2. Peroxisome Proliferator-Activated Receptors  
Regulation of lipogenesis is controlled through multiple transcription factors. Peroxisome 
proliferator-activated receptors (PPARs) are major factors in the regulation of lipid metabolism. 
To date, three isoforms have been identified: PPARγ, PPARα, and PPARβ/δ [114]. All of these 
isoforms are ligand-binding nuclear receptors that respond to various natural and synthetic 
molecules. Of these isoforms, PPARγ and PPARα are the most well-studied and control opposing 
mechanisms in lipid metabolism. PPARα is a controller of genes involved in lipolysis and fatty 
acid oxidation. PPARα is most strongly expressed in the heart, kidney, small intestine, liver, and 
skeletal muscle [115]. PPARα regulates the expression of carnitine palmitoyltransferase 1 α/β 
(Cpt1α/β), acyl-coenzyme A oxidase 1 (Acox1), and acyl-coenzyme A dehydrogenase (Acad1), 
all of which are key enzymes in fatty acid oxidation [116].   
PPARγ controls genes encoding crucial enzymes in TG synthesis and lipid storage. 
Adipose tissue expresses the highest levels of PPARγ; however, PPARγ can be upregulated in the 
liver during hepatic steatosis. In the adipose tissue, PPARγ is vital for adipocyte development and 
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alongside CCAAT/enhancer-binding protein α (C/EBPα) controls adipocyte differentiation [117]. 
Knocking down hepatic PPARγ has been shown to reduce de novo lipogenesis and TG synthesis 
[118]. In obese patients, PPARγ mRNA is significantly upregulated [119]. In obese mice, the 
mRNA of a splice variant, PPARγ2, is strongly upregulated in response to HFD, suggesting it is 
more nutritionally-responsive than PPARγ1 [120]. Some PPARγ target genes include: Scd1, 
cluster of differentiation 36 (Cd36), fatty acid binding protein 4 (Fabp4) [121], lipoprotein lipase 
(Lpl) [122], and glucose transporter 4 (Scl2a4) [123]. Thus, PPARγ plays a vital role in TG 
accumulation within tissues. It may be hypothesized that PPARγ is responsible for hepatic steatosis 
because its positive association with steatosis and lipogenic genes [124]. However, PPARγ 
agonists such as thiazolidinediones decrease the accumulation of hepatic lipids in type II diabetes 
patients likely through improving adipose tissue insulin sensitivity [125-127]. This suggests that 
while hepatic PPARγ is nutritionally-responsive and contributes to hepatic steatosis, other 
transcription factors and adipose insulin resistance could be important contributors to hepatic 
steatosis associated with obesity.  
2.3.3. Liver X Receptor 
Liver X receptor (LXR) is a major nuclear receptor controlling lipid metabolism [128]. The natural 
ligands for LXR are the oxysterols, which are produced when cellular cholesterol levels are high 
[129]. LXR is partially responsible for maintaining cellular cholesterol balance. Two isoforms of 
this transcription factor exist, LXRα/β. LXRα is more prominent in major metabolic tissues such 
as the intestines, liver, and adipose [130], while LXRβ is ubiquitously expressed and at its highest 
in the brain [130]. LXRα target genes include inducible degrader of the low-density lipoprotein 
receptor (Idol) [131], proprotein convertase subtilisin/kexin type 9 (Pcsk9), Niemann-pick C1 like-
1 (Npc1l1), and the ATP-binding cassette transporter sub family (Abca1, Abcg1, Abcg5, Abcg8). 
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Pcsk9 [132] and Idol [133] will both impair the recycling and induce the degradation of low-
density lipoprotein receptor (LDLr), decreasing its presence on the cellular membrane, and 
ultimately reducing LDL uptake. Npc1l1 is required for cholesterol absorption in the intestine and 
will be increased when intestinal cholesterol levels are lowered [134]. Abcg5 functions in a 
heterodimer with Abcg8 and will efflux free cholesterol back into the intestinal lumen [135]. 
Overall, LXRα functions to reduce cellular cholesterol levels.  
2.3.4. Sterol Response Element Binding Proteins 
Three major SREBP isoforms exist, -1a, -1c, and -2. Classically, nascent SREBP is bound to 
SREBP cleavage-activating protein (SCAP) and insulin-induced gene product (INSIG) [136]. 
When cellular cholesterol levels are high, SREBP is retained within the endoplasmic reticulum 
and effectively inactive [137]. When the ER membrane is depleted of cholesterol, SCAP and 
INSIG dissociate, releasing SREBP from the ER and it is shuttled to the Golgi apparatus where it 
is further matured by enzymatic cleavage [137]. Insulin can stimulate SREBP-1c protein 
expression through LXR activity [138, 139]. However, LXR does not seem to strongly induce 
SREBP-1c maturation [140]. Insulin also downregulates the expression of INSIG 
posttranslationally, which has been shown to increase SREBP-1c maturation [136]. SREBP-1c 
contributes to de novo fatty acid synthesis by controlling the gene expression of several related 
enzymes. Some of its target genes are Fas, Scd1, and Acc [141]. SREBP-2 stimulates cholesterol 
biosynthesis upon activation. Most notably, SREBP-2 positively regulates the transcription of 3-
hydroxy-3-methyl-glutaryl-coenzyme A reductase (Hmgcr) [142] and Ldlr [143]. The rate-
limiting enzyme in cholesterol biosynthesis is Hmgcr. Additionally, Ldlr is an apolipoprotein (apo) 
B-100 and apoE-recognizing receptor that is responsible for uptake of LDL, a cholesterol-rich 
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lipoprotein, into the liver. Thus, the SREBPs help increase de novo lipogenesis when cellular 
cholesterol is depleted.  
 The network of transcriptional regulation for lipid metabolism in the liver, adipose, and 
skeletal muscle is diverse and extensive. The focus of this review was to orient the reader to some 
of the key transcription factors and target genes used in the following aims to evaluate the 
metabolic phenotype of mice. Although many pharmaceuticals have targeted the numerous 
pathways mentioned above, they are not without negative consequences. One such pathway is at 
the level of intestinal lipid absorption. Two drugs commonly used to inhibit lipid absorption are 
orlistat and ezetimibe. Ezetimibe inhibits intestinal cholesterol absorption leading to lower plasma 
low-density lipoprotein cholesterol (LDL-C) and CVD risk [144]. In obese patients with IR, 
therapies targeting cholesterol absorption (e.g., ezetimibe) are effective in treating dyslipidemia 
[145, 146], reducing visceral fat mass [146], and systemic inflammation [145]. Orlistat inhibits 
lipid absorption by disrupting lipase activity. This would inhibit fatty acid uptake by not allowing 
TGs to be hydrolyzed. Orlistat has been found to be an effective weight loss drug and improves 
the metabolic outcomes of patients [147]. However, as with most drugs, undesirable side effects 
may occur, including liver damage (e.g., ezetimibe, orlistat) [148, 149], gastrointestinal distress 
(e.g., orlistat) [150], and potentially cancer-promoting effects (e.g., orlistat) [151].  Therefore, a 
need exists for alternative or complementary therapies targeting lipid absorption.  
2.4. Dietary Sphingomyelin for the Prevention of Metabolic Dysfunction 
2.4.1. Structure of Sphingomyelin 
Sphingomyelin (SM) is a dietary lipid found in eggs, dairy, and meat. Sphingomyelin is considered 
a sphingolipid. Despite their immense structural diversity, all sphingolipids are grouped together 
by their amino alcohol backbone [152]. Although >60 sphingoid backbones exist, the most 
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common in mammalian tissues is sphingosine ((2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol) [153]. 
Some of the most common variations include sphinganine, also known as dihydrosphingosine 
((2S,3R-2-aminooctadecane-1,3-diol), which lacks the 4C double bond and phytosphingosine 
((2S,3S,4R)-2-aminooctadecane-1,3,4-triol), which replaces the 4C double bond of sphingosine 
with an additional hydroxyl group [153, 154]. Shorthand nomenclature for sphingoid backbones 
are similar to fatty acids, in that they follow the form C:D, where C is the number of carbons and 
D is the number of double bonds. The distinction between fatty acids and sphingoid bases is the 
inclusion of a “d” or “t” to indicate the number of hydroxyl groups. For instance, sphingosine can 
be written as d18:1, sphinganine is d18:0, while phytosphingosine is t18:0 [155]. Ceramide is 
generated with the addition of an N-acylated fatty amide. In general, SM is a ceramide with 
phosphodiester bound choline. For a comparison of the structures of sphingoid backbones, 
ceramide, and SM refer to Figure 2.2.  
Figure 2.2. Structure of common bases, ceramide, and SM
 
2.4.2. Sphingolipids in the Typical Diet 
On average, a Western diet contains 200-400 mg/day of sphingolipids [156]. Most dietary 
sphingolipids are supplied by animal products, such as meat, eggs, and dairy. Sphingomyelin is 
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the predominant sphingolipid in mammalian cells, and therefore, most dietary sphingolipids are 
SM. Table 2.1 contains a list of some of the most common dietary sphingolipids.  
It is inaccurate to think of dietary SM as a single molecular species. In fact, SM is an 
umbrella term for a family of related lipid molecules containing a sphingoid backbone, fatty amide, 
and phosphorylcholine group. For comparison, both milk-derived SM and egg-derived SM vary 
greatly from each other. In terms of the N-acyl linked fatty amide, milk-derived SM species have 
a more varied fatty amide composition (16:0-24:0) compared to egg-derived SM species, which 
contain primarily palmitate. Similarly, milk-derived SM species have sphingoid backbones 
ranging from d16:0-d19:0 in contrast to egg-derived SM species, which contain almost exclusively 
sphingosine [157, 158]. Figure 2.3 illustrates the comparison of milk and egg SM structures from 
a commercial supplier (Avanti Polar Lipids). This difference in sphingoid backbones means milk 
SM contains higher levels of dihydroSM [158]. DihydroSM binds more tightly to cholesterol than 
SM in an in vitro model membrane [159]. Sphingomyelin is a potential bioactive component of 
the milk fat globular membrane (MFGM) and milk polar lipid (MPL) fractions, both of which have 
shown beneficial effects [160]. Studies containing these provide insight into possible whole-food 
sources of dietary sphingolipids, but the bioactive effects of other phospholipids cannot be ruled 
out [160, 161]. 
Sphingomyelin hydrolysis begins in the intestinal tract by the action of alkaline SMase 
(alk-SMase) [168]. Ceramide will then be hydrolyzed further to sphingosine and a FA by neutral 
ceramidase [169]. Sphingosine itself is readily absorbed [170]. Sphingomyelin digestion is delayed 
by other dietary lipids through the inhibition of alk-SMase activity [171]. Alk-SMase activity 
peaks around the middle of the intestines after most 
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most other lipids have been absorbed. Due to the delayed activation of alk-SMase, around 20% of 
intact dietary SM reaches the ileum in humans [172]. Once absorbed, sphingosine has two 
metabolic fates. It can be resynthesized into ceramide or, through a two-step process, be converted 
to hexadecane and ethanolamine after conversion to sphingosine-1-phosphate.  The majority of 
intestinal sphingosine follows the latter path [169].  
Table 2.1. Common dietary sphingolipids 
 
2.4.3. Dietary Sphingomyelin and Lipid Absorption 
Dietary SM dose-dependently reduces intestinal absorption of cholesterol, TG, and long-chain FAs 
in rodents [173-177]. In vitro experiments demonstrated that the products of SM digestion, 
ceramide and sphingosine, inhibit both cholesterol and FA uptake [178-180]. The inhibitory effects 
of SM are seemingly dependent on the source. When comparing egg SM to milk SM, milk SM 
Sphingolipid Dietary Sources Content (mg/100g) Ref 
Sphingomyelin 




Cottage Cheese 139 
Mackerel 224 
Chicken Liver 291 
Ceramide 
Rice Bran 5.6 [163] 
Soybean 11.5 [164] 
 
Cerebroside 
Corn 11.5 [163] 
Rice Bran 11.5 [164] 
Soybean 20 [165] 
 310 [166] 
Amaranth Grain 39 [165] 
Ganglioside 
Bovine Milk, Whole 0-11 
[167] 
Mackerel 6.48 
Chicken Egg Yolk 15.9 
Chicken Liver 29 






inhibited the intestinal absorption of fat and cholesterol more so than egg SM in dual-cannulated 
rats [176]. This is likely due to the structural differences as mentioned above (see Figure 2.3).  
Figure 2.3. Compositional differences between egg- and milk-derived SM 
 
A) Fatty Amide Composition of Egg- and Milk-derived SM B) Sphingoid Backbone of Egg- and Milk-
Derived SM 
2.4.3.1 Animal Studies and Serum Lipids 
Due to the scarcity of studies that fed purified SM and examined serum lipids, we will review the 
studies feeding any purified sphingolipid or sphingolipid-rich extracts. In several rodent feeding 
studies, dietary sphingolipids or sphingolipid-rich fractions have shown mixed effects on serum 
lipids. Most studies reported reductions [177, 181-185], however, others observed no effect [185-
188], and some found increases [181, 189]. Duivenvoorden et al. fed hyperlipidemic 
APOE*3Leiden mice a Western-type diet (15% cocoa butter, 0.25% cholesterol by weight) 
supplemented with various sphingolipids, ranging from SM to sphingosine [177]. At 0.2% and 
0.4% (w/w of the diet) all dietary sphingolipids caused more than a 20% reduction of plasma 
cholesterol and TG [177].  Zucker-fatty rats fed chicken-derived SM or corn-derived 
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glycoceramides showed reduced plasma cholesterol after 4 weeks compared to control [183]. In 
contrast, the addition of egg SM to a milkfat-containing high-cholesterol diet fed to C57BL/6J 
mice had no effect on plasma lipids [186]. Apolipoprotein E-/- mice fed a HFD with and without 
egg SM (1.2% wt:wt) demonstrated no differences in plasma lipids and no effect on atherosclerosis 
development [188]. However, low-fat fed apoE-/- mice demonstrated a decrease in en face aortic 
plaques with 1.2% (wt:wt) egg SM supplementation [188].  
Mixed fractions of polar lipids containing SM also show equivocal results. When feeding 
SM as part of a milk-derived polar lipid extract to mice fed a HFD (21% w:w butter fat, 0.15% 
cholesterol), serum cholesterol and hepatic lipids were significantly reduced [184]. Similarly, MPL 
fractions, fed to genetically obese AAy mice, reduced plasma cholesterol after only 4 weeks [182]. 
Conversely, a milk phospholipid concentrate (1.2% phospholipid w/w of diet, containing ~ 0.25% 
wt:wt of the diet SM) added to a HFD (20% fat by weight) had no effect on plasma lipids over 8 
weeks [187]. Plasma cholesterol, plasma SM, and aortic plaques were increased by a modified 
AIN-76A diet with 1% (w/w) ox brain sphingolipids (28% SM) fed to female LDLr-/- mice for 12 
weeks [189]. In the context of HFD or obesity, dietary sphingolipids generally reduce plasma 
cholesterol or hepatic lipids, which will be discussed below. Only in genetically 
hypercholesterolemic mice on a chow diet were elevations in plasma cholesterol reported. 
Therefore, there is sufficient evidence to suggest dietary SM has hypolipidemic effects when 
chronically fed to rodents.  
2.4.3.2 Clinical Trials and Serum Lipid Outcomes 
Unlike rodents, human bile contains alk-SMase, so the relative efficiency of SM digestion is likely 
increased [172]. There is currently one study that supplemented humans with purified SM [190]. 
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Ramprasath et al. found that 1 g/day of purified milk SM supplementation over 2 weeks of 
prepared meals raised high-density lipoprotein cholesterol (HDL-C) but did not affect non-HDL-
C or cholesterol absorption in healthy adults [190]. There are studies examining the effects of other 
sphingolipids or sphingolipid-rich extracts on clinical lipid profiles. These may provide insight 
into potential effects of feeding sphingolipids to humans. A double-blind, placebo-controlled 
crossover trial supplying 1 g/day of phytosphingosine for 4 weeks to adult men with metabolic 
syndrome reported a significant reduction in plasma LDL-C [191]. Rosqvist et al. supplemented 
overweight adults with 40 g of milkfat/day as whipping cream in a single-blind, randomized, 
controlled, isocaloric parallel study for 8 weeks. Consuming 40 g of milkfat/day as whipping 
cream significantly lowered plasma LDL-C, non-HDL-C, and apoB:apoA-I ratio compared to the 
same amount of milkfat as butter oil [192]. Compared to butter oil, whipping cream is rich in milk-
fat globular membranes, the polar lipid rich fraction in milk [192]. Two clinical trials 
supplementing buttermilk for 4 weeks found different results. Ohlsson et al. observed no effect of 
4-week supplementation of a buttermilk drink enriched in MFGM, supplying 700 mg milk SM/day 
when measuring plasma lipids, in a placebo-controlled parallel study with healthy adults. There 
was a trend for a reduction in plasma LDL-C (p = 0.056) in women who drank the treatment drink 
[193]. This study was relatively small with 18 participants, and the parallel design does not help 
the statistical power. In contrast, 4-week ingestion of 45 g/day of buttermilk resulted in significant 
reductions in both plasma cholesterol and TG compared to a calorically-matched placebo [194]. 
This study was a double-blind randomized cross-over study with healthy adults and indirectly 
measured cholesterol absorption through measuring serum β-sitosterol concentration.  Serum β-
sitosterol concentration was correlated with the reductions in plasma LDL-C, suggesting a 
reduction in cholesterol absorption was responsible [194]. This study was much more robust with 
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38 participants, and the crossover design improved statistical power. In aggregate, there is some 
clinical data supporting the hypolipidemic effects found in animals. Due to the scarcity of studies 
and the sample sizes used (see Table 2.2), there is a clear need for further clinical trials to confirm 
the effects. It is worth noting that rodent studies typically use larger doses of sphingolipids, even 
when correcting for body surface area, therefore the smaller effect sizes in clinical studies are 
expected.  
2.4.4. Dietary Sphingolipids and Other Markers of Metabolic Dysfunction 
As reviewed above, obesity can lead to IR and hepatic lipid accumulation. Although no studies at 
this point have examined dietary SM for its effects on IR, it is important to recognize that 
phytosphingosine (t18:0) has shown potential to reduce IR in both rodents [195] and humans [191]. 
Feeding a HFD supplemented with 0.2% (w/w) phytosphingosine to mice for 24 weeks reduced 
the expression of a macrophage marker (F4/80) in adipose tissue and improved the response to a 
glucose tolerance test [195]. A clinical trial examining the daily intake of phytosphingosine (1 
g/day) reported a significant reduction in fasting glucose (-5%) along with an improved index of 
insulin sensitivity (+10%) in men with MetS and with only minor gastrointestinal distress [191]. 
A substantial amount of research that examines dietary sphingolipids for the prevention of 
hepatic lipid accumulation, the hepatic manifestation of IR, show an inhibitory effect towards 
steatosis (see Table 2.3). Supplementing Western-type (21% butter fat, 0.15% cholesterol by 
weight) diet-fed mice with egg SM at 0.6% and 1.2% (w/w) for 4 weeks reduced hepatic total lipid 
content by 33% and 40%, respectively [186]. These mice also demonstrated reduced in hepatic 
total cholesterol content. Meanwhile, mRNA expression of genes involved in fatty acid synthesis 
increased in the 0.6% egg SM-fed mice [186]. Male Zucker fatty rats fed an AIN-76A diet with
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Table 2.2. Clinical trials evaluating hypolipidemic effects of dietary sphingolipids 





(n = 48) 
Parallel, placebo  
4 weeks of 2 drinks/day totaling 975 
mg SL (700 mg SM, 180 mg GC, 95 
mg GS) of test drink or 119 mg total SL 
in isocaloric placebo drink 
↔ Plasma lipids between groups  
trend for ↓ plasma LDL-C (p = 0.056) in 






(n = 12) 
Double-blind, 
placebo, crossover 
4 weeks of phytosphingosine (1 g/day) 
 or placebo in capsule form 
↓ Serum cholesterol (-5.6%), 
 ↓ LDL-C (-8.8%), ↔ TG, ↔ HDL-C 





(n = 34) 
Double-blind, 
placebo, crossover 
4 weeks of buttermilk powder (187.5 
mg total PL, 23.6 mg SM per day) or 
placebo (34.6 mg total PL) matched for 
calories and minerals  
↓ Plasma cholesterol (-3.1%),  
↓ TG (-10.7%),  
trended for ↓ LDL-C (p = 0.057) compared 
to placebo,  
↓ LDL-C (-5.6%) in participants with highest 





(n = 10) 
Controlled diets, 
crossover 
2 weeks of prepared diets (30% kcal 
from fat, 240 mg cholesterol/day) with 
or without 1 g/day added milk SM 
↑ HDL-C (+13%), 
 ↔ total cholesterol,  








(n = 57)  
Single-blind, 
parallel 
8 weeks of intervention meals with 
either 40 g milkfat/day as whipping 
cream (19.8 mg total PL) or control diet 
with butter oil (1.3 mg total PL), 
matched for calories, macronutrients, 
and calcium 
↓ Plasma cholesterol, ↓ LDL-C, 
 ↓ non-HDL-C, 
 ↓ apoB:apoA-I ratio with whipping cream 
vs. control group 
1ApoA-I, apolipoprotein A-I; ApoB, apolipoprotein B; GC, glucosylceramide; GS, gangliosides; MetS, metabolic syndrome; PL, phospholipid; SL, 
sphingolipids; SM, sphingomyelin; TG, triglyceride; ↑, increase; ↓ decrease; ↔, no change. 
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and without either 0.5% (w/w) SM prepared from chicken skin, or 0.5% (w/w) glucosylceramide 
from corn had significantly lower hepatic lipid content on both treatment diets compared to control 
[183]. Additionally, these rats had reduced fasting plasma insulin as well as lower hepatic Scd1 
and Acc mRNA in the treatment groups. Conversely, hepatic Pparα mRNA expression was 
increased in the SM and glucosylceramide-fed rats, suggesting greater fatty acid oxidation [183]. 
Chronic supplementation of mice fed a Western-type diet (21% butter fat, 0.15% cholesterol 
wt:wt) with milk phospholipid extracts (0.25%-0.35% SM w/w of diet) significantly lowered both 
hepatic cholesterol and TG [184, 196]. Milk-derived ceramides (0.35% w/w of diet) given to 
genetically obese KK-Ay mice for 4 weeks also reduced hepatic cholesterol and TG [182].  
Mechanistically, mice fed a milk SM-enriched HFD (0.35% SM w/w, 28% fat by weight) tended 
(p = 0.058) to have lower fractional synthesis of hepatic TG and palmitic acid incorporation (p = 
0.062). These mice had a significant reduction in the ratio of hepatic palmitoleic acid (C16:1n7) 
to palmitic acid (C16:0), an index of SCD1 activity [197]. In addition, in vitro studies that applied 
very-long chain ceramides (C22:0- & C24:0-ceramides) to primary mouse hepatocytes and Huh7 
hepatoma cells reduced the expression of both Pparg and Cd36 [198, 199]. This reduction in 
lipogenic genes may explain the effect found in vivo [181, 182, 185]. Duivenvoorden et al. found 
when female APOE*3Leiden mice were fed a Western-type diet (15% cocoa butter, 0.25% 
cholesterol by weight) supplemented with 1% phytosphingosine (w/w of the diet) for 5 weeks, 
their hepatic TG and cholesterol content, as well as plasma alanine transaminase and serum 
amyloid A were significantly reduced. This demonstrates a less steatotic liver that is potentially 
less inflamed. Interestingly, hepatic mRNA expression indicated lipid biosynthesis was 
upregulated compared to control, suggesting some compensatory mechanism [177]. 
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Structurally distinct ceramides seemingly have different biological functions [200]. Thus, the 
distribution of ceramide species could be important for normal tissue function. Notably, the 
ceramide profile of rodent livers is associated with hepatic function. As an example, primary 
hepatocytes from mice lacking ceramide synthase 2, an enzyme required for C22- and C24-
ceramide synthesis, have reduced insulin sensitivity [198, 201, 202]. C16-ceramide synthesis 
increases in these mice [202], C16:0-ceramide is also associated with deleterious effects on 
hepatocyte function [203, 204]. Therefore, a balance may be required between different length 
ceramides. Diet-induced obesity causes an increased hepatic C16:0-ceramide concentration and 
ceramide synthase 5 and 6 expression, the major enzymes responsible for C16:0-ceramide 
synthesis [204, 205]. Thus, a balance between the C22-/C24-ceramides and C16-ceramide may be 
important for proper liver function. Consequently, the effects of dietary sphingolipids on hepatic 
sphingolipid profiles could be an important endpoint. Unfortunately, this is largely unknown. One 
study reported no change in total ceramide in the livers of mice supplemented with 0.6% egg SM 
(wt:wt), although C16:0-ceramide was reduced and C22- and C24- ceramides were unaffected 
[186]. This was reported with an overall improved hepatic phenotype. 
 In summary, dietary SM has shown promise to reduce the occurrence of dysfunctional lipid 
metabolism in mice. Although there are few clinical trials in the field, they show either beneficial 
effects of dietary sphingolipids or may have suffered from a lack of statistical power. Therefore, 
more research is needed to fully determine the efficacy of dietary SM for improvements in lipid 
metabolism, especially in humans. Additionally, absorption studies suggest a functional difference 
between SM derived from egg and milk due to their structural differences. This coupled with a 
lack of studies comparing the two, leaves an obvious gap in the literature to directly compare the 
hypolipidemic effects of dietary SM from different sources. 
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Table 2.3. Dietary sphingolipids and hepatic steatosis 







Leiden mice (n = 
6) 
5 weeks of Western-type diet (15% cocoa 
butter; 0.25% cholesterol) supplemented with 
0.1% (w/w) phytosphingosine (PS) 







(n = 10) 
8 weeks of either LFD or Western-type diet 
(21% milkfat; 0.15% cholesterol) with and 
without 1.2% PL (w/w) from phospholipid-rich 
dairy milk extract (PLRDME) (0.26% of diet by 
weight as SM) 
PLRDME with LFD: ↔ total lipid, 
↔ TG, ↔TC, ↔PL PLRDME with 
Western-type diet: ↓ total lipid (-







 (n = 10) 
8 weeks of Western-type diet (21% milkfat; 
0.15% cholesterol) with and without 1.2% PL 
(w/w) from phospholipid-rich dairy milk extract 
(PLRDME) (0.26% SM w/w) or 0.2% (w/w) 
milk phospholipid concentrate (PC-700) (0.34% 
SM w/w) 
PLRDME (0.26% SM w/w): ↓ total 
lipid (-41%), ↓ TG (-47%), ↓ TC (-
39%)PC-700 (0.34% SM w/w): ↓ 





Male Zucker rats  
 (n = 6)  
45 days of AIN-93 diet supplemented with 0.5% 
(w/w) of chicken skin SM or 0.5% (w/w) corn 
GC 
SM: ↓ total lipid (-24%), ↔ TC GC: 








(n = 7) 
4 weeks of AIN-93G diet with1.7% (w/w) of 
lipid-concentrated butter serum (LC-BS) (0.13% 
SM, 0.18% ceramides by weight in diet) or 
0.5% (w/w) ceramide-rich fraction (Cer-fr) 
(0.34% ceramide by weight in diet) or 0.5% 
(w/w) SM-rich fraction (SM-fr) (0.25% SM by 
weight in diet) 
LC-BS: ↓ TG (-27%), ↔ TCCer-fr: 
↓ TG (-38%), ↓TC (-47%) SM-fr: ↔ 






(n = 10) 
4 weeks on a Western-type diet (21% milkfat; 
0.15% cholesterol) with 0.3, 0.6, 1.2% (w/w) 
egg SM  
0.3% SM: ↓ total lipid (-20%), ↓ TC 
(- 36%), ↓ TG (-31%)0.6% SM: ↓ 
total lipid (-33%), ↓ TC (- 48%), ↓ 
TG (-46%)1.2% SM:  ↓ total lipid (-
40%), ↓ TC (- 67%), ↓ TG (-56%) 
Cer-fr, ceramide-rich fraction; FC, free cholesterol; GC, glucosylceramides; HFD, high-fat diet; LC-BS, lipid-concentrated butter serum; 
LFD, low-fat diet; PL, phospholipids; PLRDME, phospholipid-rich dairy milk extract; PS, phytosphingosine; SL, sphingolipids; SM, 
sphingomyelin; SM-fr, sphingomyelin-rich fraction; TC, total cholesterol; TG, triglycerides; ↑, increase; ↓, decrease; ↔, no change. 
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2.5. Other potential bioactive roles of dietary SM 
In addition to the reported hypolipidemic and insulin-sensitizing effects, dietary SM may have 
other bioactivities. Thus, it may confer additional benefits compared to the hypolipidemic drugs 
orlistat and ezetimibe. Two of these effects include modulation of the gut microbiota and 
attenuation of inflammatory signalling.   
2.5.1. Anti-inflammatory Effects of Dietary Sphingolipids In Vitro 
Several cell studies utilizing exogenous sphingolipids have shown these lipids to be anti-
inflammatory. J774 immortalized cells and thioglycollate-elicited peritoneal macrophages had 
lowered LPS-induced TNF-α and macrophage inflammatory protein 2 (MIP-2) secretion when 
pretreated with either 10 µM C8-ceramide or sphingosine treatment [206]. Aiming to elucidate the 
mechanism, this study proceeded to explore the potential for the synthesis of sphingosine-1-
phosphate, a sphingolipid metabolite, to be anti-inflammatory. Supporting this hypothesis, 
sphingosine-1-phosphate was found to be a PPARγ ligand [207]. However, sphingosine-1-
phosphate synthesis was found to be dispensable, as a sphingosine kinase inhibitor had no effect 
on ceramide and sphingosine’s effects on LPS-induced TNF-α production [206]. Exogenous 
sphingosine given to RAW 264.7 macrophages transfected with a PPARγ luciferase plasmid acted 
as a modest agonist of PPARγ [208]. PPARγ binding can repress NF-κB activity [209], giving a 
putative mechanism for the inhibition of inflammatory gene expression. Bovine brain SM was 
shown to inhibit LPS-stimulation of granulocytes [210]. C8-ceramide (10 µg/mL) inhibited LPS-
stimulated secretion of IL-10 and IL-5 from bone marrow-derived mast cells, although ceramide 
did not alter TNF-α, IL-13, or IL-6 [211]. Additionally, thioglycollate-elicited peritoneal 
macrophages treated with C8-ceramide had a reduced production of IL-6, IL-12p40, and TNF-α 
in response to LPS. The difference between macrophage and mast cell responses were attributed 
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to variations in PI3K-Akt and mitogen-activated protein kinase (MAPK) phosphorylation between 
the two cell types [211]. Thus, exogenous sphingolipids may not affect all cells similarly. Treating 
RAW 264.7 macrophages with 10-50 μM of C2-ceramide inhibited both the activation of NF-κB 
and adapter protein-1 by LPS, while reducing the production of nitric oxide and prostaglandin 
[212].  
Other complex sphingolipids and sphingolipid-rich dairy fractions have shown anti-
inflammatory effects. Gangliosides administered ex vivo to infant bowel epithelial cells, taken 
from viable infants, inhibited LPS- and hypoxia-induced inflammation, measured by nitrite 
release, IL-8, IL-6, IL-1β, eicosanoid, and hydrogen peroxide production [213]. Most studies used 
LPS as the inflammatory stimuli, suggesting there may be a lipid-lipid interaction with the 
sphingolipids as the potential mechanism. Interestingly, sphingolipid-rich dairy fractions inhibited 
monosodium urate-induced IL-8 mRNA and protein expression in THP-1 monocytes. Although, 
in this study the dairy fraction had no effect on cytokine production in response to LPS [214]. 
Some in vivo observations support sphingolipids for inhibiting LPS activity. For example, 
sphingolipid-containing lipoproteins neutralize LPS activity by forming phospholipid:LPS 
complexes [210, 215]. After intraperitoneal (IP) injection of LPS, the liver increases sphingolipid 
production, enriching circulating lipoproteins [216], possibly in an effort to detoxify LPS. 
Sphingosine is known to potently inhibit protein kinase C [217], an enzyme that drives 
inflammatory signalling in macrophages [218].  
In summary, these studies illustrate mechanistic evidence for exogenous sphingolipids and 
its derivatives to have inhibitory effects on inflammation. Due to the dynamic nature of 
sphingolipid metabolism, at this time it is impossible to pinpoint which metabolite is responsible. 
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If the catabolic metabolites are the causal factor, the effects of glycosphingolipids could be applied 
to SM.  
 In contrast to the above studies, some experiments demonstrate pro-inflammatory effects 
of exogenous sphingolipids. Treating thioglycollate-elicited peritoneal macrophages with 50-100 
µM milk-derived SM, C16-SM, or C24-SM elevated iNOS mRNA [219]. Human embryonic 
kidney (HEK) cells transfected with TLR4 have an increase in TNF-α production in response to 
exogenous 1.5 µM C8- and C2-ceramide treatment, however, adding soluble CD14 inhibited the 
effect of C2-ceramide [220]. It should be noted that HEK cells lack CD14, while both membrane-
anchored and soluble CD14 are expressed across many cell types to varying degrees [221]. Thus, 
disparity in CD14 expression may cause cell type-specific effects, as cells that express less CD14 
may respond differently to sphingolipids. Interestingly, longer-chain ceramides may actually 
compete with LPS and block TLR4 signalling, as they bind CD14 in monocytes and appear to 
reduce TLR4-CD14 interactions [222]. C2-ceramide (50 μM) induces c-Jun N-terminal kinase 
(JNK) and MAPK in macrophages [223]. However, C2-ceramide failed to activate NF-κB. 
Furthermore, C2-ceramide had no effect on LPS-stimulated translocation of NF-κB. In another 
study, RAW 264.7 macrophages incubated with 100 μM C2-ceramide stimulated JNK activity, 
despite no effect on MAPK and NF-κB [224]. Although some studies report pro-inflammatory 
effects, the studies with long-chain sphingolipids use much higher concentrations. C2 and C8-
ceramides have questionable biological relevance since they are not naturally produced and are 
typically only used because they are cell permeable, unlike their long chain counterparts.   
In summary, results from several studies supporting an anti-inflammatory role of 
exogenous long-chain sphingolipids. However, the evidence indicating pro-inflammatory effects 
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of sphingolipids in the absence of LPS when given in high doses warrants more research to uncover 
the precise molecular mechanisms of exogenous sphingolipids and inflammation.  
 
2.5.2. Animal Models of Acute Inflammation 
The anti-inflammatory effects of dietary sphingolipids found in cell studies have also been 
demonstrated in rodents. After chronically feeding young male Sprague Dawley rats a HFD 
containing dairy-derived ganglioside (0.02% wt:wt of the diet), elevations in serum IL-1β and 
TNF-α were attenuated six hours after IP injection of LPS compared to the HFD control group 
[225]. The intestinal mucosa of these rats expressed less platelet activating factor, leukotriene B4, 
prostaglandin E2, IL-1β, and TNF-α, alongside elevated ganglioside content, suggesting that 
dietary ganglioside protected against both systemic and intestinal LPS-induced inflammation 
[225]. Supporting these findings, Sprague Dawley rats fed the same ganglioside-supplemented diet 
had heightened plasma and intestinal IL-10 when treated with LPS, while iNOS expression as well 
as nitrate and nitrite production were blunted with ganglioside treatment [226]. These ganglioside-
rich diets also impaired the LPS-induced loss of occludin protein from intestinal mucosa 
suggesting improved gut barrier function [226]. Male BALB/c mice on a chow diet fed a MFGM-
supplemented (12.5% wt:wt) for 5 weeks were resistant to the effects of an IP LPS-challenge [227]. 
The MFGM mice had reduced gut permeability and reductions in serum interferon γ (IFNγ), IL-6, 
IL-10, IL-17, IL-12p70, monocyte chemoattractant protein 1 (MCP-1), and TNF-α after 24 hours 
[227]. MFGM also improved mouse survival at 48 hours compared to control [227]. Upon IP 
injection of monosodium urate, mice fed a diet supplemented with phospholipid- and sphingolipid-
rich dairy fractions (0.8-7.0% wt/wt of the diet) had reduced cell migration into the peritoneal 
space compared to control [214]. The dietary phospholipids seemingly reduced the recruitment of 
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immune cells. Overall, animal studies examining the effects of sphingolipid and polar lipid 
mixtures on acute inflammation showed a reduced inflammatory response. There are no studies 
examining the effects of purified SM on acute inflammation. However, again if the effects are due 
to the catabolic products as suggested by the in vitro studies, these findings could be applicable to 
dietary SM.  
2.5.3. Dietary Sphingolipids and Inflammation: Clinical Trials  
Like the hypolipidemic effects, there are limited clinical trials exploring the potential benefits of 
dietary sphingolipids in inflammation. These studies examined post-prandial inflammation due to 
ethical restrictions on inducing sepsis in humans. Additionally, increased post-prandial 
inflammation is linked with increased risk for cardiometabolic disease [228]. Thus, treatments that 
can attenuate this inflammation could be preventative in cardiometabolic diseases. A milk fat 
globular membrane fraction supplementation given to overweight adults during saturated fat-rich 
meals increased serum IL-10 and decreased soluble intercellular adhesion molecule (sICAM) 
compared to isocaloric control meals [229]. IL-10 and sICAM are inversely related, as IL-10 is 
anti-inflammatory and sICAM is associated with inflammation [230]. A pilot study comparing 
isocaloric smoothies containing palm oil, made with and without MFGM, found modest reductions 
in sICAM when MFGM was fed to obese adults [231]. This study did not match fatty acids 
between the meals making the detection of differences in post-prandial inflammation difficult. The 
limited number of human studies, along with the use of complex mixtures of phospholipids, makes 
it difficult to pinpoint the effects of sphingolipids on post-prandial inflammation in humans. Thus, 
more research is needed with both polar lipid extracts and purified sphingolipids to elucidate the 




2.5.4. Dietary Sphingolipids Attenuate Animal Models of Chronic Inflammation 
2.5.4.1. Colitis Models 
Dietary SM (0.1% wt/wt, unspecified source) reduced colonic myeloperoxidase and histological 
damage induced by dextran sodium sulfate (DSS) [232]. Additionally, feeding milk SM (0.1% 
wt:wt) to DSS-treated mice moderately attenuated colitis in a PPARγ-dependent manner. These 
mice had immunostimulatory gene expression including Ccl11/19/20 and Cxcl9/11 [208]. 
However, some anti-inflammatory genes were also upregulated and therefore, may have reduced 
the potential histological damage. BALB/c mice fed a maize glucosylceramide-supplemented 
(0.1% wt/wt) diet were resistant to 1,2-dimethylhydrazine induced colonic expression of TNF-α, 
regulated on activation, normal T cell expressed and secreted (RANTES), macrophage colony 
stimulating factor, and interferon-inducible T-cell alpha chemoattractant (I-TAC) [233]. 
Corroborating this, DSS-treated BALB/c mice fed glucosylceramide (0.1% wt:wt) also had 
reduced colonic expression IL-1α/β, sICAM1, IL-16, interferon gamma-induced protein 10, 
monokine induced by gamma interferon, and tissue inhibitor metallopeptidase 1 [234]. Overall, 
there are studies suggesting an inhibitory role for dietary sphingolipids in chemically-induced 
colitis. Conversely, 4 mg/day of egg SM administered via gavage exacerbated colitis and apoptosis 
in both DSS and IL-10-/- colitis mouse models [235]. This study found increased ceramide content 
in the intestinal epithelium. Although this study found pro-inflammatory effects, the administration 
method could account for the differences. The gavage method administered the 4 mg in one dose, 
whereas the chronic feeding studies dispersed the dose throughout the day. In line with what has 




Other potential roles of sphingolipids in the intestine are related to the gut barrier. Rat pups 
fed milk SM have shown improved markers of gut maturation [236], suggesting dietary SM found 
in breast milk [237] may be important for new-born gut development and health. Furthermore, egg 
SM protects intestinal epithelial cells from the cytotoxic detergent effects of bile salts [238]. This 
could have implications in HFD as deoxycholic acid plays a crucial role in HFD-induced gut 
barrier dysfunction [239]. 
2.5.4.2. Animal Models of High-Fat Diet-Induced Inflammation 
As reviewed above, inflammation is crucial in the development of metabolic dysfunction. Lecomte 
et al. supplemented mice fed a HFD (40% kcal from fat) with 2% (wt/wt) MPL, supplying about 
0.3% milk SM. In general, MPL protected mice from the deleterious effects of HFD [240]. For 
instance, MPL increased the intestinal expression of Mucin2, suggesting increased intestinal 
integrity. The adipose tissue of MPL-fed mice had reduced CD68 mRNA, a marker of adipose 
macrophage infiltration [240]. The effects on inflammation may be due in part to MPL ability to 
reduce intestinal leakiness [227], thus limiting endotoxin translocation. The complexity of 
phospholipid extracts makes it difficult to discern the causal agent in these studies. Not only have 
dietary phospholipids been reported to have their own beneficial health effects [160], they can also 
increase milk SM-derived ceramide appearance in the lymph [241], and thus potentially increase 
SM absorption. Further studies are needed to link dietary sphingolipids to diet-induced 
inflammation, however, there is potential for anti-inflammatory effects as shown by MPL feeding.   
2.4.5. Dietary Sphingolipids Interactions with the Gut Microbiota 
The gut microbiota spans the length of the intestines but is orders of magnitude more  
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concentrated in the colon [242]. It is important to note that significant quantities of both dietary 
SM and its hydrolytic products can reach the colon in humans [172] where they may affect the 
bulk of the gut microbiota. Sprong et al. reported sphingosine has in vitro bactericidal properties 
against a variety of enteropathogens including bacteria from different phyla, as well as both Gram-
negative and -positive bacteria [243]. Examining the translatability of this is difficult, only a few 
studies report gut microbiota or microbiota-related outcomes (e.g. serum LPS) after sphingolipid 
feeding. Milk fat globular membrane consumption attenuated gastrointestinal complications 
associated with the administration of a diarrheagenic strain of E. coli in humans [244]. Infant 
formulas containing gangliosides significantly altered the fecal microbiota by decreasing E. coli 
and increasing Bifidobacterium [245]. This study suggested the effects may be related to the 
oligosaccharide moieties acting as prebiotics. However, the broad spectrum bactericidal effects of 
sphingosine [243] and interactions of specific ceramide moieties with bacteria may also play a role 
[246]. In contrast, Reis et al. did not observe any significant differences in cecal microbiota of 
mice in response to various sphingolipid-rich diets for 5 weeks [197]. Another consideration for 
interactions between dietary SM and gut microbiota is the production of trimethylamine by the gut 
microbiota when in the presence of excess choline. Trimethylamine is a precursor to 
trimethylamine N-oxide, which has been tentatively related to CVD disease [247]. However, 
recently Rye and colleagues demonstrated that only at excessively large doses of dietary egg SM 
did serum trimethylamine N-oxide modestly increase [188]. Furthermore, there was a reduction in 
aortic lesion area when mice were fed egg SM on a low-fat diet but, there was no difference 
between the control and SM group when broad-spectrum antibiotics were used to deplete the gut 
microbiota. This suggests there is an important, potentially protective interaction between SM and 
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gut microbiota on atherosclerosis [188]. At this moment, more research is needed to fully 
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Chapter 3. Dietary Milk Sphingomyelin 
Improves Lipid Metabolism and Alters 




This chapter is reprinted from “Norris GH, Jiang C, Ryan J, Porter CM, Blesso CN: Milk 
sphingomyelin improves lipid metabolism and alters gut microbiota in high fat diet-fed mice. 
J Nutr Biochem 2016, 30:93-101.” As the author of this Elsevier article, Gregory Norris retains 




High dietary fat intake can cause elevated serum and hepatic lipids, as well as contribute to gut 
dysbiosis, intestinal barrier dysfunction and increased circulating lipopolysaccharide (LPS). 
Dietary milk sphingomyelin (SM) has been shown to inhibit lipid absorption in rodents. We 
evaluated the effects of milk SM on lipid metabolism and LPS levels in C57BL/6J mice fed a high-
fat diet for 4 weeks and compared it with egg SM. Mice were fed a high-fat diet (45% kcal from 
fat) (CTL, n = 10) or the same diet modified to contain 0.25% (wt/wt) milk SM (MSM, n = 10) or 
0.25% (wt/wt) egg SM (ESM, n = 10). After 4 weeks, MSM had gained significantly less weight 
and had reduced serum cholesterol compared to CTL. ESM had increases in serum cholesterol, 
triglycerides, phospholipids and SM compared to CTL. MSM significantly decreased, while ESM 
increased, hepatic triglycerides. This may have been related to induction of hepatic stearoyl-CoA 
desaturase-1 mRNA observed in ESM. MSM displayed intestinal and hepatic gene expression 
changes consistent with cholesterol depletion. MSM had significantly lower serum LPS compared 
to CTL, which may have been due to altered distal gut microbiota. Fecal Gram-negative bacteria 
were significantly lower, while fecal Bifidobacterium were higher, in MSM. These results suggest 
that milk SM is more effective than egg SM at combating the detrimental effects of a high-fat diet 
in mice. Additionally, distal gut microbiota is altered with milk SM and this may have contributed 
to the lower serum LPS observed. 
3.2. Introduction 
High dietary fat is thought to contribute to obesity incidence due to its high energy density and 
therefore higher risk of overconsumption [1]. Compared with low-fat diets, feeding mice high-fat 
diets or “Western”-type diets (40–60% kcal as fat) ad libitum results in development of obesity 
and diabetes, characterized by increased adiposity, hepatic steatosis, systemic inflammation and 
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insulin resistance [2]. In addition, high-fat diets contribute to elevated serum LPS concentrations 
(also known as endotoxin), which may precede the associated increases in systemic inflammation, 
insulin resistance and hepatic steatosis [3,4]. Dietary fat may increase appearance of gut-derived 
LPS in circulation by enhancing transcellular transport via chylomicrons [5,6] and/or paracellular 
leakage across the gut barrier [7]. High-fat-diet feeding of mice has also been shown to markedly 
alter the gut microbiota [8,9]. Gut dysbiosis has been linked with endotoxin-mediated hepatic 
steatosis in mouse models [10]. Detrimental effects of high-fat diet in mice appear to be influenced 
by gut microbes, since administration of broad-spectrum antibiotics attenuated the elevation in 
plasma LPS and improved metabolic parameters [8]. Along with excessive dietary fat, higher 
cholesterol absorption is linked with deleterious health effects. Cholesterol absorption is widely 
recognized to influence fasting plasma lipids and risk for cardiovascular disease [11]. Besides the 
well-known effects on plasma lipids, dietary cholesterol exacerbates inflammation in adipose 
tissue [12] and liver [13,14] in mouse models of obesity. Therefore, an important strategy to 
manage complications of obesity would be to reduce lipid absorption as a means to improve 
complications such as dyslipidemia, hepatic steatosis and low-grade inflammation. 
Dietary sphingomyelin (SM) and other sphingolipids have been shown to dose-
dependently reduce the absorption of cholesterol, triglycerides and fatty acids in rodents [15–18]. 
SM consists of a ceramide (a fatty acid linked to a long-chain sphingoid base through an amide 
linkage) with a phosphorylcholine head group. Digestion of SM in the intestine is slow and 
incomplete but yields ceramide and sphingosine that can be absorbed into intestinal mucosal 
cells [19]. Products of SM digestion, such as ceramide and sphingosine, also appear to reduce lipid 
absorption [18,20]. Sphingosine has been shown to exhibit antimicrobial properties against 
pathogenic bacteria, such as Escherichia coli and Salmonella enteritidis [21], suggesting that 
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dietary sphingolipids can alter the gut microbiota, along with lipid absorption. The estimated 
dietary intakes of sphingolipids is 300–400 mg/day in Western diets, most of which comes from 
SM found in dairy products, meats and eggs [22]. SM is abundant in animal cell membranes but 
is not found in plants or fungi. Egg SM and milk SM differ in their fatty acid and sphingoid base 
composition and, therefore, may have different biological effects on lipid metabolism in vivo. In 
rats, milk SM has been shown to be a more potent inhibitor of cholesterol and fatty acid absorption 
when compared to egg SM [16]. Although milk SM has been shown repeatedly to inhibit lipid 
absorption in rodents [16,17,23], the effects of chronic milk SM intake on lipid metabolism in 
vivo have not been studied extensively. While milk SM and digestion products can impact 
intestinal luminal interactions and absorption of cholesterol, the sphingolipids themselves may 
demonstrate bioactivity and affect lipid metabolism after absorption. Furthermore, whether milk 
SM displays a more potent hypolipidemic effect than egg SM is not known. A comparison of 
dietary milk SM and egg SM on lipid metabolism has not yet been examined in vivo. 
Therefore, we investigated the effects of dietary milk SM on lipid metabolism in C57BL/6J 
mice fed a high-fat diet and compared it with egg SM feeding. We hypothesized that milk SM 
would improve lipid metabolism, while also being more potent than egg SM at preventing the 
elevations in serum and hepatic lipids that occur in mice fed a high-fat diet. We also hypothesized 
that the addition of dietary milk SM would result in lower circulating LPS compared with a high-
fat control diet, by protecting the gut barrier from the damaging effects of absorbed dietary lipids 








3.3. Materials and Methods 
3.3.1 Animals and Diets 
Male C57BL/6J mice (8 weeks old, n = 30) were obtained from the Jackson Laboratory (Bar 
Harbor, ME) and allowed to acclimate to the animal facility for 2 weeks before being fed 1 of 3 
anhydrous milk-fat-based, high-fat diets for 4 weeks: high-fat diet control (CTL; 45% kcal as 
fat; n = 10), high-fat diet with 0.25% of milk SM added by weight (MSM; 45% kcal as fat; n = 10) 
and high-fat diet with 0.25% of egg SM added by weight (ESM; 45% kcal as fat; n = 10). Detailed 
composition of the diets is listed in Table 3.1. The ingredients for experimental diets were obtained 
from Dyets, Inc. (Bethlehem, PA). Milk SM (bovine) and egg SM (chicken egg) were both 
obtained at > 99% purity in powdered form from Avanti Polar Lipids, Inc. (Alabaster, AL) and 
were substituted into test diets for an equal amount of anhydrous milk fat. The fatty acid 
distribution of the SM obtained varied between milk SM (34% C23:0, 21% C24:0, 20% C22:0, 
16% C16:0, 3% C24:1 and 6% unknown) and egg SM (86% C16:0, 6% C18:0, 3% C22:0, 3% 
C24:1 and 2% unknown). The sphingoid base composition has also been reported to be different 
between egg SM and milk SM, with egg SM containing almost entirely sphingosine (d18:1) bases, 
whereas milk SM has a more varied distribution (d16:0 to d19:0) [24]. The anhydrous milk fat 
used in high-fat diets generally contains phospholipid concentrations of ~ 0.2–1% (wt/wt) [25,26], 
~ 20–25% is SM [25]. Therefore, the overall contribution of SM to the control high-fat diet is 
minimal (0.008–0.0525%, wt/wt) compared to what is found in the diets with added SM (0.258–
0.3025%, wt/wt). The amount of dietary SM provided by the 0.25% SM diets is equivalent to 
22 mg/kg of body weight in a human or roughly 1.5 g/day to a 70-kg human, based on body surface 




Table 3.1. Diet composition  
g/kg of diet 
 
CTL MSM ESM 
Casein 195 195 195 
L-Cystine 3 3 3 
Sucrose 340 340 340 
Corn Starch 56.86 56.86 56.86 
Maltodextrin 60 60 60 
Anhydrous Milk Fat 210 207.5 207.5 
Soybean Oil 20 20 20 
Cellulose 50 50 50 
Mineral Mix, AIN-93G-MX 43 43 43 
Vitamin Mix, AIN-93-VX 19 19 19 
Choline Bitartrate 3 3 3 
TBHQ 0.04 0.04 0.04 
Milk Sphingomyelin 0 2.5 0 
Egg Sphingomyelin 0 0 2.5 
 
Food intake was assessed biweekly and body weight was assessed weekly. Fresh food was 
provided on a weekly basis. After 4 weeks on experimental diets, mice were fasted for 6–8 h prior 
to blood collection by cardiac puncture following euthanasia. Blood was allowed to clot at room 
temperature for 30 min before serum was isolated by centrifugation (10,000gfor 10 min at 4°C) 
and then stored at − 80°C. Tissues were perfused with saline before being harvested, snap-frozen 
in liquid nitrogen and stored at − 80°C. The liver, skeletal muscle (quadriceps femoris), epididymal 
adipose and small intestines were collected from animals. The entire small intestine from the 
pylorus to the cecum was collected, cleaned and divided into four segments (SI-I, SI-II, SI-III and 
SI-IV) before being snap-frozen. During the last 3 days prior to sacrifice, fecal samples were 
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collected directly from the mouse into sterile tubes and stored frozen at − 20°C until analysis. All 
mice were housed in a temperature-controlled room and maintained in a 12-h light/12-h dark cycle 
at the University of Connecticut-Storrs vivarium. The Animal Care and Use Committee of the 
University of Connecticut-Storrs approved all procedures used in the current study. 
3.3.2. Serum Biochemical Analysis 
Total serum cholesterol, triglycerides, phospholipids, SM, glucose and nonesterified fatty acids 
(NEFA) were measured using enzymatic assays according to manufacturer instructions. 
Cholesterol, triglycerides, NEFA and choline-containing phospholipids (choline oxidase method) 
were measured using kits obtained from Wako Diagnostics (Richmond, VA). Serum SM was 
analyzed using an enzymatic kit obtained from Abcam (Cambridge, MA). Serum 
phosphatidylcholine (PC) was estimated by subtracting serum SM values from the serum choline-
containing phospholipid values. Glucose was measured using a hexokinase kit obtained from 
Pointe Scientific, Inc. (Canton, MI). Serum LPS was assessed by using a chromogenic limulus 
amebocyte lysate (LAL) assay (QCL-1000) obtained from Lonza (Basel, Switzerland). 
3.3.3. Hepatic Lipid Extraction and Analysis 
Hepatic lipids were extracted using methods previously reported [28]. Briefly, liver lipids were 
extracted with chloroform:methanol (2:1), dried under nitrogen at 60°C and solubilized in Triton 
X-100. The solubilized lipid isolates were analyzed for total cholesterol and triglycerides by 
enzymatic methods. 
3.3.4. RNA Isolation, cDNA Synthesis and qRT-PCR 
Total RNA was isolated using TRIzol reagent (Life Technologies, Carlsbad, CA) from liver, 
skeletal muscle, proximal small intestine (SI-I and SI-II segments) and distal small intestine (SI-
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IV segment). Total RNA was treated with DNase I and reverse transcribed using iScript cDNA 
synthesis kit (Bio-Rad, Hercules, CA). Gene expression was assessed by quantitative real-time 
polymerase chain reaction (qRT-PCR) using iTaq Universal SYBR Green Supermix (Bio-Rad) 
and a CFX96 real-time PCR detection system (Bio-Rad). Gene expression was normalized to the 
geometric mean of the reference genes, glyceraldehyde 3-phosphate dehydrogenase, β-actin and 
ribosomal protein, large, P0 using the 2− ΔΔCt method. Primer sequences used for qRT-PCR 
analysis are listed in Appendix A. 
3.3.5. Gut Permeability Analysis 
Intestinal permeability to macromolecules was examined using a low-molecular-weight (4-kDa) 
fluorescent dextran (Sigma-Aldrich, St. Louis, MO). After 4 weeks on experimental diets, mice 
were fasted for 6 h and administered fluorescein isothiocyanate (FITC)-dextran by gavage 
(600 mg/kg body weight, 125 μg/μl). After 1 h, ~ 100-μl blood was collected from the tail vein. 
Plasma was isolated, diluted 1:2 in PBS (pH 7.4) and analyzed for FITC-dextran on a fluorescence 
spectrophotometer (BioTek Instruments, Inc. Winooski, VT) at excitation 485 nm and emission 
535 nm. A standard curve was generated by diluting FITC-dextran in untreated, diluted mouse 
plasma. 
3.3.6. Gut Microbiota Analysis 
Fecal samples were collected directly from separately housed mice and submitted to the University 
of Connecticut-Storrs Microbial Analysis, Resources and Services facility for microbiota 
characterization utilizing 16S V4 analysis. DNA was extracted from 0.25 g of fecal sample using 
the MoBio PowerMag Soil 96-well kit (MoBio Laboratories, Inc., Carlsbad, CA) according to the 
manufacturer's protocol for the Eppendorf epMotion liquid handling robot. DNA extracts were 
quantified using the Quant-iT PicoGreen kit (Thermo Fisher Scientific, Waltham, MA). Partial 
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bacterial 16S rRNA genes (V4) were amplified using 30 ng extracted DNA as template. The V4 
region was amplified using 515F and 806R with Illumina adapters and golay indices on the 3′ 
end [29]. Samples were amplified in triplicate using Phusion High-Fidelity PCR master mix (New 
England BioLabs, Ipswich, MA) with the addition of 10 μg BSA (New England BioLabs). PCR 
products were pooled for quantification and visualization using the QIAxcel DNA Fast Analysis 
(Qiagen, Venlo, Netherlands). PCR products were normalized based on the concentration of DNA 
from 250 to 400 bp then pooled using the QIAgility liquid handling robot. The pooled PCR 
products were cleaned using the Gene Read Size Selection kit (Qiagen) according to the 
manufacturer's protocol. The cleaned pool was sequenced on the MiSeq using v2 2 × 250 base-
pair kit. 
Demultiplexing of the sequences was done with a custom script [30] requiring 0 
mismatches in the index sequences and Q25 minimum. Sequences were merged using SeqPrep 
then filtered for length (maximum 300 bp) before clustering into OTUs with QIIME (for exact 
commands, see https://github.com/mcnelsonphd/16S-RDS/blob/master/Qiime_Process). 
3.3.7. Statistical Analysis 
Differences between groups were evaluated by one-way ANOVA with post hoc comparisons 
(Holm-Sidak) or by independent t tests (P <.05 deemed significant). Bivariate Pearson correlations 
were used to assess relationships between variables. All statistical analyses were conducted using 
GraphPad Prism version 6 software. Data are reported as mean ± SEM. 
3.4. Results 
3.4.1. Body and Tissue Weights 
Body and tissue weights are shown in Table 1. No significant changes in food intake, week 4 body 
weight or liver weight were observed between the groups. However, MSM reduced the total 
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amount of weight gained over the 4 weeks. ESM experienced an increase in epididymal adipose 
both in absolute weight and as a percentage of body weight compared with both CTL and MSM 
groups. 
3.4.2. MSM Reduced Cholesterol, While ESM Increased Serum Lipids 
Fasting serum lipids and glucose values are presented in Table 3.2. MSM had significantly lower 
serum cholesterol (−15%) compared to CTL. In contrast, ESM had significantly higher serum 
cholesterol (+15%) and serum triglycerides (+30%) compared to CTL. Serum NEFA were 23% 
lower in both SM groups compared to CTL (P =.05). ESM had significantly elevated serum 
choline-containing phospholipids compared to CTL (+ 19%) and MSM groups (+ 31%), which 
was primarily accounted for by higher serum SM levels 
Table 3.2. Body and tissue weights of C57BL/6J mice after 4 weeks of high-fat diets 
Parameter Control Egg SM Milk SM 
Body weight (g) 29.47 ± 0.77 28.53 ± 0.68 27.26 ± 0.74 
Weight change (g)    5.14 ± 0.58a 4.48 ± 0.34ab 3.35 ± 0. 25b 
Food intake (g/day) 3.80 ± 0.20 4.08 ± 0.09 4.06 ± 0.10 
Liver weight (g) 1.19 ± 0.05 1.25 ± 0.04 1.12 ± 0.05 
% Liver weight 4.07 ± 0.20 4.14 ± 0.13 4.09 ± 0.12 
Epididymal fat (g) 0.62 ± 0.11a 0.88 ± 0.07b 0.43 ± 0.04a 
% Epididymal weight 2.05 ± 0.32a 3.07 ± 0.22b 1.44 ± 0.10a 
Each value represents the mean ± SEM of the values for n = 10 mice. Superscripts with different letters indicate 










Table 3.3. Serum markers of C57BL/6J mice after 4 weeks of high-fat diets 
Parameter Control Egg SM Milk SM 
Total cholesterol (mmol/L) 3.47 ± 0.12a 4.03 ± 0.18b 2.96 ± 0.17c 
Triglycerides (mmol/L) 0.61 ± 0.04a 0.80 ± 0.05b 0.64 ± 0.05ab 
NEFA (mmol/L) 0.68 ± 0.05 0.49 ± 0.03# 0.49 ± 0.04# 
Total phospholipids (mmol/L) 2.36 ± 0.10a 2.85 ± 0.10b 2.25 ± 0.13a 
SM (mmol/L) 1.15 ± 0.09a 1.55 ± 0.10b 1.23 ± 0.05a 
PC (mmol/L) 1.22 ± 0.09 1.29 ± 0.13 0.93 ± 0.08 
SM:PC ratio 0.845 ± 0.07 1.37 ± 0.19 1.31 ± 0.17 
Fasting glucose (mmol/L) 8.02 ± 0.66 8.59 ± 0.64 7.31 ± 0.46 
Each value represents the mean ± SEM of the values for n = 10 mice. Superscripts with different letters indicate 
differences at P <.05 using post hoc comparisons. #P =.05 vs. control using post hoc comparisons. 
 
(+25–35%). Serum SM was positively associated with serum cholesterol across groups 
(r = 0.623, p =.0002; Figure 3.1A), whereas serum PC was not correlated with serum cholesterol 
(r =− 0.011, P =.956; Figure 3.1B). No significant differences were found for fasting glucose 
levels between groups. 
Figure 3.1. Serum cholesterol is correlated with serum SM but not serum PC. Bivariate Pearson correlations 
between serum cholesterol and serum SM (A) or serum PC (B) are shown 
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3.4.3. MSM Alters Intestinal mRNA Expression of Cholesterol Transporters 
In the proximal small intestine, MSM significantly increased Niemann-Pick C1-like 1 (Npc1l1) 
mRNA compared to ESM (+110%) (Figure 3.2). Abcg5 mRNA expression was reduced by 42% 
in MSM compared to CTL. Both Npc1l1 and Abcg5 are major transporters of free cholesterol on 
the apical surface of epithelial cells. No differences were detected in the expression of genes related 
to chylomicron formation or triglyceride absorption (Figure 3.2). There were also no differences 
between groups in gene expression of tight junction-related proteins involved in gut barrier 




Figure 3.2. MSM significantly altered gene expression related with intestinal cholesterol flux. Small intestine 
mRNA was measured by qRT-PCR. Data were normalized to endogenous reference gene expression (n = 10 per 
group, mean ± SEM). ABCG5, ATP-binding cassette subfamily G member 5; APOA4, apolipoprotein A-IV; DGAT2, 
diacylglycerol O-acyltransferase 2; FABP2, fatty-acid-binding protein 2, intestinal; MTTP, microsomal triglyceride 
transfer protein; OCLN, occludin; TJP1, tight junction protein 1. Values with different superscripts are P <.05 
using post hoc comparisons. 
 
3.4.4. MSM Reduced, While ESM Increased Hepatic Lipids 
MSM reduced hepatic triglyceride accumulation by 47% compared with CTL, while ESM 
increased triglycerides by 37% (Figure 3.3A). No significant differences were observed for liver 
cholesterol between groups. MSM had significant inductions in both hepatic Srebp2 mRNA 
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(+50%) and HMG-CoA reductase (Hmgcr) mRNA (+190%) compared with CTL (Figure 3.3B), 
which may have impacted liver cholesterol via compensatory induction in cholesterol 
biosynthesis. Further within cholesterol-regulated genes, both SM groups tended to lower hepatic 
IDOL expression compared with CTL, but these changes were not significant (p = 0.1). ESM 
increased stearoyl-CoA desaturase-1 (Scd1) mRNA expression by 3-fold compared to CTL. Scd1 
is an enzyme involved in de novo lipogenesis. No other differences between groups were detected 
for mRNA expression of genes related to lipid metabolism (Srebp1c, Lxrα, Acox and Pparα), 
lipoprotein uptake (Ldlr and Pcsk9) or inflammation (Mcp1). These data show that MSM induced 
the hepatic expression of a majority of the cholesterol-responsive genes examined, while ESM 
induced Scd1 gene expression, which may explain the elevated hepatic triglycerides in this group. 
3.4.5. SM Increases Skeletal Muscle GLUT4 mRNA Expression with No Effects on Fatty Acid 
Oxidation-related Gene Expression 
Skeletal muscle (quadriceps femoris) was examined for mRNA expression of genes involved in 
lipid metabolism, inflammation and glucose disposal (Figure 3.4). Both SM-fed groups 
experienced a 3-fold increase in Glut4 mRNA. Interleukin-6 (Il-6) mRNA expression was 70% 
lower in MSM compared to CTL. There were no other differences observed between groups for 
other gene expression related to fatty acid oxidation (Acad, Acox, Pgc-1α and Lpl). 
3.4.6. MSM Reduce Serum LPS but Does Not Change Gut Permeability to FITC-dextran 
High-fat-diet feeding of mice has been shown to increase plasma LPS after only 4 weeks [3]. Since 
milk SM feeding lowered serum and liver lipids, we examined its effects on serum LPS. MSM 




Figure 3.3. MSM reduces hepatic triglycerides and alters cholesterol-responsive gene expression. Hepatic lipids were extracted 
with chloroform:methanol (2:1), dried under nitrogen at 60°C and solubilized in Triton X-100 as described in Materials and Methods. 
Cholesterol and triglyceride were measured by enzymatic methods (A) (n = 10 per group, mean ± SEM). Hepatic mRNA expression 
was measured by qRT-PCR (B). Data were normalized to endogenous reference gene expression (n = 10 per group, mean ± SEM). 
ACOX, acyl-CoA oxidase 1; IDOL, inducible degrader of the LDL receptor; LDLr, LDL receptor; LXRα, liver X receptor α; MCP1, 
monocyte chemotactic protein 1; PCSK9, proprotein convertase subtilisin/kexin type 9; PPARa, peroxisome proliferator-activated 
receptor α; SREBP1c, sterol regulatory element-binding protein 1c; SREBP2, sterol regulatory element-binding protein 2. Values with 
different superscripts are P <.05 using post hoc comparison
84 
 
(Figure 3.5A). Serum LPS was significantly associated with the amount of weight gain over the 
4 weeks (Figure 3.5B). We examined effects of milk SM on gut permeability in fasting mice by 
the appearance of FITC-dextran (4 kDa) in plasma after gavage. Gut permeability to FITC-dextran 
was 5% lower on average in MSM (Figure 3.5C); however, this was not significantly different 
compared to 
 average in MSM (Figure 3.5C); however, this was not significantly different compared to CTL. 
Therefore, coinciding with the lack of differences in small intestine tight junction- related gene 
expression (Fig. 1), it appeared that differences in serum LPS were not due to damage to the gut 
barrier. Since sphingosine has been shown to display bactericidal activity against several Gram-
negative strains [21], we next examined if there were differences in distal gut microbiota between 
MSM and CTL. 
3.4.7. MSM Alters Distal Gut Microbiota Phylogenetic Abundance and Gram-negative Bacteria 
Fecal microbiota composition from separately caged mice was examined by 16S rRNA sequence 
analysis and results are presented in Figure 3.6. Comparing the major bacterial phyla (Figure 
3.6B), MSM had significantly higher phylogenetic relative abundance of the predominately Gram-
positive Firmicutes phylum (p<0.05) and significantly lower of the Gram-negative Bacteroidetes 
phylum (p <0.05). Comparing the minor bacterial phyla (Figure 3.6C), MSM had significantly 
higher relative abundance of the Gram-positive Actinobacteria phylum (p <0.001) and less of the 
Gram-negative Tenericutes phylum (p <0.001). The relative abundance of the Gram-negative 
Proteobacteria phylum did not differ between MSM and CTL groups. LPS is a component of the 
outer membrane of the cell wall of Gram-negative bacteria. When classified based on Gram 
staining (Figure 3.6D), MSM had significantly lower relative abundance of Gram-negative 





Figure 3.4. MSM increases skeletal muscle GLUT4 and decreases IL-6 mRNA. Skeletal muscle mRNA 
(quadriceps femoris) was measured by qRT-PCR. Data were normalized to endogenous reference gene expression 
(n = 10 per group, mean ± SEM). ACAD, acyl-CoA dehydrogenase; ACOX, acyl-CoA oxidase 1; CD68, cluster of 
differentiation 68; GLUT4, glucose transporter type 4; LPL, lipoprotein lipase; PGC-1α, peroxisome proliferator-





data suggest that the lower serum LPS levels may be due to a reduction in LPS-containing Gram-
negative bacteria in the gut microbiota. At the genus level (Figure 3.6E), MSM had significantly 
higher relative abundance of the beneficial bacteria, Bifidobacterium (p <0.001), although no 
difference in relative abundance of Lactobacillus was observed between groups. Interestingly, 
MSM tended to have higher relative abundance of Bacteroides (p = 0.06), one of the few microbes 






Figure 3.5. MSM reduces serum LPS but does not influence gut permeability. Serum LPS was measured as described in Materials 
and Methods using an endpoint chromogenic LAL assay (A) (n = 10 per group, mean ± SEM). Values with different superscripts 
are P <.05 using post hoccomparisons. A bivariate Pearson correlation between serum LPS and 4-week weight change is shown (B). 
Mice (n = 6 per group, mean ± SEM) were fasted for 6 h prior to a gavage of 4 kDa FITC-dextran (600 mg/kg body weight, 125 μg/μl) 





High-fat diet has been shown to induce dyslipidemia [32] and gut dysbiosis [33], which are both 
associated with the development of diet-induced obesity. Sphingolipids are bioactives found in 
food, which have been shown to reduce lipid absorption in rodents [15–18] and have potential to 
alter gut microbiota [21]. In this study, C57BL/6J mice were fed SM derived from milk or egg for 
4 weeks and then studied for effects on lipid metabolism. Surprisingly, egg SM increased several 
serum lipids and hepatic triglycerides. In contrast, milk SM was shown to reduce serum 
cholesterol, serum LPS and hepatic triglycerides. Serum LPS can be influenced by differences in 
gut microbiota [8], chylomicron production [6] and differences in gut permeability [7]. In this 
study, milk SM was shown to alter the gut microbiota, although no differences were found for in 
vivo gut permeability in the fasted state. This study suggests that milk SM can ameliorate the 
negative metabolic effects of a high-fat diet in mice. 
SM and its hydrolytic byproducts have been shown to reduce the intestinal absorption of 
cholesterol, triglycerides and fatty acids in rodents [15–18,20]. SM interacts with high affinity to 
cholesterol and is thought to influence its micellar solubilization. Eckhardt et al. [17] observed that 
feeding mice diets with milk SM at 0.1%, 0.5% or 5% (wt/wt) reduced intestinal cholesterol 
absorption measured by dual-isotope method by approximately 20%, 54% and 86%, respectively. 
Intestinal hydrolysis of SM is initiated by alkaline sphingomyelinase that hydrolyzes the 
phosphorylcholine head, resulting in ceramide [34]. Alkaline sphingomyelinase is inhibited by 
acylglycerides (monoglycerides, diglycerides and triglycerides), free fatty acids, cholesterol and 
ceramide [35], all of which are highly present in the duodenum and proximal jejunum where the 
majority of lipid  absorption occurs. Feng et al. [36] showed that ceramide and sphingosine can 
also inhibit the absorption of cholesterol by Caco-2 cells. Ceramide is a major signal for apoptosis 
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and is shown to be beneficial in reducing chemically induced colorectal cancer [37]. Neutral 
ceramidase functions through hydrolysis of the fatty acid ester linkage of ceramide, releasing the 
sphingoid backbone, which is predominantly sphingosine [38]. Sphingosine may act as an 
antimicrobial [21] and is absorbed in higher quantities than ceramide and SM [39]. As SM moves 
down the intestinal tract, the activity of sphingomyelinase and ceramidase will increase due the 
depletion of luminal lipids. This would likely result in the cecal and colonic bacteria being exposed 
to appreciable levels of sphingosine and ceramide. 
In the current study, MSM decreased (−15%) total serum cholesterol compared to the high-fat control. In 
contrast, ESM increased cholesterol (+15%), triglycerides (+30%), SM (+ 35%) and total phospholipids 
(+20%). Serum lipids in mice fed dietary sphingolipids has been shown to decrease [18], not change [40], 
and even increase in some studies [41]. Li et al. [41] reported that feeding LDLr−/− mice for 12 weeks a 
modified AIN-76A diet supplemented with 1% (wt/wt) ox brain sphingolipids (28% SM) increased plasma 
cholesterol (+ 62%), plasma SM (+50%) and aortic atherosclerosis. Recently, Chung et al. [40] reported 
that egg SM feeding (0.6%, wt/wt) for 18 days reduced hepatic lipid levels and increased fecal cholesterol 
output in mice fed a high-fat diet (21% by weight butter fat; 0.15% by weight added cholesterol). Chung et 
al. [40] also reported that egg SM feeding led to an ~ 30% reduction in cholesterol absorption, although it 
did not affect plasma cholesterol or triglyceride levels. Duivenvoorden et al. [18] observed significant  
reductions in plasma cholesterol and triglycerides when 0.2–0.4% egg SM (wt/wt) was added to a 
Western-type diet (15% by weight cocoa butter; 0.25% by weight cholesterol added)and fed to 
APOE3*Leiden female mice for 3 weeks. Overall, studies in mice where large amounts of cholesterol were 
added to diets in addition to sphingolipids displayed reductions in serum cholesterol and hepatic lipids, 
whereas those that did not observed elevations in serum and hepatic lipids (including the current study). 




Figure 3.6. MSM group distal gut microbiota has significantly reduced Gram-negative bacteria. Fecal samples were collected 
directly from separately housed mice and microbiota composition was assessed by 16S rRNA sequencing as described in Materials and 
Methods. Phyla phylogenetic abundance (% of total sequences) of individual mice (A). Phylogenetic relative abundance of major phyla 
Firmicutes and Bacteroidetes (B), and minor phyla Actinobacteria, Tenericutes and Proteobacteria (C). Relative abundance of Gram-
negative and Gram-positive phyla (D). Relative abundance of Bifidobacterium, Lactobacillus and Bacteroides genera (n = 3 per group, 
mean ± SEM, *P <.05 using t test).
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 may require excess dietary cholesterol to influence serum cholesterol and hepatic lipids. Another 
explanation for discrepancies in serum and hepatic cholesterol responses in the studies discussed 
may be due to the different strains of mice used (i.e., wild type or transgenic). Recently, 
Ramprasath et al. [42] reported that 4-week supplementation of milk SM (1 g/day) in healthy 
humans significantly increased plasma HDL-C in a small crossover study (n = 10), although no 
effects on non-HDL-cholesterol and cholesterol absorption were found. Lack of effects of milk 
SM on cholesterol absorption in this human study may be related to greater SM digestion 
efficiency in humans compared with rodents [19] or potentially related to the healthy population 
examined. 
The differences in serum cholesterol between groups were supported by changes in 
cholesterol-regulated gene expression in the proximal intestine. Intestinal NPC1L1 mRNA, which 
was increased in MSM (+110% vs. ESM), is responsible for cholesterol uptake at the apical 
membrane of intestinal epithelial cells. Intestinal NPC1L1 mRNA has been shown to be reduced 
by excessive cellular cholesterol and induced by cholesterol depletion [43]. ABCG5, which was 
reduced in MSM (-42% vs. CTL), constitutes half of the ABCG5/8 heterodimer that enables free 
cholesterol and phytosterol efflux from the intestinal cell back into the lumen [44]. The observed 
changes in the gene expression of these transporters in MSM-fed mice suggest that the intestines 
were compensating for cellular cholesterol depletion, likely due to lower cholesterol absorption. 
Noh and Koo [15,16] reported that dietary egg SM and milk SM could both acutely reduce 
intestinal lipid absorption in rodents, with milk SM being a more potent inhibitor [16]. 
Inhibition of intestinal cholesterol absorption through ezetimibe, a pharmacological 
inhibitor of NPC1L1, can lower serum cholesterol levels and reduce hepatic lipids in mice [45]. 
The current study demonstrated significantly lower triglycerides in MSM livers (−47%) and higher 
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in ESM (+37%), compared to CTL. Hepatic cholesterol biosynthesis may have increased with SM 
treatment, suggested by the 190% increase in HMGCR mRNA in MSM and the increasing trend 
(p=0.07) in ESM. Additionally, hepatic mRNA expression of SREBP2, a transcription factor that 
induces genes for cholesterol biosynthesis, was increased in MSM (+54% vs. ESM, 51% vs. CTL). 
In this study, compensatory increases in cholesterol biosynthesis potentially masked differences 
in hepatic cholesterol levels between groups. Interestingly, egg SM increased hepatic SCD1 
mRNA (+189% vs. CTL), which was not seen with milk SM feeding. SCD1 is involved in de 
novo lipogenesis, enhancing hepatic triglyceride formation [32]. 
Skeletal muscle GLUT4 expression increased in ESM (+172%) and MSM (+ 162%) 
compared to CTL. Skeletal muscle GLUT4 expression is regulated by the transcription factor 
myocyte enhancer factor 2 (MEF2) [46]. PGC-1α serves as a coactivator of MEF2 transcriptional 
activity and has been shown to participate in an autoregulatory loop where it induces PGC-1α 
expression in skeletal muscle [47]. Milk SM (0.2% by weight) fed for 12 weeks to BALB/c mice 
was reported to increase endurance capacity, associated with induction of skeletal muscle PGC-1α 
mRNA [48]. We did not observe a change in PGC-1α at the mRNA level, which may be due to 
differences in background diet, duration or strain of mice. There is also a possibility that PGC-1α 
coactivator activity was altered, which we did not measure. Further studies examining the effects 
of dietary SM on skeletal muscle lipid and glucose metabolism are warranted. 
In the current study, milk SM reduced serum cholesterol and NEFA (p =0.05), suggesting 
a reduction in dietary lipid absorption. Dietary lipid absorption may increase the translocation of 
gut-derived LPS by enhancing transcellular transport via chylomicrons secretion [6] and/or 
paracellular leakage across the gut barrier [7]. Based on these relationships, it is not surprising that 
we observed 35% lower serum LPS in MSM compared to CTL. This difference did not appear to 
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be due to differences in fasting gut permeability. LPS is a major constituent of the outer membrane 
of cell walls of Gram-negative bacteria. Sphingosine has been shown to have strong bactericidal 
effects on Gram-negative and Gram-positive bacterial pathogens in vitro [21]. As dietary SM is 
slowly digested and absorbed, it is likely that much of it reaches the colon where bacteria are most 
abundant. Remarkably, dietary milk SM strongly altered fecal phyla composition, with 
significantly reduced relative abundance of Gram-negative phyla, such as Bacteroidetes and 
Tenericutes, and reciprocal increases in predominately Gram-positive phyla, such as Firmicutes 
and Actinobacteria. Interestingly, one study reported that nonobese mice fed a high-fat diet, which 
are diabetes-resistant, have lower plasma LPS and gut permeability and increased cecal Firmicutes 
and Actinobacteria than diabetes-prone mice [49]. Notably, milk-SM-fed mice had significantly 
greater relative abundance of fecal Bifidobacterium, a genus of mutualistic “beneficial” bacteria. 
Fecal Bifidobacterium are known to be dramatically reduced in mice fed high-fat diets, and 
selective increases are associated with reduced plasma LPS and improvements in metabolic 
parameters in mice [50]. Bifidobacteria can protect against enteropathogens [51] and are well 
known to ferment prebiotic oligosaccharides and increase the production of short-chain fatty acids 
(SCFA) in the colon [52]. In addition to bifidobacteria, milk-SM-fed mice tended to have higher 
relative abundance of fecal Bacteroides (p =0.06), one of the few microbes that synthesize and 
utilize sphingolipids [31]. Species of the Bacteroides genus are also known to ferment prebiotics 
to SCFA [52], with some species shown to prevent metabolic complications of obese mice induced 
with a high-fat diet when used as a probiotic [53]. 
The current study has several strengths. We used purified, natural sources of milk and egg 
SM (> 99% pure), as opposed to a mixed phospholipid concentrate or milk globule membrane 
extract, which have been studied previously [54,55]. Thus, using purified SM allows us to attribute 
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the effects observed on lipid metabolism and gut microbiota directly to the additional dietary SM 
ingestion. We also examined effects of dietary SM on markers of metabolic endotoxemia and gut 
microbiota, which to our knowledge have never been reported. Although egg SM did not reduce 
serum LPS, we did not examine effects of egg SM on gut permeability and gut microbiota, which 
could be a limitation of the current study. The dose chosen for this study roughly equates to an 
amount of SM (1.5 g/day) which is above the estimated sphingolipid intake (300–400 mg/day) of 
Western diets. This high dosage may also be a limitation. However, it is possible that this dose 
could be achievable through supplementation or through careful selection of SM-rich foods. 
Overall, we observed significant differences in the effects of milk SM and egg SM on lipid 
metabolism in mice fed a high-fat diet. Milk SM reduced serum cholesterol and altered gene 
expression consistent with intestinal and hepatic cholesterol depletion. Milk SM also reduced 
hepatic triglycerides and induced gene expression associated with cholesterol biosynthesis. 
Unexpectedly, egg SM increased several serum lipids and hepatic triglycerides. A possible 
explanation for the increase in lipids in egg-SM-fed mice was increased hepatic de 
novo lipogenesis; however, the mechanism is not yet clear. Both SM groups demonstrated a strong 
induction of GLUT4 mRNA in skeletal muscle, suggesting an increase in glucose utilization. Milk 
SM also significantly lowered serum LPS and was associated with bifidogenic effects and 
alterations in distal gut microbiota. In conclusion, milk SM appears to have beneficial effects in 
protecting against the deleterious effects of a high-fat diet in mice. Further research is warranted 
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Western-type diets can induce obesity and related conditions such as dyslipidemia, insulin 
resistance, and hepatic steatosis. We evaluated the effects of milk sphingomyelin (SM) and egg 
SM on diet-induced obesity, the development of hepatic steatosis, and adipose inflammation in 
C57BL/6J mice fed a high fat, cholesterol-enriched diet for 10 weeks. Mice were fed either a low-
fat diet (10% kcal from fat) (LFD, n = 10), a high fat diet (60% kcal from fat) (HFD, n = 14), or a 
high fat diet modified to contain either 0.1% (w/w) milk SM (HFMSM, n = 14) or 0.1% (w/w) egg 
SM (HFESM, n = 14). After 10 weeks, egg SM ameliorated weight gain, hypercholesterolemia, 
and hyperglycemia induced by HFD. Both egg SM and milk SM attenuated hepatic steatosis 
development, with significantly lower hepatic triglycerides (TG) and cholesterol relative to HFD. 
This reduction in hepatic steatosis was stronger with egg SM supplementation relative to milk SM. 
Reductions in hepatic TG observed with dietary SM were associated with lower hepatic mRNA 
expression of PPARγ-related genes; Scd1 and Pparg2 in both SM groups, and Cd36 and Fabp4 
with egg SM. Egg SM, and to a lesser extent milk SM, reduced inflammation and markers of 
macrophage infiltration in adipose tissue. Egg SM also reduced skeletal muscle TG content 
compared to HFD. Overall, the current study provides evidence of dietary SM improving 
metabolic complications associated with diet-induced obesity in mice. Further research is 
warranted to understand the differences in bioactivity observed between egg and milk SM. 
4.2. Introduction 
The National Center for Health Statistics reported that 36.5% of American adults were considered 
obese from 2011-2014 [1]. Obesity can contribute to the development of several non-
communicable diseases, including non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes 
mellitus (T2DM). Concurrent with rises in obesity and an aging population, the prevalence of 
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T2DM and NAFLD have increased dramatically in recent decades [2, 3]. Obesity, particularly 
abdominal obesity, is often accompanied by chronic low-grade inflammation in both adipose tissue 
and systemic circulation, which may result in metabolic abnormalities such as insulin resistance 
[4, 5]. Localized adipose tissue inflammation is thought to arise from a dysfunction in the normal 
metabolic handling of nutrients by adipocytes, as a consequence of excessive adipocyte 
enlargement, insulin resistance, and infiltration of adipose tissue with macrophages [4, 5]. Insulin 
resistance and metabolic defects in lipid metabolism are associated with NAFLD, related to an 
increased flux of non-esterified fatty acids (NEFA) from inflamed adipose tissue to the liver [6]. 
NAFLD consists of a broad spectrum of conditions occurring in the absence of alcohol use, 
including steatosis, non-alcoholic steatohepatitis (NASH), and liver cirrhosis. Hepatic steatosis 
has been estimated to be present in over two-thirds of the obese population [7-9]. Simple steatosis 
is relatively benign; however, once steatosis has developed, the liver is “sensitized” to various 
inflammatory stimuli, which can precipitate NASH [10]. Consequently, NASH can progress to 
cirrhosis and may result in hepatocellular carcinoma or liver failure [11]. Currently, there is a lack 
of effective management options for NAFLD besides weight reduction, which can be difficult to 
maintain long-term. 
Dietary lipids, such as cholesterol and triglycerides (TG), have been shown to exacerbate 
adipose tissue inflammation and NAFLD in animal models [12-16]. Dietary phospholipids, 
however, are a potential source of bioactive lipids which may improve cardiometabolic health [17]. 
Dietary sphingomyelin (SM), a sphingolipid found exclusively in animals, has been shown to dose-
dependently reduce the absorption of cholesterol, TG, and fatty acids both in vitro [18, 19] and in 
rat models [20, 21]. Although dietary SM is often overlooked, it demonstrates potential to 
influence chronic diseases, such as obesity and NAFLD. Only a few studies have evaluated the 
102 
 
effects of chronic dietary SM intake on lipid metabolism in rodents [22-25]. Little is known about 
an optimal intake of SM and whether an increased dietary intake of SM is beneficial to health. 
Consumption of dietary sphingolipids in Western diets is relatively common (0.3-0.4 g/day) and 
comes mainly from animal-based foods, including eggs and dairy [26, 27]. 
Previously, Chung et al. [22] reported that supplementation with egg-derived SM at 0.3%, 
0.6%, and 1.2% (w/w) reduced hepatic TG in a dose-dependent manner in mice on a 4-week 
Western-type diet. We have recently reported that dietary milk-derived SM (0.25% w/w) reduced 
both serum lipids and hepatic TG in mice on a 4-week high fat diet (HFD) [23]. However, since 
both studies were relatively short term, the efficacy of dietary SM in preventing diet-induced 
obesity, adipose tissue inflammation, and hepatic steatosis were not fully examined. Furthermore, 
egg SM and milk SM differ in their amide-linked fatty acid and sphingoid base compositions [28-
30], and therefore, may have different biological effects on lipid metabolism in vivo [21, 23]. Thus, 
the current study evaluated the effects of dietary SM from both egg and milk on hepatic steatosis 
and obesity in C57BL/6J mice fed a cholesterol-enriched HFD for 10 weeks. We hypothesized 
that both sources of dietary SM would attenuate hepatic steatosis and obesity development, due to 
their abilities to inhibit lipid absorption. Furthermore, we expected milk SM to be more effective 
than egg SM, based on its greater potency to inhibit lipid absorption in rodent models [21]. 
4.3. Materials and Methods 
4.3.1 Animals and Diets 
Male C57BL/6J mice (6 weeks old) were obtained from Jackson Laboratory (Bar Harbor, ME) 
and allowed to acclimate for 2 weeks before being fed 1 of 4 lard-based diets for 10 weeks: low 
fat diet control (LFD; 10% kcal from fat; n = 10); high fat, high cholesterol diet control (HFD; 
60% kcal from fat, 0.15% cholesterol added by weight; n = 14); HFD modified to contain 0.1% of 
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milk SM added by weight (HFMSM; n = 14); or HFD with 0.1% of egg SM added by weight 
(HFESM; 60% kcal from fat; n = 14). Diet composition details are provided in Table 4.1. 
Experimental diets were made using ingredients obtained from Dyets, Inc. (Bethlehem, PA). Milk 
SM (bovine; >99% purity) and egg SM (chicken egg; >99% purity) powders were obtained from 
Avanti Polar Lipids, Inc. (Alabaster, AL) and were substituted for an equal weight of lard in their 
respective experimental groups. Fatty acid composition varied between the milk SM (34% C23:0, 
21% C24:0, 20%, C22:0, 16% C16:0, 3% C24:1 and 6% unknown) and egg SM (86% C16:0, 6% 
C18:0, 3%, C22:0, 3% C24:1 and 2% unknown) powders. Egg SM and milk SM also vary in the 
distribution of sphingoid bases; egg SM contains almost entirely sphingosine (d18:1) bases, while 
milk SM contains a more varied distribution (d16:0 to d19:0) [30]. Based on body surface 
normalization and accounting for weight gain throughout the study, the experimental diets 
provided the equivalent of consuming approximately 405-670 mg/day in a 70 kg human [31]. 
Fresh food was provided biweekly and mice were allowed to eat ad libitum. Body weights 
were recorded on a weekly basis, while food intake was estimated biweekly. After 10 weeks on 
their respective diets, mice were fasted for 6-8 hours prior to blood collection by cardiac puncture 
following euthanasia. Blood was allowed to clot at room temperature for 30 minutes before serum 
was isolated by centrifugation (10,000 x g for 10 minutes at 4°C) and then stored at -80°C. Tissues 
were perfused with sterile saline before being harvested, snap-frozen in liquid nitrogen and stored 
at -80˚C. The liver, skeletal muscle (quadriceps femoris), and epididymal adipose tissues were 
collected from animals. Pieces of liver were harvested from the left lateral lobe for histology and 
lipid analysis. Liver and epididymal adipose tissues were fixed in 10% neutral-buffered formalin 
for at least 48 hours prior to histological processing. Mice were housed in the University of 
Connecticut-Storrs vivarium in a temperature-controlled room and maintained in a 12-hour 
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light/12-hour dark cycle. The Animal Care and Use Committee of the University of Connecticut-
Storrs approved all procedures used in the current study. 
Table 4.1. Diet composition     
Diet Component 
 (g/kg)  
  LFD HFD 
HFMSM / 
HFESM 
Casein 210 265 265 
L-Cystine 3 4 4 
Corn Starch 467 0 0 
Maltodextrin 100 0 0 
Sucrose 90 253.5 253.5 
Lard 20 310 309 
Soybean Oil  20 30 30 
Cellulose 37.15 64 64 
Mineral Mix, AIN-93G-MX (94046) 35 48 48 
Vitamin Mix, AIN-93-VX (94047)  15 21 21 
Choline Bitartrate 2.75 3 3 
Cholesterol 0 1.5 1.5 
Milk or Egg Sphingomyelin 0 0 1 
 
4.3.2. Serum Biochemical Analysis 
Total serum cholesterol, TG, NEFA, liver enzymes, and glucose concentrations were measured 
using commercial assays according to manufacturer instructions. Serum cholesterol, NEFA, and 
TG were measured using enzymatic kits obtained from Wako Diagnostics (Richmond, VA). 
Fasting glucose, serum alanine transaminase (ALT), and aspartate transaminase (AST) were 
measured using kits obtained from Pointe Scientific, Inc. (Canton, MI). Serum insulin and C-C 
motif chemokine ligand 2 (CCL2) were measured by ultra-sensitive ELISA (Crystal Chem, Inc., 
Downers Grove, IL) and magnetic bead-based assay (EMD Millipore, Billerica, MA), 
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respectively. The homeostasis model assessment (HOMA-IR) equation was used to estimate 
insulin resistance based on fasting serum insulin and glucose concentrations [32]. 
4.3.3. Tissue Lipid Extraction and Analysis 
Hepatic and skeletal muscle lipids were extracted using a modified Folch method as previously 
reported [33], with solubilization and enzymatic analysis of lipid extracts by the methods of Carr 
et al. [34]. Briefly, tissue lipids were extracted with chloroform:methanol (2:1), dried under 
nitrogen, and solubilized in Triton X-100. The solubilized lipid extracts were analyzed for total 
cholesterol (TC), free cholesterol (FC), choline-containing phospholipids (PL), and TG by 
enzymatic methods. Cholesteryl ester (CE) mass was calculated as (TC – FC) X 1.67 to account 
for the fatty acid moiety contribution to CE [35]. 
4.3.4. Tissue Histology 
Formalin-fixed liver and epididymal adipose tissues were embedded in paraffin and cut into 5-μm 
sections prior to staining with hematoxylin and eosin (H&E). All histological procedures were 
conducted at the Connecticut Veterinary Medical Diagnostic Laboratory (Storrs, CT). The stained 
tissue sections were viewed under bright field microscopy at ×200 magnification and images were 
taken with an AxioCam ICc3 camera (Zeiss, Thornwood, NY, USA). The infiltration of 
macrophages into adipose tissue was assessed by the counting of crown-like structures (3 slides 
per animal) by a technician blinded to group assignment. 
4.3.5. RNA Isolation, cDNA Synthesis, and Real Time qRT-PCR 
Total RNA from liver, epididymal adipose, and skeletal muscle was isolated using TRIzol reagent 
(Life Technologies, Carlsbad, CA). Total RNA was treated with DNase I, and reverse transcribed 
using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Real-time qRT-PCR was performed 
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using iTaq Universal SYBR Green Supermix (Bio-Rad) on a CFX96 real-time PCR detection 
system (Bio-Rad). For liver, gene expression was normalized to the geometric mean of the 
reference genes, glyceraldehyde 3-phosphate dehydrogenase (Gapdh) and beta actin, using the 2-
ΔΔCt method. The geometric mean of Gapdh and ribosomal protein, large, P0 (36B4) was used as 
a reference gene control for both adipose tissue and skeletal muscle. Primer sequences used for 
qRT-PCR analysis are listed in Appendix A. 
4.3.6. SDS-PAGE and Immunoblotting 
Hepatic protein was isolated and analyzed by SDS-PAGE and immunoblotting as previously 
described [36]. Briefly, livers were homogenized in a tissue lysate RIPA buffer (Cell Signaling 
Technologies, Beverly, MA) containing 2 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma 
Aldrich, St. Louis, MO). Total protein concentrations of the lysates were determined by 
bicinchoninic acid (BCA) assay (Cell Signaling Technologies). Sixty µg of total protein was mixed 
with loading buffer containing dithiothreitol (DTT) (BioRad) and loaded onto 4-20% SDS Stain-
Free gels (BioRad). Gels were activated using the Stain-Free protocol on a ChemiDoc XRS+ 
imager (BioRad). Protein was then transferred to a PVDF membrane (Thermo Fisher Scientific, 
Waltham, MA) through a semi-dry protocol using a Trans-Blot Turbo System (BioRad). Stain-
Free blot images were captured and membranes were blocked for 1 hour at room temperature with 
blocking buffer (20 mM Tris base, 150 mM NaCl, 0.05% Tween-20, 5% w/v non-fat dry milk). 
Primary rabbit anti-mouse PPARγ antibody was obtained from Santa Cruz Biotechnology (Dallas, 
TX), diluted according to manufacturer’s recommendation, and incubated overnight at 4°C. After 
washing the membrane with TBS buffer (20 mM Tris base, 150 mM NaCl, 0.05% Tween-20), a 
1:10,000 dilution of secondary HRP-anti-rabbit antibody (Thermo Fisher Scientific) was incubated 
with the membrane at room temperature for 1 hour. Pierce ECL Western Blotting Substrate 
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(Thermo Fisher Scientific) was used for the final imaging of the blot. PPARγ relative abundance 
was quantified after standardizing to total protein images obtained from the Stain-Free blot using 
ImageLab Software V5.1 (BioRad). 
4.3.7. Statistical Analysis 
Differences between groups were evaluated by one-way ANOVA with post hoc comparisons 
(Holm-Sidak). Bivariate Pearson correlations were used to assess relationships between variables. 
All statistical analyses were conducted using GraphPad Prism version 6 software. Data are 
reported as mean ± SEM. 
4.4. Results 
4.4.1. Egg SM Reduced HFD-induced Weight Gain and Increases in Adiposity 
Ten weeks of a high fat, high cholesterol diet induced significant gains in body weight, epididymal 
fat, and liver weight in the HFD control group compared to LFD (Figure 4.1). Egg SM 
supplementation attenuated these effects, significantly decreasing body weight (Figure 4.1B) and 
epididymal fat pad mass (Figure 4.1D) compared to HFD by 14% and 19%, respectively. Liver 
weight tended to be lower in HFESM compared to HFD, however, the weight change did not reach 
statistical significance (Figure 4.1D). No differences were observed in food intake (Figure 4.1C) 
between HFD groups. 
4.4.2. Egg SM Reduced Serum Total Cholesterol and Fasting Glucose 
Serum lipids and glycemic markers are presented in Table 4.2. Serum cholesterol (+135%), fasting 
glucose (+108%), fasting insulin (+340%), and HOMA-IR (+848%) were significantly increased 
with HFD relative to LFD. Supplementation of egg SM significantly reduced serum cholesterol (-



















Figure 4.1. Egg SM reduces body weight and epididymal fat with no change in food intake. Body weight was assessed weekly (A, 
B). Food intake (C) was measured biweekly and daily food intake calculated. Wet tissue weights were taken at the time of sacrifice (D). 
Each value represents the mean + SEM for n = 10 mice for low fat diet control (LFD) and n = 13-14 mice each for high fat diet control 
(HFD), HFD + milk SM (HFMSM), and HFD + egg SM (HFESM). Mean values with unlike letters indicate differences at P < 0.05 
using post hoc comparisons.
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both dietary SM groups compared to HFD. No significant differences were detected in serum 
TG, fasting insulin, or HOMA-IR between HFD groups. 
Table 4.2. Serum markers of C57BL/6J mice after 10 weeks of diets. 
Each value represents the mean ± SEM of the values for n = 10-14 mice. NEFA, non-esterified 
fatty acids; HOMA-IR, homeostasis model assessment-insulin resistance. Superscripts with 
different letters indicate differences at p < 0.05 using post-hoc comparisons. 
 
4.4.3. Dietary SM Attenuated HFD-induced Hepatic Steatosis and Reduced PPARγ-related mRNA 
Expression 
H&E stained livers showed extensive lipid droplet accumulation in the HFD group (Figure 4.2A). 
Milk SM attenuated the accumulation of hepatic lipid droplets compared to HFD, while egg SM 
further reduced the hepatic steatosis observed with HFD. These observations were confirmed by 
liver lipid analysis; HFD significantly increased hepatic TG, TC, and CE compared to LFD 
(Figure 4.2B). Egg SM strongly reduced hepatic TG (-60%) compared to HFD, while milk SM 
lowered hepatic TG to a lesser extent (-33%). Both dietary SM groups lowered hepatic TC and CE 
by ~25-30%. HFD increased serum ALT (+43%) compared to LFD, but this effect was not 
significantly altered by dietary SM (Figure 4.2C).  
Parameter LFD HFD HFMSM HFESM 
Total Cholesterol 
(mmol/L) 1.94 ± 0.09
a 4.56 ± 0.27
b 4.33 ± 0.33b 3.54 ± 0.26c 
Triglycerides 
(mmol/L) 0.29 ± 0.03 0.29 ± 0.03
 0.36 ± 0.05 0.38 ± 0.04 
NEFA (mmol/L) 0.44 ± 0.06a 0.46 ± 0.07a 0.28 ± 0.02b 0.31 ± 0.02b 
Fasting Glucose 
(mmol/L) 8.86 ± 0.61
a 18.48 ± 1.68b 16.03 ± 0.66bc 13.24 ± 0.73c 
Insulin (ng/mL) 0.15 ± 0.01a 0.66 ± 0.09b 0.53 ± 0.06b 0.55 ± 0.10b 

















Figure 4.2. Dietary SM attenuates hepatic steatosis and reduces hepatic PPARγ-related gene expression. Liver sections were 
formalin-fixed, sectioned and H&E stained (A) for visualizing hepatic steatosis. Liver lipids were extracted using a modified Folch 
extraction and measured by enzymatic methods (B), (triglycerides, TG; total cholesterol, TC; cholesteryl ester, CE; free cholesterol, FC; 
choline-containing phospholipids, PL) (n = 10-14 per group, mean + SEM). Serum activities of hepatic enzymes (alanine transaminase, 
ALT; aspartate transaminase, AST) were determined using a kinetic assay (C) (n = 10-14 per group, mean + SEM). Hepatic mRNA 
expression was determined using real-time qRT-PCR and standardized to the geometric mean of Gapdh and β-actin reference genes 
using the 2
(-ΔΔCt)
 method (D) (n = 13-14 per group, mean + SEM). Mean values with unlike letters indicate differences at P < 0.05 using 
post hoc comparisons.  
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Compared to HFD, both egg SM (-54%) and milk SM (-33%) significantly reduced Pparg2 
mRNA (Figure 4.2D). This corresponded with reductions in the expression of PPARγ target genes 
related to TG accumulation; Scd1 was reduced in both SM groups, while Cd36 and Fabp4 (p = 
0.05) were reduced in egg SM. Egg SM also reduced Ccl2 mRNA expression compared to HFD 
(p = 0.05). No other significant differences were detected in the hepatic expression of other 
lipogenic or gluconeogenic genes. Hepatic Pparg2, Scd1, and Cd36 mRNA expression were 
significantly associated with hepatic TG among all mice fed HFD (Figure 4.3). Thus, changes in 
the expression of these genes were associated with hepatic steatosis. However, there were no 
significant differences in PPARγ protein abundance between HFD-fed groups; milk SM tended to 
be higher, while egg SM tended to be lower than HFD control (Figure 4.4A,B,C). Total PPARγ 
protein abundance had no correlation with hepatic TG (Figure 4.4D). Thus, inconsistent findings 
with hepatic PPARγ protein across SM-fed groups suggests that differences in the expression of 
PPARγ target genes may be related to altered PPARγ activity, or possibly due to other 
transcriptional regulators. 
Figure 4.3. Hepatic PPARγ-related lipogenic gene expression positively correlates with 
hepatic TGs. Pearson correlations between hepatic Pparg2 (A), Scd1 (B) and Cd36 (C) mRNA 




Figure 4.4. Dietary SM does not alter total PPARγ protein in liver. Hepatic PPARγ protein expression was visualized by 
immunoblotting. (A), and total protein was imaged from Stain-Free protein blot (B). Quantitative relative abundance was measured 
through densitometry analysis (C) after normalizing to Stain-Free total protein images. Each value represents the mean ± S.E.M. for n 
= 12 mice per group. Pearson correlation of total hepatic PPARγ protein with hepatic TGs for HFD, HFMSM and HFESM (D)
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4.4.4. Dietary Egg SM, and to a Lesser Extent Milk SM, Reduces Epididymal Adipose Tissue 
Inflammation 
 Compared to LFD, the HFD control group showed a noticeable enlargement in adipocyte 
size and increased macrophage infiltration into epididymal adipose tissue, indicated by the number 
of crown-like structures (CLS) (Figure 4.5A,B). The number of CLS was markedly attenuated 
with egg SM feeding (-68%) but was unchanged with milk SM feeding (Figure 4.5B). However, 
both dietary SM fed groups significantly reduced serum CCL2 compared to HFD control (Figure4. 
5C). Compared to HFD control, markers of macrophage infiltration were reduced with egg SM 
feeding (F4/80, Cd68, Cd11c) and to a lesser extent milk SM (F4/80) (Figure 4.5D). For 
inflammatory gene expression, egg SM reduced both Ccl2 and Tnfa mRNA, whereas milk SM 
only reduced Tnfa. Egg SM also increased the expression of GLUT4 and adiponectin (Adipoq) 
mRNA, genes that are regulated by PPARγ and CCAAT/enhancer-binding protein alpha 
(C/EBPα). Correspondingly, egg SM significantly increased C/EBPα (Cebpa) mRNA and tended 
to increase PPARγ (Pparg) mRNA (p = 0.07). Overall, markers of adipose tissue inflammation 
were reduced with egg SM feeding and to a lesser extent with milk SM. 
4.4.5. Dietary Egg SM Reduces Skeletal Muscle Lipid Accumulation Induced by HFD 
Total lipids were extracted from skeletal muscle (quadriceps femoris) and examined for TG 
content. HFD significantly increased TG concentration of muscle, whereas only egg SM attenuated 
this effect (Figure 4.6A). Both dietary SM groups had significantly lower expression of β-
oxidative genes in muscle compared to HFD (Figure 4.6B), whereas only egg SM reduced Cd36 
and Acad expression. No differences were observed for GLUT4 and Lpl mRNA expression 
















Figure 4.5. Dietary SM attenuates inflammation in adipose tissue. Epididymal adipose tissue sections were formalin-fixed, sectioned 
and H&E stained (A). Crown-like structures (CLS) were manually counted from adipose H&E stains and averaged across 3 random 
200X high-powered fields (HPF) (B) (n = 4 per group, mean + SEM). Serum CCL2 was determined by magnetic bead-based assay (C) 
(n = 13-14 per group, mean + SEM). Epididymal adipose tissue mRNA expression was determined using real-time qRT-PCR and 
standardized to the geometric mean of Gapdh, 36B4, and β-actin reference genes using the 2
(-ΔΔCt)
 method (D) (n = 13-14 per group, 




High fat and cholesterol-enriched diets have been linked with the development of obesity, hepatic 
steatosis, and dyslipidemia in animal models [12-15]. Sphingolipids are dietary bioactives shown 
to reduce lipid absorption and alter lipid metabolism both in vitro and in rodent models [18-25]. 
In the current study, we examined the development of diet-induced obesity and hepatic steatosis 
in mice while supplementing with dietary SM. Both dietary egg SM and milk SM supplementation 
were able to attenuate the development of hepatic steatosis. Hepatic TG reductions were confirmed 
with histological changes in steatosis and reductions in PPARγ-related gene expression. Adipose 
tissue inflammation and markers of macrophage infiltration were also decreased with dietary SM. 
Contrary to our hypothesis, egg SM reduced serum cholesterol, adipose tissue inflammation, 
hepatic TG, and skeletal muscle TG more effectively than milk SM. Overall, the current findings 
show dietary SM can attenuate hepatic steatosis and adipose tissue inflammation observed with 
diet-induced obesity, with a substantial difference in potency between egg SM and milk SM. 
In the current study, egg SM attenuated hypercholesterolemia and hyperglycemia induced 
by HFD. Dietary SM is well-documented to acutely reduce cholesterol absorption [18-21], and in 
some cases, the absorption of other lipids and fat-soluble compounds [20, 21].  This inhibitory 
effect provides the rationale for studies examining chronic intake of dietary SM and lipid 
homeostasis [22-25]. We predicted that milk SM would be more effective than egg SM in 
preventing diet-induced obesity complications, based on previous studies in rats showing milk SM 

















Figure 4.6 Egg SM attenuates skeletal muscle triglyceride accumulation with HFD. Skeletal 
muscle (quadriceps femoris) lipids were extracted using a modified Folch extraction and TG was 
measured by enzymatic methods (n = 6 per group, mean + SEM) (A). Muscle mRNA was 
measured by real-time qRT-PCR (B). Data was normalized to endogenous reference gene 
expression (n = 13-14 per group, mean + SEM). Mean values with unlike letters indicate 




egg SM [21]. However, this was not observed, and may be related to differences in study design, 
such as duration or animal model. The ratio of cholesterol and SM in lipid emulsions is known to 
impact the magnitude of cholesterol absorption in vitro and in vivo [18]. Cholesterol and SM 
mutually inhibit each other’s absorption [19]. As little as 0.1% (w/w) dietary milk SM was shown 
to reduce cholesterol absorption by 20% in mice on a chow diet [18]. Egg SM (0.2% w/w) 
supplemented over 6 weeks to a high fat, high cholesterol diet lowered serum lipids in APOE*3-
Leiden mice [25]. We have previously shown that milk SM (0.25% w/w) supplementation of a 
HFD for 4 weeks, without added cholesterol, was able to reduce serum and hepatic lipids in mice, 
while egg SM supplementation (0.25% w/w) surprisingly increased serum and hepatic lipids [23]. 
Serum lipids in rodents fed various animal-sourced sphingolipids have been shown to decrease 
[23-25], not change [22], and even increase in some studies [23, 37]. In general, sphingolipid 
supplementation in rodents consuming large amounts of dietary cholesterol typically reduces 
serum cholesterol and hepatic lipids, whereas in the absence of large doses of cholesterol, 
supplementation with sphingolipids resulted in increased serum and hepatic lipids in some studies 
[23, 37]. While in the current study milk SM did not lower serum cholesterol, it successfully 
reduced hepatic lipids. Dietary SM has been previously reported to reduce hepatic lipids 
independent of changes in serum lipids [22]. More research is required to determine the optimal 
conditions for dietary sources of SM to reduce serum and hepatic lipids. 
The most striking observation between dietary SM-supplemented groups and HFD control 
were the histological and biochemical differences in hepatic steatosis. Both SM groups had lower 
hepatic TG and cholesterol concentrations compared to HFD; however, hepatic TG were reduced 
most prominently with egg SM. It has been estimated that up to 60% of hepatic TG are derived 
from serum NEFA [38]. In the current study, both SM groups lowered serum NEFA concentrations 
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compared to HFD. Reduced NEFA uptake by the liver is further supported by the reduction in 
hepatic Cd36 and Fabp4 mRNA observed in the egg SM group. CD36 mediates long-chain fatty 
acid uptake into cells to be used for TG synthesis [39]. FABP4 is responsible for binding fatty 
acids and transporting them inside cells [40]. Differences in oxidation, synthesis, or secretion could 
also contribute to the observed reductions in hepatic TG and cholesterol. In the current study, no 
differences in hepatic expression of various genes related to β-oxidation, de novo fatty acid 
synthesis, or cholesterol biosynthesis were detected, suggesting that fatty acid oxidation and fatty 
acid/cholesterol biosynthesis were unchanged. However, Scd1 mRNA was significantly reduced 
in both SM groups. SCD1 is an important enzyme in TG synthesis, enzymatically desaturating 
stearic and palmitic acid to oleic and palmitoleic acid, respectively [41]. Dietary fatty acids can 
also be a source of NEFA for hepatic TG synthesis [38]. Dietary sphingolipids have been 
previously shown to reduce the absorption of dietary fat in rodents [20, 21, 25]. While we observed 
differences between HFD groups in hepatic steatosis, an early marker of NAFLD, we did not 
examine long-term sequelae, such as inflammation and fibrosis. Longer studies are necessary to 
determine any effects of dietary SM on more severe stages of NAFLD, such as NASH and fibrosis. 
Endogenous ceramide content has been linked with altered hepatic function. Hepatic insulin 
sensitivity is reduced in mice lacking ceramide synthase 2 (CerS2), an enzyme required for very-
long chain ceramide (C22-C24) synthesis in hepatocytes [42-44]. C16:0-ceramide and the 
expression of its major synthetic enzymes, ceramide synthase 5 and 6, markedly increase in the 
livers of obese mice [44, 45]. Other studies have reported reductions in very-long chain ceramides 
(C22-C24) in the livers of HFD-fed mice [45, 46]. Thus, it will be important in future studies to 
determine if there are alterations in hepatic ceramide species with dietary SM intake. 
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The hepatic expression of Scd1 [47], Fabp4 [48], Cd36 [49], and Pparg2 [50] mRNA are 
known to be induced by PPARγ agonists. Hepatic PPARγ activity is associated with the 
accumulation of lipid droplets [51]. PPARγ overexpression in mice accelerates the development 
of hepatic steatosis [52]. PPARγ is a ligand-activated transcription factor, shown to be activated 
by long-chain fatty acids [53]. In obesity, more long-chain fatty acids would be available to the 
liver, offering more potential ligands for PPARγ and substrates for TG synthesis. We failed to 
detect significant differences in total PPARγ protein in livers of SM-supplemented mice compared 
to HFD control. However, PPARγ protein expression is not a complete picture of PPARγ activity. 
PPARγ activity is heavily regulated by post-translational modifications and ligand availability [54, 
55]. Both dietary SM-supplemented groups reduced lipid accumulation relative to HFD control. 
We speculate that an overabundance of fatty acids, known ligands for PPARγ, are responsible for 
driving the higher hepatic expression of Pparg2, Cd36, Fabp4, and Scd1 mRNA detected in HFD 
control vs egg SM. Further research should investigate if dietary SM has any direct effects on 
altering hepatic PPARγ activity or indirect effects by reducing fatty acid ligand availability. 
Obesity-related metabolic complications are associated with adipocyte dysfunction and the 
recruitment of inflammatory macrophages into adipose tissue, contributing to adipose tissue 
inflammation and insulin resistance [56]. We observed a significant attenuation of adipose tissue 
macrophage infiltration and inflammation by egg SM, with a smaller effect by milk SM. The 
recruitment of macrophages into adipose tissue is driven by increases in CCL2, a chemokine factor 
otherwise known as monocyte chemoattractant protein-1 (MCP-1) [57]. Both dietary SM groups 
reduced serum CCL2, while only egg SM had a significant effect on all markers of macrophage 
infiltration measured (Cd68, F4/80, Cd11c, crown-like structures). This may be related to the 
stronger effect of egg SM on reducing CCL2 mRNA expression in the adipose tissue. However, 
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both SM groups had significant reductions in adipose tissue F4/80 and TNFα mRNA expression, 
suggesting a general reduction in adipose tissue inflammation with dietary SM. Umemoto et al. 
[13] had previously shown a marginal effect of the cholesterol absorption inhibitor, ezetimibe, on 
preventing adipose tissue macrophage infiltration and inflammation in diet-induced obese mice. 
However, we observed strong effects with egg SM, thus, suggesting dietary SM works through 
other mechanisms besides inhibiting dietary cholesterol absorption. Additionally, the stronger 
effects observed with egg SM, which is reportedly less effective at inhibiting cholesterol 
absorption than milk SM [21], supports this assumption. Along with reduced inflammation, egg 
SM increased the expression of GLUT4 and adiponectin (Adipoq) mRNA in adipose tissue, 
suggesting an improvement in metabolic function. While skeletal muscle is considered the major 
organ involved in whole-body glucose disposal [58], adipose GLUT4 has been shown to promote 
glucose tolerance in mice [59] and, thus, may have contributed to the reduced fasting glucose in 
egg SM-fed mice compared to HFD.  
Skeletal muscle TG content of mice fed egg SM was reduced compared to HFD, and this 
may have also contributed to an improvement in fasting glucose [60]. However, we did not observe 
differences in skeletal muscle Glut4 mRNA expression between HFD groups and also failed to 
observe differences in serum insulin and HOMA-IR. Although lower skeletal muscle TG was 
observed with egg SM relative to HFD, the expression of several genes involved in β-oxidation 
was reduced (Acox1, Acadl, Cpt1b). It seems plausible that β-oxidative genes were induced in 
HFD skeletal muscle to compensate for an increased fatty acid load, an effect which was reversed 
with egg SM.  
We observed a substantial difference in potency between egg SM and milk SM in the 
current study. Compositional variation between egg SM and milk SM would be expected to result 
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in differences in bioactivity. Egg SM species are mostly uniform, with amide-linked palmitic acid 
(16:0) and sphingosine bases (d18:1) as primary components [28, 29]. In contrast, bovine milk SM 
has a more variable fatty acid (16:0, 22:0-24:0) and sphingoid base (d16:0-d19:0 and d16:1-19:1) 
composition [28, 30]. The longer amide-linked fatty acyl chains in milk SM are thought to form 
tighter hydrophobic interactions with other dietary lipids, inhibiting their absorption to a greater 
extent than the 16:0 chains found in egg SM [21]. Saturated sphingoid bases are also more 
pervasive in milk SM. SM with saturated sphingoid backbones are known as 
dihydrosphingomyelin (DHSM). DHSM has been shown to display stronger interactions with 
cholesterol than SM [61]. Dihydroceramide, the hydrolytic product of DHSM, demonstrates a 
lower bioactivity to induce apoptosis of cells than ceramide [62]. Therefore, variations in 
bioactivity and affinity for cholesterol, driven by length of the amide-linked fatty acyl chains and 
the saturation of the sphingoid backbone, could have resulted in the differences in bioactivity of 
egg SM and milk SM observed in the current study. Another possible explanation for variations in 
bioactivity of dietary SM could be related to their hydrolysis in the gut. Alkaline 
sphingomyelinase’s in vitro activity is inhibited by excess lipid, especially longer chain fatty acids 
and higher cholesterol-to-fatty acid ratios [63]. Ceramide derived from milk SM is a potent 
inhibitor of in vitro cholesterol absorption [64]. Sphingosine can also inhibit cholesterol absorption 
but is not as effective as ceramide [64] and is readily absorbed [65]. Structural variations between 
egg SM and milk SM may result in differential hydrolysis in the gut. Milk SM may not be 
hydrolyzed as efficiently as egg SM by alkaline sphingomyelinase, due to its longer fatty acid 
chains. Further supporting this notion, increases in very long-chain fatty acids (22:0–24:0) have 
not been observed in rat mesenteric lymph after feeding milk SM, whereas palmitic acid (16:0) 
increased in rat mesenteric lymph after feeding egg SM [21].  
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In conclusion, the current study demonstrates a decrease in the development of hepatic 
steatosis and adipose tissue inflammation in diet-induced obese mice when supplemented with egg 
SM, and to a lesser extent with milk SM. The visible decreases in hepatic steatosis were confirmed 
by reductions in both liver TG and CE in the SM-supplemented groups. These reductions in hepatic 
lipids were associated with the reduced expression of PPARγ-related genes involved in TG 
synthesis, especially with egg SM. Egg SM was more effective than milk SM in preventing hepatic 
steatosis, while also reducing adiposity, fasting glucose, and serum cholesterol. The reason for 
such differences observed is unclear, although there are likely additional bioactive effects of 
dietary SM beyond impairing lipid absorption. More research is warranted to determine the effects 
of dietary SM on other obesity-related outcomes and to delineate mechanisms underlying the 
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Chapter 5. Dietary Milk Sphingomyelin 
Reduces Systemic Inflammation in Diet-




This chapter is reprinted from “Norris GH, Porter CM, Jiang C, Blesso CN: Dietary Milk 
Sphingomyelin Reduces Systemic Inflammation in Diet-Induced Obese Mice and Inhibits 
LPS Activity in Macrophages. Beverages 2017, 3:37.” As the author of this MDPI article, 
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High fat diets increase lipopolysaccharide (LPS) activity in the blood and may contribute to 
systemic inflammation with obesity. We hypothesized that dietary milk sphingomyelin (SM), 
which reduces lipid absorption and colitis in mice, would reduce inflammation and be mediated 
through effects on gut health and LPS activity. C57BL/6J mice were fed high fat, high cholesterol 
diets (HFD, n = 14) or the same diets with milk SM (HFD-MSM, 0.1% by weight, n = 14) for 10 
weeks. HFD-MSM significantly reduced serum inflammatory markers and tended to lower serum 
LPS (p = 0.08) compared to HFD. Gene expression related to gut barrier function and macrophage 
inflammation were largely unchanged in colon and mesenteric adipose tissues. Cecal gut 
microbiota composition showed greater abundance of Acetatifactor genus in mice fed milk SM, 
but minimal changes in other taxa. Milk SM significantly attenuated the effect of LPS on pro-
inflammatory gene expression in RAW264.7 macrophages. Milk SM lost its effects when 
hydrolysis was blocked, while long-chain ceramides and sphingosine, but not dihydroceramides, 
were anti-inflammatory. Our data suggest that dietary milk SM may be effective in reducing 
systemic inflammation through inhibition of LPS activity and that hydrolytic products of milk SM 
are important for these effects. 
5.2. Introduction 
Chronic low-grade inflammation is involved in the pathogenesis of cardiovascular disease, type 2 
diabetes and non-alcoholic fatty liver disease [1]. Metabolically-related chronic low-grade 
inflammation may be exacerbated by circulating lipopolysaccharide (LPS), also called 
“endotoxin”, a pro-inflammatory molecule found in the outer membrane of Gram-negative 
bacteria [2]. Recognition of bacterial LPS by host cells can trigger a pro-inflammatory signaling 
cascade mediated by Toll-like receptor-4 (TLR4), a pattern recognition receptor [3]. The human 
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gastrointestinal tract has a “gut barrier” to limit the passage of microbes between host intestinal 
cells (e.g., tight junctions between enterocytes) and into the bloodstream [4]. These features of the 
gut barrier function to reduce permeability to LPS, which may otherwise trigger host inflammation 
and disease [5]. However, LPS translocation from the gut to circulation is enhanced by the 
absorption of dietary lipids [6]. High fat diets (HFD) have been shown to promote inflammation 
of the distal intestine, causing an impairment of the protective gut barrier and translocation of LPS 
into host circulation [7]. Diets high in fat can also alter the gut microbiota [8], resulting in 
diminished amounts of beneficial bacteria, such as some bifidobacteria, which would promote gut 
barrier permeability [7]. Additionally, diets rich in triglyceride and cholesterol increase 
chylomicron production during digestion and absorption. It has been shown that LPS can be 
incorporated into chylomicrons and transported into the bloodstream of mice [6]. Overall, these 
effects of HFD result in the paracellular and transcellular translocation of LPS from the gut into 
the circulation. The presence of LPS in the circulation activates the inflammatory response of the 
immune system, mainly through the activation of TLR4 [3]. Lipopolysaccharide engages the 
TLR4/MD-2 receptor complex via LPS-binding protein (LBP) and CD14. Toll-like receptor 4 
signaling then activates the nuclear factor-kappa B (NF-κb) transcription factor resulting in the 
production of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) [3]. 
Macrophages in the colon have been shown to be the first pro-inflammatory immune responders 
to an HFD [9]; thus, inhibiting LPS translocation and the subsequent inflammatory responses of 
macrophages shows great potential in reducing the detrimental effects of a diet rich in fat and 
cholesterol. 
Dietary phospholipids, including sphingolipids, show potential in mitigating chronic 
disease through effects on lipid absorption and inflammation [10, 11]. Dietary sphingolipids, 
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which include sphingomyelin (SM), ceramides, and sphingosine, are mainly found in milk, eggs, 
and soybeans [12]. It is estimated that the average American consumes 0.3 to 0.4 grams of 
sphingolipids per day [12]. Sphingomyelin is considered a zoochemical, being present in animal 
cell membranes but absent from plants [13]. Sphingomyelin found in milk is an important 
component of milk fat globule membranes [14]. Dietary SM and other sphingolipids have been 
studied for their effects on dyslipidemia because they interfere with the absorption of dietary fat 
and cholesterol [15-21]. In addition to effects on lipid absorption, dietary SM may have additional 
bioactive effects by reducing inflammation and LPS activity, potentially influencing chronic 
disease. Dietary milk SM has been shown to reduce DSS-induced colitis in mice, suggesting anti-
inflammatory effects in the gut [22]. Although, the effect of dietary SM on colon inflammation is 
controversial, as exacerbation of colitis in mice has been observed with feeding egg-derived SM 
[23, 24]. Phospholipids and sphingolipids appear to impact LPS activity, as they have been shown 
to dampen LPS-induced inflammation [23, 24]. The presence of LPS in circulation also results in 
the liver upregulating sphingolipid biosynthesis via the sphingolipid rate-limiting biosynthetic 
enzyme, serine palmitoyltransferase (SPT), possibly as a compensatory mechanism [25]. We have 
previously shown that feeding 0.25% (w/w) milk SM reduced serum LPS and altered the gut 
microbiota in HFD-fed mice after 4 weeks [26]. We also recently reported that feeding dietary SM 
(0.1% w/w) attenuated hepatic steatosis and adipose tissue inflammation in diet-induced obese 
mice [27]. The current study aimed to assess the effects of dietary milk SM on systemic and gut 
inflammation using a high fat diet-induced obese mouse model. We also sought to elucidate 
whether milk SM and its hydrolytic products (ceramides, dihydroceramides, and sphingosine) 




5.3. Materials and Methods 
5.3.1. Animals and Diets 
Male C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor, ME) at 6 weeks 
of age. Mice were housed in a temperature-controlled room and maintained in a 12-h light/12-h 
dark cycle within the University of Connecticut-Storrs vivarium. The Animal Care and Use 
Committee of the University of Connecticut-Storrs approved all procedures used in the current 
study. Mice were acclimated to the facility for two weeks before being placed on either a lard-
based high fat, high cholesterol diet (HFD; 60% kcal from fat, 0.15% cholesterol added by weight; 
n = 14) or HFD supplemented with 0.1% of milk SM added by weight (HFD-MSM; n = 14). 
Detailed diet compositions are presented in Table 4.1. Experimental diets were prepared using 
purified ingredients commercially available from Dyets, Inc. (Bethlehem, PA). Milk SM (bovine; 
>99% purity) was obtained from Avanti Polar Lipids, Inc. (Alabaster, AL) and then substituted for 
an equal weight of lard in the treatment group. Accounting for weight gained throughout the study, 
HFD-MSM provided the equivalent of consuming approximately 405-670 mg milk SM/day in a 
70-kg human based on body surface normalization [28]. 
 
Mice consumed the diets ad libitum and fresh food was provided twice per week. Body 
weight was assessed weekly, while food intake was calculated at each feeding. After 10 weeks, 
mice were fasted for 6–8 h followed by euthanasia and subsequent blood collection via cardiac 
puncture. Blood clotted at room temperature for 30 min before serum isolation by centrifugation 
(10,000×g for 10 min at 4°C) and then stored at -80°C. Special precautions were taken to minimize 
endotoxin contamination of the serum samples. Mesenteric adipose and colon tissues were isolated 
and snap frozen in liquid nitrogen before storage in -80°C.  
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5.3.2. Serum Biochemical Analysis  
Serum IL-6, TNF-α, IFNγ, and MIP-1β were measured by Luminex/xMAP magnetic bead-based 
multiplexing assay using MAGPIX instrumentation from EMD Millipore (Billerica, MA). Serum 
LPS was measured using a chromogenic limulus amebocyte lysate (LAL) assay (QCL-1000) 
obtained from Lonza (Basel, Switzerland).  
5.3.3. Gut Microbiota Analysis 
Cecal fecal samples were collected from mice and submitted to the University of Connecticut-
Storrs Microbial Analysis, Resources and Services (MARS) facility for microbiota 
characterization utilizing 16S V4 analysis. DNA was extracted from 0.25 g of fecal sample using 
the MoBio PowerMag Soil 96 well kit (MoBio Laboratories, Inc, Carlsbad, CA) according to the 
manufacturer’s protocol for the Eppendorf epMotion liquid handling robot. DNA extracts were 
quantified using the Quant-iT PicoGreen kit (ThermoFisher Scientific). Partial bacterial 16S rRNA 
(V4) and fungal ITS2 genes were amplified using 30 ng extracted DNA as template. The V4 region 
was amplified using 515F and 806R with Illumina adapters and dual indices (8 basepair golay on 
3’[29], and 8 basepair on the 5’ [30]). Samples were amplified in triplicate using Accuprime PFX 
PCR master mix (ThermoFisher) with the addition of 10 µg BSA (New England BioLabs, Ipswich, 
MA). The PCR reaction was incubated at 95˚C for 2 min., the 30 cycles of 15 s at 95.0°C, 1 min. 
at 55°C and 1 min. at 68°C, followed by final extension as 68°C for 5 min. PCR products were 
pooled for quantification and visualization using the QIAxcel DNA Fast Analysis (Qiagen, Hilden, 
Germany). PCR products were normalized based on the concentration of DNA from 250-400 bp 
then pooled using the QIAgility liquid handling robot. The pooled PCR products were cleaned 
using Mag-Bind RXNPure Plus (Omega Bio-Tek, Norcross, GA) according to the manufacturer’s 
protocol. The cleaned pool was sequenced on the MiSeq using v2 2x250 base pair kit (Illumina, 
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Inc, San Diego, CA).  Sequences were demultiplexed using onboard bcl2fastq. Demultiplexed 
sequences were processed in Mothur v. 1.39.4 following the MiSeq SOP [30]. Exact commands 
can be found here https://github.com/krmaas/bioinformatics/blob/master/mothur.batch. Merged 
sequences that had any ambiguities or did not meet length expectations were removed. Sequences 
were aligned to the Silva nr_v119 alignment [31]. Taxonomic identification of OTUs was done 
using the RDP Bayesian classifier [32] against the Silva nr_v119 taxonomy database.  
5.3.4. Cell Culture 
Murine RAW264.7 macrophages were obtained from ATCC (Manassas, VA) and cultured in a 
humidified incubator at 37°C and 5% CO2. Cells were maintained in DMEM (4 g/L glucose) 
containing sodium pyruvate, 10% fetal bovine serum (Hyclone, Logan, UT), 2 mM L-glutamine, 
100 U/mL penicillin, 100 µg/mL streptomycin antibiotic (ThermoFisher Scientific, Waltham, MA) 
and 100 µg/mL Normocin (Invitrogen, Carlsbad, CA). Cell counts and viability were routinely 
measured using Trypan blue and TC-20 automated cell counter (Bio-Rad, Hercules, CA).  
5.3.5. Effects of Sphingolipids on LPS Stimulation of RAW264.7 Macrophages  
Milk sphingomyelin (bovine), sphingosine (d18:1), C16-ceramide (d18:1/16:0), C24-ceramide 
(d18:1/24:0), C16-dihydroceramide (d18:0/16:0), and C24-dihydroceramide (d18:0/24:0) were 
obtained from Avanti Polar Lipids at >99% purity. Milk SM and sphingosine were dissolved in 
100% ethanol (EtOH), while ceramides were dissolved in EtOH/dodecane (98.8/0.2, v/v). 
RAW264.7 cells were seeded in 24-well plates and allowed to adhere overnight prior to 
experimentation. To examine possible anti-inflammatory effects of milk SM, RAW264.7 
macrophages were pre-incubated with milk SM (0.8-8 µg/mL) or EtOH vehicle control for 1 h, 
followed by a 4 h co-incubation in the presence or absence of 1 ng/mL LPS (E. coli 0111:B4) 
(Sigma-Aldrich, St. Louis, MO). Since milk SM comprised of a natural mixture of SM species, 
135 
 
concentrations are reported in 0.8-8 µg/mL, which is comparable to 1-10 µM of a pure SM species. 
To determine if effects were dependent on SM hydrolysis, cells incubated for 2 h with 100 μM 
imipramine (Sigma-Aldrich) prior to 1 h incubation with milk SM or control ± 4 h co-incubation 
with LPS. Imipramine has been shown to reduce acid sphingomyelinase (SMase) activity to ~20% 
of basal levels after 2 h of incubation [33]. To test the effects of various ceramides and sphingosine, 
RAW264.7 macrophages were incubated for 4 h with ceramides (10 µM), dihydroceramides (10 
µM), sphingosine (1-10 µM), or vehicle control ± LPS (1 ng/mL). Ethanol was used as a vehicle 
control for milk SM and sphingosine treatments, while EtOH/dodecane (98.8/0.2, v/v) was used 
as a control for ceramide treatments. To test for cytotoxicity, Cell Counting Kit-8 (CCK-8) (Sigma-
Aldrich) was used after cells were treated with the different sphingolipids. Sodium dodecyl sulfate 
(SDS, 50 μM) was used as a cytotoxic positive control. Caspase 3 activity was also determined as 
an indicator of apoptosis using a colorimetric protease assay kit (ThermoFisher Scientific) 
according to manufacturer instructions. Cisplatin (ThermoFisher Scientific) at 50 µM 
concentration was used on cells as a positive control to induce apoptosis. 
5.3.6. RNA isolation, cDNA Synthesis, and qRT-PCR 
Total RNA from small intestine, colon, mesenteric adipose tissue and RAW264.7 macrophages 
was isolated using TRIzol reagent (Life Technologies, Carlsbad, CA). RNA was treated with 
DNase I before reverse transcription using iScript cDNA synthesis kit (Bio-Rad). Real-time qRT-
PCR using the iTaq Universal SYBR Green Supermix was performed on a CFX96 real-time-PCR 
detection system (Bio-Rad). For small intestine, colon, and mesenteric adipose tissues, the 
geometric mean of the reference genes, glyceraldehyde 3-phosphate dehydrogenase (Gapdh) and 
beta actin was used to standardize mRNA expression using the 2−ΔΔCt method. The macrophage 
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mRNA was standardized to Gapdh expression. All primer sequences used are listed in Appendix 
A. 
5.2.7. Statistical Analysis  
Data were analyzed using GraphPad Prism 6. Means were compared using Student’s t test or one-
way analysis of variance with Holm-Sidak post hoc analysis where indicated. For gut microbiota 
analysis, alpha and beta diversity statistics were calculated by taking the average of 1000 random 
subsampling to 10,000 reads per sample in Mothur. NMS and Permanova were run in R 3.3.2. A 
subsampled species matrix was used for indicator species analysis [34]. Figures were drawn in R 
3.3.2 using ggplot2 2.2.1 and RColorBrewer 1.1-2. Data are reported as mean ± SEM. Significance 
is reported as p < 0.05. 
5.4. Results 
5.4.1. Dietary milk SM reduces systemic inflammation and tends to lower circulating LPS  
All mice fed the lard-based HFD were obese and insulin-resistant after 10 weeks, while 
supplementation of 0.1% (w/w) milk SM did not affect food intake, body or tissue weight gain 
compared to HFD control [27]. However, feeding milk SM strongly decreased serum 
inflammatory cytokines/chemokines compared to HFD control (Figure 5.1A). Milk SM tended to 
reduce LPS compared to HFD control (-36%), but it was not significantly different (p = 0.08) 
(Figure 5.1B). Milk SM tended to increase Niemann-Pick C1-Like 1 (NPC1L1) mRNA 
expression (p = 0.07) in the small intestine (Figure 5.2A), which is induced by cellular cholesterol 
depletion [35]. No other significant changes were observed in the small intestine for gene 
expression related to lipid absorption. Interestingly, C-C motif chemokine ligand 2 (CCL2) mRNA 
expression was significantly increased in the colon by milk SM (Figure 5.2B). However, this did 




Figure 5.1. Dietary milk SM reduces serum inflammation markers in diet-induced obese mice. Male C57BL/6J mice were fed 
high fat diet (60% kcal fat, 31% lard, 0.15% added cholesterol) (HFD) or HFD supplemented with 0.1% (w/w) milk SM (HFMSM) 
for 10 weeks. Serum cytokines/chemokines (A) and endotoxin concentrations (B) were by magnetic bead-based assay and 







Figure 5.2. Intestinal and mesenteric adipose tissue mRNA expression of diet-induced obese mice. Small intestine mRNA (A), 
colon mRNA (B), and mesenteric adipose tissue mRNA (C) was determined using real-time qRT-PCR and standardized to the 
geometric mean of Gapdh, 36B4, and β-actin reference genes using the 2
(-ΔΔCt)
 method. Mean ± SEM, n = 13-14 per group. **p < 
0.01 compared to HFD. 
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infiltration/inflammation (F4/80, Cd68, Cd11c, Tnf) and gut barrier function (Tjp1, Alpi, Ocln) 
was mostly unaffected by milk SM (Figure 5.2B). Furthermore, mesenteric adipose tissue mRNA 
expression related to inflammation was also unchanged, while there was a trend in GLUT4 mRNA 
expression to be increased by milk SM (p = 0.09) (Figure 5.2C). 
5.4.2. Gut microbiota composition is mostly unaffected by 0.1% (w/w) dietary milk SM 
To determine if alterations in gut microbiota could explain differences in systemic inflammation 
in the present study, cecal feces microbiota composition was examined by 16S rRNA sequence 
analysis and results are presented in Figure 5.3. Verrucomicrobia was the major phylum in cecal 
feces, but there were no significant differences between groups in its relative abundance or that of 
its major genus, Akkermansia (Figure 5.3B). Additionally, no significant differences were 
observed in the relative abundance of Firmicutes or Bacteroidetes phyla between groups (Figure 
5.3B) or when phyla were grouped as Gram-negative bacteria (HFD: 76.9% ± 1.5% vs. HFD-
MSM: 73.5% ± 2.8%, p = 0.31). However, relative abundance of Acetatifactor, a genus of the 
Firmicutes phylum, was significantly higher in the group fed milk SM compared to HFD control 
(Figure 5.3B). Alpha-diversity analysis (diversity within a sample) determined by inverse 
Simpson index was not significantly different between groups (HFD: 2.19 ± 0.16 vs. HFD-MSM: 
2.46 ± 0.32, p = 0.45). Furthermore, beta-diversity analysis (between sample diversity) by Bray-
Curtis revealed no significant clustering of samples according to diet (Figure 5.3C). Therefore, in 
the context of diet-induced obesity, gut microbiota composition was generally unaffected by 
supplementation of 0.1% (w/w) milk SM in the diet. 
5.4.3. Milk SM inhibits LPS stimulation of macrophages 
Since dietary milk SM may directly influence inflammatory processes beyond inhibiting lipid 
















Figure 5.3. Gut microbiota composition of diet-induced obese mice.  Cecal fecal samples were collected and microbiota 
composition was assessed by 16S rRNA sequencing as described in Materials and Methods. Mean phylogenetic abundance (% of 
total sequences) of mice (A) and taxa comparisons (B). Beta diversity shown by Bray-Curtis based non-metric multidimensional 
scaling plot to visualize between sample diversity (C). Mean ± SEM, n = 10 per group. *p < 0.05 compared to HFD. Abbreviations: 
Lachnospiraceae_u, Lachnospiraceae_unclassified; Ruminococcaceae_u, Ruminococcaceae_unclassified
141 
 
macrophages. Increases in TNF-α and CCL2 mRNA with 4 h LPS stimulation were both 
significantly reduced with milk SM (0.8 and 8 μg/mL) (Figure 5.4A,B). Milk SM in the absence 
of LPS did not influence pro-inflammatory gene expression. Furthermore, cell viability was not 
affected by milk SM at concentrations shown to affect pro-inflammatory gene expression (Figure 
5.4C). With the addition of imipramine, LPS-stimulated inflammation was not reduced in the 
presence of milk SM (Figure 5.4D). Imipramine causes proteolytic degradation of acid 
sphingomyelinase, which hydrolyzes SM to ceramide and phosphorylcholine. This suggests that a 
hydrolytic product of SM (e.g. ceramide, sphingosine) is important for milk SM’s effect on 
inflammation. 
5.4.4. Ceramides and sphingosine, but not dihydroceramides, inhibit LPS stimulation of 
macrophages 
Since milk SM contains a mixture of SM species with different fatty acid chain lengths and 
sphingoid backbones, we tested the effects of C16-ceramide, C24-ceramide, C16-
dihydroceramide, and C24-dihydroceramide on macrophage pro-inflammatory gene expression 
(Figure 5.5A,B). Interestingly, both C16-ceramide and C24-ceramide at 10 µM concentrations 
significantly reduced TNF-α mRNA (Figure 5.5A) and CCL2 mRNA (Figure 5.5B) in LPS-
stimulated macrophages, but their corresponding dihydroceramides did not. None of the ceramides 
tested altered inflammatory gene expression in the absence of LPS. The anti-inflammatory effects 
of ceramides (sphingosine base), but not dihydroceramides (sphinganine base), suggest 
sphingosine is important for bioactivity Supporting this notion, sphingosine significantly reduced 
LPS-stimulation of TNF-α mRNA (Figure 5.6A) and CCL2 mRNA (Figure 5.6B) in 
macrophages. Neither ceramides nor sphingosine significantly affected cell viability (Figure 
5.7A,B) or caspase 3 activity (Figure 5.7C) at the concentrations tested, suggesting cell death was 





Figure 5.4. Milk SM inhibits LPS-activation of macrophages. RAW264.7 macrophages were pre-incubated with milk SM 
(MSM) or EtOH vehicle control for 1 h, followed by a 4 h co-incubation ± LPS (1 ng/mL). TNF-α mRNA (A) and CCL2 mRNA 
(B) were measured by real-time qRT-PCR. Cell viability determined using Cell Counting Kit-8 (C). Sodium dodecyl sulfate (SDS) 
(0.5 mM) was used on cells as a positive control to induce cell death, **p < 0.001 compared to control. TNF-α mRNA was measured 
in cells incubated for 2 h with 100 μM imipramine prior to a 1 h incubation with milk SM or control ± a 4 h co-incubation with LPS 





Figure 5.5. Long-chain ceramides inhibit LPS-activation of macrophages. RAW264.7 macrophages were incubated for 4 h 
with ceramides (10 µM), dihydroceramides (10 µM), or vehicle control ± LPS (1 ng/mL). C16-ceramide (d18:1/16:0), C24-
ceramide (d18:1/24:0), C16-dihydroceramide (d18:0/16:0), and C24-dihydroceramide (d18:0/24:0) were tested. TNF-α mRNA (A) 
and CCL2 mRNA (B) measured by real-time qRT-PCR. Mean ± SEM, n = 3-7 independent experiments. Unlike letters p < 0.05 by 





Figure 5.6. Sphingosine inhibits LPS-activation of macrophages. RAW264.7 macrophages were incubated for 4 h with 
sphingosine (1-10 µM) or vehicle control ± LPS (1 ng/mL). TNF-α mRNA (A) and CCL2 mRNA (B) measured by real-time qRT-





Figure 5.7. Ceramides and sphingosine do not affect cell viability or apoptosis.  Cell viability determined using Cell Counting 
Kit-8 for ceramides (A) and sphingosine (B). Sodium dodecyl sulfate (SDS) (0.5 mM) was used on cells as a positive control to 
induce cell death. Caspase 3 activity measured as an indicator of apoptosis (C). Cisplatin (50 µM) was used on cells as a positive 




Chronic low-grade inflammation is a common underlying factor in many diseases afflicting 
Western societies, including diabetes, non-alcoholic fatty liver disease, and atherosclerosis [36]. 
Low-grade inflammation in these states may be exacerbated by circulating LPS, also known as 
endotoxin [2]. LPS translocation from the gut to circulation is enhanced by lipid absorption [6]. 
Dietary SM has been studied for its effects on dyslipidemia because it reduces the absorption of 
other lipids (e.g., fat and cholesterol), and therefore, could potentially influence systemic 
inflammation. In this study, the addition of 0.1% (w/w) dietary milk SM to a lard-based HFD 
significantly reduced systemic inflammation markers and tended to lower circulating LPS but had 
no effect on gene expression of inflammation or gut barrier function markers in the mesenteric 
adipose tissue or colon. Furthermore, microbiota composition of cecal feces was mostly unaffected 
by the addition of milk SM to the HFD diet, suggesting gut microbiota compositional differences 
did not play a major role in altering systemic inflammation markers. Milk SM directly attenuated 
LPS stimulation of pro-inflammatory gene expression in RAW 264.7 macrophages. Interestingly, 
hydrolytic products of milk SM (C16-ceramide, C24-ceramide, and sphingosine) showed similar 
anti-inflammatory effects, whereas the inhibition of SM hydrolysis with imipramine prevented 
such effects. These results suggest that dietary SM may have additional bioactive effects beyond 
inhibiting lipid absorption through the lowering of macrophage inflammatory responses, 
potentially influencing metabolic disease. 
In rodent studies, dietary patterns rich in saturated fat and cholesterol, so called “Western” 
diets, have been linked to chronic disease through increasing inflammation [37, 38]. Detrimental 
effects of Western diets in mice appear to be influenced by the presence of microbes in the GI 
tract, since depletion of gut microbiota with oral antibiotics reduces the inflammatory response 
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[39]. This is partly related to the effect that Western diets have on increasing LPS in circulation, 
termed “metabolic endotoxemia”, which has been shown to precede increases in systemic 
inflammation in animal models [2, 39]. There is also evidence that diets high in fat and cholesterol 
increase endotoxin concentration in the bloodstream of humans [40, 41]. With the current study, 
we fed milk SM (0.1%) for 10 weeks to HFD-fed mice (60% kcal as fat; 0.15% cholesterol added) 
to determine if dietary SM could affect chronic low-grade inflammation. Milk SM strongly 
reduced serum inflammatory cytokines/chemokines and tended to reduce serum LPS (p = 0.08). 
Lower serum CCL2 and mRNA expression of inflammation markers in epididymal adipose tissue 
were also previously shown in mice fed milk SM [27]. We have previously reported that the 4-
week dietary supplementation of a higher dose of milk SM (0.25% w/w) reduced circulating LPS 
by 35% in mice fed a milkfat-based high fat diet [26]. Although we did not observe any differences 
in mRNA expression of gut barrier markers in the small intestine, reductions in circulating LPS 
are expected to be partly due to the inhibitory effect of milk SM on lipid absorption. Supporting 
this notion, we have previously observed reductions in serum and hepatic lipids with the feeding 
of milk SM [26, 27].  
Recently, chronic feeding of HFD to mice was shown to increase colonic pro-inflammatory 
macrophages and gut inflammation, which promoted LPS translocation, insulin resistance, and 
adipose tissue inflammation [9]. These effects were mediated by early induction of CCL2 in 
intestinal epithelial cells, which attracted pro-inflammatory macrophages to colon tissue [9]. In 
this study, although we observed significantly greater colon CCL2 mRNA expression with milk 
SM intake, we did not observe any significant changes between groups in gene expression of gut 
barrier markers or macrophage infiltration/inflammation in colon and mesenteric adipose tissues. 
This suggests that CCL2 mRNA expression was possibly induced with milk SM because of greater 
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dietary fat/cholesterol reaching the colon, but this did not induce macrophage infiltration and TNF-
α expression in the colon and surrounding adipose tissue. Although dietary SM is known to inhibit 
cholesterol absorption, luminal cholesterol can reciprocally inhibit SM digestion [16]. Feeding 
mice a high fat diet has also been shown to reduce the expression of the key enzyme in SM 
digestion, alkaline sphingomyelinase [45, 46]. Therefore, it is possible that the use of a high fat 
lard diet with added cholesterol in this study influenced ileal and colonic exposure to SM and 
bioactive metabolic products (ceramide, sphingosine, and sphingosine-1-phosphate), which in turn 
could affect colon inflammation [47, 48].  
The intake of HFD has been shown to negatively alter the gut microbiota [42]. Gut 
dysbiosis has been linked with endotoxin-mediated chronic disease in mouse models [43, 44]. 
Sphingosine, a hydrolytic product of dietary SM, is known to have bactericidal effects [45]. We 
have previously reported that supplementation of 0.25% (w/w) milk SM to high fat diet-fed mice 
altered the fecal microbiota composition by reducing Gram-negative bacterial phyla and increasing 
Bifidobacterium [26]. In the current study, however, we did not observe such large changes in gut 
microbiota composition, possibly related to the lower dose used or the more severe high fat diet 
challenge. We observed a significant difference in the relative abundance of Acetatifactor genus, 
with higher levels in mice fed milk SM. This genus was shown to be isolated from the intestine of 
obese mice and produces the short-chain fatty acids, acetate and butyrate [46]. The abundance of 
Acetatifactor in the gut was also related to lard intake in mice and correlated with the 
concentrations of secondary bile acids in mouse cecum [47]. We also have observed increases in 
Acetatifactor genus with 0.25% (w/w) milk SM feeding on a low-fat diet background (Norris and 
Blesso, unpublished observations 2016). At this point, it is unclear if these bacteria contribute to 
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the inflammatory changes observed or in response to the effects of milk SM on lipid absorption. 
Further research is needed to clarify these associations.  
Milk SM significantly reduced TNF-α and CCL2 mRNA expression in LPS-stimulated 
RAW264.7 macrophages. There are several potential mechanisms that could explain this observed 
effect. First, there could be a direct interaction between milk SM and LPS within the media, where 
intact SM itself is neutralizing LPS, possibly due to the formation of a complex. In our current 
study, this would mean that the LPS would be neutralized by SM before it could enter the cell, as 
part of a lipid vesicle that masked the reactive lipid-A moiety of LPS. Incubation with 100 µM 
bovine brain SM was reported to neutralize LPS stimulation of polymorphonuclear leukocytes 
(PMN) in the presence of soluble CD14 and LBP [23]. Furthermore, SM hydrolysis can yield 
bioactive products, including ceramide and sphingosine. Imipramine is a tricyclic anti-depressant 
(TCA) that causes proteolytic degradation of the enzyme acid-SMase [33]. Imipramine may also 
have other effects besides acid-SMase degradation, as it was shown that acid ceramidase was 
down-regulated by another TCA, desipramine [48]. Interestingly, the addition of imipramine 
completely abolished the anti-inflammatory effects of milk SM. This indicates that one of the 
hydrolytic products of SM (e.g. ceramide, sphingosine, phosphorylcholine) may be responsible for 
the reduction in inflammation. If milk SM were hydrolyzed by SMase and ceramidase to ceramide 
and sphingosine, respectively, each of those products could potentially exert anti-inflammatory 
effects. Longer-chain ceramides may compete with LPS and block TLR4 signaling, as they have 
been shown to bind to CD14 in monocytes and form a multi-molecular complex that contains 
CD36, but lacks TLR4 [49]. To confirm this, ceramides containing different amide-linked fatty 
acid chain lengths (16:0 and 24:0) and sphingoid bases (dihydroceramides) were tested. We used 
ceramides with 16-carbon and 24-carbon fatty acid chain lengths because these ceramides would 
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be produced from the hydrolysis of the natural mixture of SM species that comprise milk SM. 
Additionally, these fatty acid chain lengths within the ceramide have the ability to alter its 
bioactivity [50]. Specifically, it has been shown that intracellular C16-ceramide is particularly pro-
apoptotic, whereas C24-ceramide and dihydroceramides antagonize apoptosis induced by shorter 
ceramides [51-53]. Interestingly, both C16-ceramide and C24-ceramide treatment of macrophages 
resulted in significant reductions in TNF-α and CCL2 mRNA expression, while dihydroceramides 
had no effect. None of the ceramides or dihydroceramides affected cell viability or the early 
apoptosis marker, caspase 3 activity, suggesting the effects were not due to an induction of cell 
death. Although intracellular ceramides have been shown to be pro-apoptotic [50], exogenously 
added long-chain ceramides do not affect viability of macrophages [54]. These data indicate that 
ceramides are responsible for the anti-inflammatory effect of milk SM and strengthens the findings 
of the imipramine data. However, since only the sphingosine base containing-ceramides showed 
anti-inflammatory effects and not sphinganine-containing dihydroceramides, we further tested the 
effects of sphingosine on LPS stimulation of macrophages. We observed similar effects of 
sphingosine (d18:1) on inhibiting TNF-α and CCL2 mRNA without affecting cell viability or 
apoptosis, as C16- and C24-ceramides. Sphingosine could display anti-inflammatory effects 
through the activation of the nuclear receptor, peroxisome proliferator-activate receptor-gamma 
(PPARγ) [22]. In support of our findings, exogenous C8-ceramide and sphingosine have been 
previously reported to reduce TNF-α secretion from LPS-stimulated macrophages [55]. 
Furthermore, both C16-ceramide and membrane-permeable C2-ceramide have been shown to 
reduce TNF-α secretion from LPS-stimulated macrophages by post-translational mechanisms [56]. 
In summary, dietary milk SM reduces systemic inflammation in diet-induced obese mice, 
without altering gene expression of macrophage or barrier function markers in the mesenteric 
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adipose tissue or colon. Milk SM directly attenuates LPS stimulation of pro-inflammatory gene 
expression in RAW 264.7 macrophages. The inhibition of SM hydrolysis prevents milk SM anti-
inflammatory effects, while the hydrolytic products C16-ceramide, C24-ceramide, and 
sphingosine showed anti-inflammatory effects. In addition to effects on lipid absorption, dietary 
SM may have additional bioactive effects by lowering inflammation and LPS activity, potentially 
influencing metabolic disease. Further research is warranted to confirm the mechanism and effect 
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Chapter 6. Dietary Milk Phospholipids 
Improve Dyslipidemia and Hepatic 





We have previously shown that chronic feeding of purified milk sphingomyelin (SM), a 
phospholipid (PL) component of milk fat globule membranes (MFGM), is protective against 
hepatic steatosis and dyslipidemia in high fat diet-fed mice. However, it is unclear whether 
ingestion of the total milk PL fraction can have effects similar to purified SM. Therefore, male 
LDLr-/- mice were fed ad libitum a high-fat, high-cholesterol diet (CTL; 45% kcal from fat, 0.22% 
cholesterol added by weight; n = 15), or the same diet supplemented with 1% milk PL (1%; n = 
15) or 2% milk PL (2%; n = 15) added by weight from beta serum for 14 weeks. No differences 
were detected in food intake, body weight, or tissue weights between the groups. Total serum 
cholesterol, non-HDL cholesterol, and non-esterified fatty acids (NEFAs) were significantly lower 
in the 2% group compared to CTL (-51%, -56%, and -26% respectively, p < 0.01). Hepatic total 
cholesterol concentrations were reduced by 53% (p < 0.05) and 55% (p < 0.01) compared to CTL 
in the 1% and 2% groups, respectively. These coincided with increased expression of hepatic 
Hmgcr mRNA, and decreased expression levels of Scd1 and Mip1b in the 2% group. Epididymal 
adipose Ccl2 mRNA was reduced in the 2% group. Milk PL demonstrated hypolipidemic effects 
by strongly reducing serum and hepatic cholesterol pools in LDLr-/- mice fed a Western-type diet. 
Beta serum could be utilized as a value-added source of milk PL to potentially improve 
hyperlipidemia-related disease outcomes.  
 
6.2. Introduction 
Current available research and results presented within this dissertation thus far have established 
dietary sphingomyelin (SM) as a potential mediator of chronic metabolic diseases. However, 
current commercially-available purified forms of dietary SM are likely too expensive to be used 
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as a daily supplement in humans (~$300-500 per gram). Therefore, we searched for whole foods 
or food byproducts, rich in dietary SM, that could be incorporated into diets or used for SM 
purification. Table 6.1. illustrates that beta serum is at least 2 times as concentrated in SM when 
compared to other common dietary sources. Beta serum is a polar lipid byproduct of anhydrous 
milk fat production [1]. Beta serum is particularly rich in milk polar lipids, including SM [2] and 
thus may provide a financially-viable dietary source of SM. It should be noted that milk polar 
lipids (MPLs) may influence the efficacy of milk-derived SM, as dietary MPLs have been shown 
to enhance SM absorption in animal studies [3]. Additionally, other dietary PLs have been shown 
to have beneficial effects in cardiometabolic disease [4]. Therefore, assessing MPLs’ effects in 
chronic metabolic disease is necessary. Some studies have demonstrated chronic feeding of MPL 
fractions reduces serum and hepatic lipids in rodents [5-7]. Dietary MPLs also reduce the 
inflammatory response with acute inflammatory challenges in mice [8, 9].  





Bovine Milk, Whole 9 [10] 
Beef 44-69 [11] 
Egg 82 [12] 
Cottage Cheese 139 [13] 
Chicken Liver 291 [14] 
Beta Serum 420 [2] 
Beta Serum 1015 Manufacturer’s Report 
 
Multiple rodent feeding studies have examined the effects of dietary MPLs on lipid 
homeostasis. Feeding a MPL extract at 1.7% to KK-Ay mice improved both serum and hepatic 
lipids [7].  Supplementing a high-fat diet (HFD) with MPL (2.5% wt:wt of the diet) lowered serum 
cholesterol, hepatic total lipids, hepatic cholesterol, and hepatic triglycerides, while increasing 
fecal lipids in mice, suggesting a decrease in lipid absorption [5]. However, not all animal studies 
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with MPLs have shown beneficial effects. For instance, a diet supplemented with 10% milk fat 
globular membranes (wt:wt, MFGM) increased serum triglycerides in rats compared to an 
isocaloric low-fat control diet [15]. Overall, in most animal studies dietary MPLs improved serum 
and hepatic lipids, most likely through preventing the absorption of dietary fat and/or luminal 
cholesterol.  
In this chapter, we will examine MPLs for their efficacy in reducing diet-induced metabolic 
dysfunction and inflammation in low-density lipoprotein receptor-deficient (LDLr-/-) mice. When 
fed cholesterol-enriched HFD for 12 weeks, total cholesterol of mice reaches over 1000 mg/dL 
compared to 200-300 mg/dL on a control chow diet [16]. High-fat, high-cholesterol diets given to 
LDLr-/- mice also exacerbate inflammation in adipose tissue [17] and livers [18, 19]. For these 
reasons, LDLr-/- mice are particularly useful as a model of NAFLD [16], the hepatic manifestation 
of metabolic dysfunction. This mouse model is particularly sensitive to the benefits of inhibiting 
cholesterol absorption. Treatment of Western-type diet-fed LDLr-/- mice with ezetimibe reduced 
some of the metabolic dysfunction-related consequences of the diet [18]. Therefore, we 
hypothesized that feeding LDLr-/- mice a high-fat, high-cholesterol, high-sucrose diet 
supplemented with MPLs from beta serum would attenuate the detrimental effects of the Western-
type diet.  
6.3. Materials and Methods 
6.3.1 Animals and Diets 
Male LDLr-/- mice on a C57BL/6J background (4 weeks old) were purchased from Jackson 
Laboratory (Bar Harbor, ME, USA) and allowed to acclimate for 2 weeks before being fed one of 
three milk fat-based diets over 14 weeks: high-fat control (CTL; 45% kcal from fat, 0.15% 
cholesterol added by weight; n=15); CTL adjusted to contain 1% (wt:wt) of PLs (1%; n=15) or 
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CTL with 2% PLs added by weight (2%; n=15). Beta serum powder was used as a rich source of 
PLs and was obtained from Tatua Dairy Cooperative (Morrinsville, New Zealand). The 1% and 
2% PL diets supplied 0.2% and 0.4% milk-derived SM (wt:wt of the diet), respectively. Diets were 
adjusted to have similar mineral content, lactose, milk fat, and cholesterol. Skim milk was added 
to the CTL and 1% groups to account for milk bioactives outside of the MFGMs. Diet composition 
details are provided in Table 6.2. and 6.3. Experimental diets were made using ingredients 
obtained from Dyets, Inc. (Bethlehem, PA, USA). Body weight was assessed weekly, while food 
intake was estimated biweekly. Mice were provided with fresh food weekly. At 20 weeks old, the 
mice were fasted for 6–8 h prior to blood collection by cardiac puncture following euthanasia. 
Blood samples were allowed to clot at room temperature for 30 min before serum was isolated by 
centrifugation (10,000g for 10 min at 4°C) and then stored at −80°C. Mice were perfused with 
sterile saline before tissues were harvested. The liver and epididymal adipose were collected from 
animals, snap-frozen in liquid nitrogen, and stored at −80°C. Sections of these tissues were fixed 
in 10% phosphate-buffered formalin. All mice were housed in a temperature-controlled room and 
maintained in a 12-h light/12-h dark cycle at the University of Connecticut-Storrs vivarium. The 
Animal Care and Use Committee of the University of Connecticut-Storrs approved all procedures 
used in the current study.  
6.3.2. Serum Biochemical Analysis 
Total serum cholesterol, triglycerides, glucose, non-esterified fatty acids (NEFAs), and serum 
hepatic enzymes (ALT and AST) were measured using enzymatic or spectrophotometric assays 
according to manufacturer instructions. High-density lipoprotein cholesterol (HDL-C) was 
measured by quantifying serum cholesterol after precipitating apolipoprotein B (ApoB)-containing 
lipoproteins with Mg2+/dextran sulfate [20]. Cholesterol, triglycerides, and NEFA kits were 
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obtained from Wako Diagnostics (Richmond, VA). The glucose hexokinase kit and hepatic 
enzyme kits were obtained from Pointe Scientific, Inc. (Canton, MI). Non-HDL-C was calculated 
as the difference between total cholesterol and HDL-C. Insulin and Adiponectin was measured 
using commercially available ELISA (Crystal Chem, Elk Grove Village, IL). HOMA-IR was 
calculated as in Aim 2.  
Table 6.2. Diet composition by component 
Diet Component CTL 1% 2% 
 (g/kg) 
Casein 80 80 80 
L-Cystine 3 3 3 
Sucrose 200 200 200 
Corn Starch 20 17.5 15 
Lactose 21.35 10.68 0 
Anhydrous Milkfat 207 181 155 
Soybean Oil  20 20 20 
Cellulose  50 50 50 
Mineral Mix, AIN-93G-MX (94046)  43 43 43 
Vitamin Mix, AIN-93-VX (94047)  19 19 19 
Choline Bitartrate  3 3 3 
TBHQ, antioxidant  0.04 0.04 0.04 
Cholesterol 1.5 1.31 1.13 
Skim milk powder (403150) 332 166 0 
Butter serum 0 205.5 411 
Calcium Carbonate  0 0.68 1.36 
Potassium Chloride  0 0.19 0.38 
Sodium Chloride  0 0.25 0.51 
6.3.3. Hepatic Lipid Extraction and Analysis 





Table 6.3. Diet composition by macronutrient 
Diet Component CTL 1% 2% 
Total Protein (g/kg) 200.2 200.3 200.4 
Total Carbohydrate (g/kg) 414.0 411.5 409.0 
Total Fat (g/kg) 229.7 231.3 233.0 
Total Lactose (g/kg) 194.0 194.0 194.0 
Total Cholesterol (g/kg) 2.06 2.06 2.06 
Total Phospholipid (g/kg) 0.5 10.3 20.0 
% kcal from Protein 17.7 17.7 17.7 
% kcal from Carbohydrate 36.6 36.3 36.1 
% kcal from Fat 45.7 46.0 46.2 
Calorie Density (kcal/g) 4.52 4.52 4.52 
 
6.3.4. Tissue Histology 
Paraffin-embedded formalin-fixed liver and epididymal adipose tissues were cut into 5 μm sections 
before staining with hematoxylin and eosin (H&E) by the Connecticut Veterinary Medical 
Diagnostic Laboratory (Storrs, CT). Each stained section was viewed under bright field 
microscopy at ×200 magnification and images were taken with an AxioCam ICc3 camera (Zeiss, 
Thornwood, NY, USA).  
3.3.5. RNA Isolation, cDNA Synthesis and qRT-PCR 
Total RNA was isolated from liver and epididymal adipose tissue and used for cDNA synthesis as 
in previous chapters. Gene expression was normalized to the geometric mean of the reference 
genes, glyceraldehyde 3-phosphate dehydrogenase, β-actin and ribosomal protein, large, P0 using 






3.3.6. Statistical Analysis 
Differences between groups were evaluated by one-way ANOVA with post hoc comparisons 
(Holm-Sidak) or the Kruskal-Wallis nonparametric test for non-normally distributed data (P < 
0.05 deemed significant). D’Agostino-Pearson omnibus normality test was used to assess 
normality for each data set. All statistical analyses were conducted using GraphPad Prism version 
6 software. Data are reported as mean ± SEM. 
6.4. Results 
6.4.1. Dietary Phospholipids Do Not Alter Body Weight and Food Intake 
There were no differences between the groups in body weight, tissue weight, or tissue weight as a 
percentage of body weight (Table 6.4.). Expectedly, there were no significant differences in 
estimated daily food intake.  
Table 6.4. Body and tissue weights after 14 weeks of diets 
  CTL 1% 2% 
Body Weight (g) 34.25 ± 1.49 35.27 ± 1.34 33.19 ± 0.91 
Food Intake (g/day)   3.40 ± 0.12   3.69 ± 0.13   3.73 ± 0.23 
Liver (g)   1.44 ± 0.11   1.48 ± 0.10   1.29 ± 0.04 
% Liver Weight   4.17 ± 0.16   4.16 ± 0.14   3.88 ± 0.06 
Epididymal Adipose (g)   1.29 ± 0.18   1.61 ± 0.22   1.23 ± 0.19 
% Epididymal Adipose   3.79 ± 0.53   4.34 ± 0.48   3.55 ± 0.50 
Values are presented as mean ± SEM (n = 15) 
 
6.4.2. MPL Treatment Attenuated Hypercholesterolemia and Reduced Circulating NEFAs  
The 2% had a 50% reduction in total serum cholesterol compared to the CTL group (Table 6.5). 
Additionally, HDL-C remained unchanged between the groups. After calculating non-HDL-C, it 
was found that estimated non-HDL-C was reduced by 53% in the 2% treatment. Circulating 
NEFAs were 25% lower in the 2% group compared to the control. Fasting triglycerides and glucose 
were unchanged by either treatment. Additionally, serum hepatic enzymes ALT and AST were not 
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significantly different between the groups. Lastly, insulin, HOMA-IR, resistin, and adiponectin 
were similar between all three groups (Table 6.5).  
Table 6.5. Serum values of LDLr-/- after 14 weeks of diets 
  CTL 1% 2% 
Total Cholesterol (mg/dL)   1001 ± 149a      877 ± 123ab     491 ± 69b 
non-HDL-C (mg/dL)     928 ± 158a      840 ± 134ab     433 ± 74b 
HDL-C (mg/dL) 81 ± 5 83 ± 5   84 ± 5 
Triglycerides (mg/dL) 404 ± 83 433 ± 78   268 ± 41 
ALT (U/L) 64 ± 6   92 ± 20   59 ± 8 
AST (U/L) 137 ± 18 140 ± 15 104 ± 7 
NEFA (mmol/L)    0.83 ± 0.06a    0.83 ± 0.05a      0.62 ± 0.04b 
Glucose (mg/dL) 177 ± 15 178 ± 10  195 ± 12 
Insulin (ng/mL) 0.11 ± 0.01 0.13 ± 0.01 0.10 ± 0.01 
HOMA-IR 1.31 ± 0.20 1.50 ± 0.24 1.24 ± 0.13 
Adiponectin (μg/mL) 6.18 ± 0.22 6.72 ± 0.26 6.38 ± 1.28 
Resistin (ng/mL) 45.1 ± 2.0 42.6 ± 2.2 48.4 ± 2.8 
Values are presented as mean ± SEM (n = 15), different superscripts indicate statistical significance (p = 0.05) 
 
6.4.3. Hepatic Cholesterol Accumulation and Inflammation were reduced by MPLs 
Compared to the CTL, the 2% group demonstrated reduced hepatic total cholesterol and 
cholesteryl esters by 56% and 74%, respectively. The 1% treatment reduced total cholesterol (-
50%) and free cholesterol (-23%) compared to the CTL group. Hepatic triglycerides were 
unchanged between the groups (Figure 6.1B). Histologically, the CTL H&E-stained liver sections 
appeared to have more lipid droplets compared to the 2%, although the steatosis appeared to be 
mild (Figure 6.1A). 
Notably, the observed changes in hepatic cholesterol were corroborated in the 2% group by an 
increase in Hmgcr mRNA (+46%) compared to the control (Figure 6.1C). Although the hepatic 
triglycerides were not reduced in the treatment groups, Scd1 mRNA was significantly lower in the 
2% group compared to CTL (-51%). Macrophage inflammatory protein 1β (Mip1b) was 




Figure 6.1. Dietary milk phospholipids reduced hepatic cholesterol accumulation and inflammation. Liver sections were formalin-
fixed before sectioned and H&E stained (A) (CTL, Control; 1%, 1% (wt:wt) MPL; 2%, 2% (wt:wt) MPL) for visualizing hepatic steatosis. Liver 
lipids were extracted using a modified Folch extraction and measured by enzymatic methods (B), (triglycerides, TG; total cholesterol, TC; 
cholesteryl ester, CE; free cholesterol, FC; choline-containing phospholipids, PL) (n = 15 per group, mean + SEM). Hepatic mRNA 
expression was determined using real-time qRT-PCR and standardized to the geometric mean of Gapdh and β-actin reference genes using 
the 2
(-ΔΔCt)






ligand 2 (Ccl2) mRNA data was analyzed using the Kruskal-Wallis nonparametric test because the 
data was not normally distributed. While the mean expression of Ccl2 was lower in the 2% 
treatment group by 82%, the data failed to reach significance (p = 0.1). The macrophage marker 
Adgre1 (encoding F4/80 protein) remained unchanged between the groups.  Genes related to 
lipogenesis (Cd36, Dgat2, Nr1h3, Srebf2, Srebf1, and Pparg), lipolysis (Acad1 and Acox), and 
Pepck remained unchanged by the dietary intervention.  
6.4.4. Consuming MPLs Reduces Ccl2 mRNA Expression in the Epididymal Adipose 
The epididymal adipose mRNA expression was assessed for potential changes in metabolism and 
inflammation. The expression of Ccl2 was attenuated in the 2% treatment by 56% compared to 
the CTL group (Figure 6.2B). In addition to this, Il6 mRNA expression appeared to be lower in 
both treatment groups; however, this failed to reach significance (p > 0.1). The mRNA of Slc2a4 
was non-significantly greater in the 2% (p > 0.1) compared to CTL. Target genes of PPARγ 
(aP2, AdipoQ, Lpl) were trending to be reduced in the 1% group compared to the CTL group. 
The histology between the groups revealed no major differences in H&E staining of adipose 
tissue (Figure 6.2A). 
6.5. Discussion 
High-fat, high-cholesterol diets fed to LDLr-/- will induce hypercholesterolemia and hepatic lipid 
accumulation [16, 22]. Non-alcoholic steatohepatitis (NASH) will develop if LDLr-/- mice are 
exposed to these diets for >16 weeks [16]. Dietary PLs [23] and sphingolipids have been shown 
to inhibit lipid absorption and thus may slow the progression of NASH induced by a lipid-rich diet. 
Beta serum is a dairy byproduct, rich in both PLs and sphingolipids. In this chapter, we 
demonstrated the hypolipidemic effect of dietary MPLs serum in genetically hypercholesterolemic 
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Figure 6.2. MPLs mildly reduces adipose inflammation. Epididymal adipose tissue sections were formalin-fixed, sectioned and H&E 
stained (A). Epididymal adipose tissue mRNA expression was determined using real-time qRT-PCR and standardized to the geometric 
mean of Gapdh, 36B4, and β-actin reference genes using the 2
(-ΔΔCt)
 method (B) (n = 13-14 per group, mean + SEM). Mean values with 
unlike letters indicate differences at P < 0.05 using post hoc comparisons.  
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as reduced markers of hepatic and adipose tissue inflammation compared to controls. 
Unsurprisingly, the lower dose treatment (i.e. 1% (wt:wt) MPL) was less effective, as it only 
reduced hepatic cholesterol concentration. These effects may be suggestive of inhibitory effects 
on cholesterol absorption because reducing cholesterol absorption has been shown to improve 
dyslipidemia, hepatic steatosis, and adipose inflammation in animal studies similar to a study 
examining the effects of ezetimibe on this model [17].  
In this study we used increasing doses of beta serum to supply 1% and 2% (wt:wt) MPLs. 
This is equivalent to 6 and 12 g of dietary PL/day in a 70-kg adult human. This will contribute 
0.21-0.42% milk-derived SM, or 1.2-2.4 g/day in an adult. The typical western diet consists of 6-
10 g/day of PLs and 0.3-0.4 g/day of sphingolipids [24]. The higher dose of MPLs reduced serum 
total cholesterol and non-HDL-C. Due to the fact that hepatic cholesterol was also reduced and the 
adipose phenotype was largely unchanged between the CTL and 2% group, it seems likely that 
some of this effect could be attributed to the inhibition of cholesterol absorption attributed to both 
PLs and sphingolipids [4]. It is interesting to compare these dosages of SM to the previous studies 
on dietary SM. The 1% PL diet supplied ~0.21% (wt:wt of the diet) SM to the animals, a dose 
previously shown to be effective in reducing hyperlipidemia and steatosis [25, 26]. Yet, the 1% 
PL diet did not have a strong effect on serum lipids and only reduced hepatic cholesterol levels. 
This could be due to differences in diets and/or rodent models, however it is interesting to note 
that dietary PLs have been shown to increase the appearance of SM-derived ceramide in the lymph 
[27]. Therefore, additional PLs found in the beta serum may increase the absorption of SM and 
decrease its efficacy by removing it from the lumen. High doses of dietary PLs have also been 
shown to inhibit cholesterol absorption [28-30]. The higher dose of beta serum could be providing 
enough PLs to inhibit lipid absorption. Alternatively, the additional SM (~0.42% wt:wt) could be 
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compensating for the increase in SM absorption. These results highlight the necessity to account 
for the food matrix when interpreting data concerning dietary SM. The effects of a complex PL 
mixture like this has yet to be tested directly in models of cholesterol or fatty acid absorption. 
Therefore, directly comparing the efficacy of beta serum to its individual components could be an 
effective means to understand the mechanism. 
There have been several studies reporting beneficial effects on lipid homeostasis similar to 
this study. After 5 weeks on a HFD supplemented with MPLs (2.5% wt:wt of the diet), mice in the 
treatment group had reduced serum cholesterol, hepatic total lipids, hepatic cholesterol, and 
hepatic triglycerides, while increasing fecal lipids in mice compared to HFD control [5]. KK-Ay 
mice supplemented with MPL also improved both serum and hepatic lipids [7]. Similarly, 8 weeks 
on a HFD, hepatic lipids and serum cholesterol as well as triglycerides were improved by 
supplementation of 2.5% milk polar lipids [6]. Mice supplemented with MFGM on a HFD have 
an improved lipid profile [31]. In the context of these studies, this aim further demonstrates the 
ability of dietary MPL to reduce diet-induced dyslipidemia and hepatic lipid accumulation.  
Some clinical trials have examined the effects of MPL supplements on lipid homeostasis. 
Overweight adults in a single-blind, randomized, controlled, isocaloric parallel study for 8 weeks, 
treated with 40 g of milkfat/day as whipping cream significantly reduced plasma LDL-C and 
apoB:apoA-I ratio compared to a milk fat control [32]. Whipping cream is particularly rich in PLs. 
Two clinical trials feeding buttermilk found slightly different effects. First, Ohlsson et al. observed 
that a 4-week supplementation of a buttermilk drink enriched in MFGM, in a placebo-controlled 
parallel study with healthy adults had no effect on the plasma lipids. However, a non-significant 
reduction in plasma LDL-C (p = 0.056) in women was observed [33]. This study was likely 
underpowered with a small sample size and a parallel design. However, 4-week supplementation 
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with 45 g/day of buttermilk significantly reduced both plasma cholesterol and TG in healthy adults 
[34]. This study was a double-blind, randomized, crossover study and indirectly measured 
cholesterol absorption through serum β-sitosterol concentration. The β-sitosterol concentration 
values were correlated with the reductions in plasma LDL-C. suggesting a reduction in cholesterol 
absorption may have contributed to the reduction in LDL-C [34]. This study was much more robust 
with 38 participants, and the crossover design improved statistical power. In aggregate, there is 
some clinical data that suggests the hypolipidemic effects found in animal studies described above 
is translatable to humans. 
Hepatic mRNA analysis revealed a relative increase in Hmgcr mRNA expression in the 
2% treatment group compared to the CTL. This is likely reflective of a compensatory mechanism 
in the liver. A high-cholesterol diet has been shown to decrease hepatic mRNA expression of 
Hmgcr in mice [35]. If MPLs are reducing cholesterol absorption, the dietary cholesterol is likely 
not suppressing Hmgcr mRNA to the same degree as in the control diet. Similarly, Scd1 mRNA 
expression was reduced in the 2% group compared to CTL. High-fat diets can induce hepatic Scd1 
mRNA in mice [36]. Therefore, reducing lipid absorption will cause the HFD to induce Scd1 less 
strongly. These findings are comparable to the results of Aims 1 and 2, where SM treatment 
reduced Scd1 and increased Hmgcr mRNA levels in liver. Additionally, Mip1b expression was 
significantly reduced by the 2% group compared to the CTL group, while Ccl2 was trending 
towards significance, suggesting a decrease in hepatic inflammation. However, both Mip1b and 
Ccl2 mRNA expression levels were variable in the CTL, suggesting the duration of the diet may 
have been too short to induce hepatitis, or that the diet did not have enough lipids. Most studies of 
high-fat, high-cholesterol steatohepatitis are >16 weeks and have used higher fat content diets [37-
39]. Additionally, some studies of LDLr-/- mice reveal an increase locomotor activity [40].  
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LDLr-/- mice fed a HFD had increased thermogenesis, and decreased food intake [41]. This could 
hinder their response to a HFD compared to wild-type controls [41, 42]. Therefore, although LDLr-
/- mice are a useful model of liver disease they are more resistant to early diet-induced metabolic 
dysfunction and inflammation.  
Analysis of the epididymal adipose mRNA for metabolic and inflammatory changes 
showed a reduction in Ccl2 mRNA. This suggests the adipose in this treatment group is somewhat 
less inflamed than in the CTL, which is corroborated by the significantly lower circulating NEFAs. 
Recently, it was shown that feeding increasing doses of MFGM reduces adipose weight as well as 
the expression of lipogenic genes and proteins in adipose tissue [31] returning the high fat-fed 
mice’s phenotype similar to the low-fat control. Whether inhibiting cholesterol absorption could 
be solely responsible for a decrease in adipose tissue inflammation in this model remains uncertain. 
Ezetimibe has been shown to lower both total cholesterol and hepatic cholesterol [17]. Adding 
excessive cholesterol to the diet has been shown to induce adipose tissue inflammation in LDLr-/- 
mice [17]. However, treatment of LDLr-/- mice with ezetimibe has shown only marginal effects on 
adipose tissue inflammation [43]. Therefore, an independent effect of dietary MPL may be 
responsible for the reduction in adipose inflammation. 
The potential anti-inflammatory effects of MPL cannot be ignored. Multiple recent studies 
have tested MPL fractions for anti-inflammatory effects. When examining acute inflammation in 
mice, 5 weeks of dietary MPL reduced the cytokine response within 24 hours to LPS 
intraperitoneal injection, while increasing survival rates at 48 hours [8]. Following 8 weeks of a 
HFD, mice fed MPL had decreased expression of adipose inflammatory markers (e.g., cluster of 
differentiation 68) compared to HFD control. This was in contrast to a group of mice fed soy PL, 
whom had increased responses of inflammatory markers [9]. In humans, adding MFGM to palm 
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oil-based drinks ingested by overweight and obese men reduced soluble intracellular adhesion 
molecule, while increasing IL-10 in the post-prandial state [44]. This suggests an improvement in 
post-prandial inflammation, which is usually observed in obese populations and has been 
considered a predictor of metabolic disease [45]. Ultimately, there is some evidence for the anti-
inflammatory effects of MFGM or MPL-fractions, which would be beneficial to improve 
metabolic outcomes.  
The higher dose was effective in attenuating the hypercholesterolemia and hepatic 
cholesterol accumulation associated with our model. Additionally, there were modest reductions 
in hepatic and adipose tissue inflammation, which may have been limited by the length of the 
study. Regardless, MPLs have potential to function as a preventative treatment for metabolic 
dysfunction. Therefore, more research is warranted to further understand all the potential 
mechanisms and the translatability to humans.    
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7.1. Summary and Conclusions 
The focus of this dissertation was to further define the effects of dietary SM on diet-induced 
metabolic dysfunction and inflammation. Our central hypothesis was that dietary SM would reduce 
dyslipidemia, metabolic dysfunction, and inflammation in mice fed Western-type diets. In Aim 1, 
we sought to determine the potential differences in the effects of dietary milk-derived and egg-
derived SM on serum and hepatic lipid concentrations. As expected, milk-derived SM improved 
both hepatic lipid accumulation and serum cholesterol. Surprisingly, egg-derived SM increased 
both hepatic lipid accumulation and serum lipids. These findings led to Aim 2, where we 
investigated both egg- and milk-derived SM effects on preventing metabolic dysfunction in an 
obesogenic diet. In contrast to Aim 1, egg-derived SM reduced hypercholesterolemia and 
hyperglycemia. In this aim, both SM treatments reduced hepatic steatosis and adipose 
inflammation, although egg-derived SM was more effective than milk-derived SM. While the first 
two aims highlight differences in egg-derived and milk-derived SM in the context of SM and its 
hypolipidemic effects, for Aim 3 we targeted the anti-inflammatory effects of SM. In Aim 3, we 
found that feeding milk-derived SM reduced systemic cytokines and LPS in mice fed an 
obesogenic diet. Most in vitro studies have demonstrated anti-inflammatory effects of exogenous 
sphingolipids; however, the mechanism is poorly understood. Therefore, we used LPS-stimulation 
in RAW264.7 macrophages to examine the anti-inflammatory effects of SM, ceramide, and 
sphingosine. We observed all three compounds to be effective, and that SM hydrolysis was 
required for SM effectiveness. Purified SM was used in Aims 1-3, however, consumption of 
dietary SM found in foods will be accompanied by other dietary phospholipids. Therefore, we also 
tested MPL supplied by beta-serum, a dairy byproduct that is rich in phospholipids, including SM, 
on diet-induced metabolic dysfunction and inflammation in genetically hypercholesterolemic 
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mice. We found that the highest dose of MPL (2% of diet by weight) reduced 
hypercholesterolemia, adipose tissue inflammation, hepatic cholesterol and inflammation. A 
detailed review of the findings from each of the 4 specific aims follows and is described in Figure 
7.1..  
Aim 1: To evaluate differential effects of dietary egg-derived SM and milk-derived SM on 
dyslipidemia and metabolic dysfunction in mice fed a short-term high-fat diet.  
Hypothesis 1: We hypothesized that both SM supplements would improve Western-type diet-
induced metabolic dysfunction and endotoxemia, but milk-derived SM would be more potent 
compared to egg-derived SM. This difference would be due to milk-derived SM’s more potent 
inhibitory effect on lipid absorption compared to egg-derived SM.  
Findings of Aim 1: There were clear and distinct effects of milk and egg SM. Milk-derived SM 
reduced weight gain and serum cholesterol compared to CTL. Conversely, egg-derived SM 
treatment increased serum concentrations of cholesterol, triglycerides, phospholipids, and SM 
compared to CTL. Milk-derived SM significantly decreased, while egg-derived SM increased, 
hepatic triglycerides. Milk-derived SM-fed mice displayed gene expression changes consistent 
with cholesterol depletion in the intestine and liver. In terms of inflammation, serum LPS was 
reduced in the milk-derived SM compared to CTL. Differences in serum LPS may have been 
related to changes in gut microbiota. The fecal Gram-negative bacteria were significantly lower, 
and fecal Bifidobacterium were higher, in the milk-derived SM group. There was no effect of 
dietary SM on fasting gut permeability. Thus, milk-derived SM has potential to reduce the early 
stages of diet-induced metabolic dysfunction. 
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Aim 2: To determine the effects of dietary egg-derived SM and milk-derived SM on the 
development of high-fat diet-induced NAFLD, inflammation, and metabolic dysfunction.  
Hypothesis 2: Both SM treatment groups would reduce the metabolic dysfunction phenotype due 
to SM’s effects on both lipid absorption and inflammation compared to high-fat control. However, 
milk-derived SM would be more effective than egg-derived SM because of the stronger inhibitory 
effect on lipid absorption. 
Findings of Aim 2: After 10 weeks, egg-derived SM ameliorated weight gain, 
hypercholesterolemia, and hyperglycemia induced by HFD. Both egg- and milk-derived SM 
attenuated hepatic steatosis development, with significantly lower hepatic TG and cholesterol 
relative to the HFD control. This reduction in hepatic steatosis was stronger with egg-derived SM 
supplementation relative to milk-derived SM. Reductions in hepatic TG observed with dietary SM 
were corroborated by lower hepatic mRNA expression of PPARγ-related genes; Scd1 and Pparg2 
in both SM groups, and Cd36 and Fabp4 with egg SM. Egg-derived SM, and to a lesser extent 
milk-derived SM, reduced inflammation and markers of macrophage infiltration in adipose tissue. 
Egg-derived SM also reduced skeletal muscle TG content compared to HFD control. Aim 2 
highlights dietary SM’s ability to inhibit diet-induced metabolic dysfunction associated with 
obesity.  
Aim 3: To evaluate the effects of dietary SM on HFD-induced inflammation and determine if SM 
and its metabolites directly affect macrophage inflammation.  
Hypothesis 3: We hypothesized that dietary SM would inhibit diet-induced inflammation and 
exogenous SM treatment would inhibit LPS-stimulation of RAW264.7 macrophages. Due to the 
fact that SM metabolites inhibitory properties, we anticipated that blocking hydrolysis of SM 
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would reduce SM’s effectiveness for inhibiting LPS-stimulation. Consequently, the addition of the 
hydrolytic products of SM would also inhibit LPS-stimulation. Furthermore, dihydroceramide and 
ceramide would have differential effects on macrophage inflammatory response, as they have 
previously shown different bioactivities in other contexts.  
Findings of Aim 3: Dietary milk-derived SM significantly reduced inflammatory serum cytokines 
and tended to lower serum LPS (p = 0.08) compared to HFD. Cecal gut microbiota analysis 
revealed that milk-derived SM increased the abundance of Acetatifactor genus, with minimal 
changes in other taxa. Milk SM significantly attenuated the in vitro effect of LPS on pro-
inflammatory gene expression in RAW264.7 macrophages. This effect was dependent on SM 
hydrolysis, as blocking sphingomyelinase activity caused SM to be ineffective. Additionally, the 
metabolites ceramide and sphingosine inhibited the pro-inflammatory changes. Overall, this aim 
revealed there are possibly direct anti-inflammatory effects of dietary SM. Additionally, these anti-
inflammatory effects may be independent of the effects of lipid absorption and are likely dependent 
on SM hydrolysis. 
Aim 4: To evaluate the effects of dietary milk phospholipids, rich in SM, on the development of 
metabolic dysfunction in LDLr-/- mice fed a high-fat, high-cholesterol diet. 
Hypothesis 4: Phospholipid supplementation would reduce dyslipidemia and insulin resistance in 
Western-type diet-fed LDLr-/- mice. This would result in an improved hepatic phenotype and 
decreased adipose inflammation.  
Findings of Aim 4: Supplementation of milk phospholipids (2% PL) reduced total serum 
cholesterol, non-HDL cholesterol, and NEFAs compared to CTL (-51%, -56%, and -26% 
respectively). Hepatic total cholesterol concentrations were reduced compared to CTL by 53% and 
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55% in the 1% and 2% groups, respectively. These changes came with an increased hepatic Hmgcr 
mRNA, decreased Scd1 and Mip1b in the 2% group. Histology analysis corroborated these 
findings although the steatosis was mild. Ccl2 mRNA in the epididymal adipose tissue was reduced 
in the 2% group. This aim provides further evidence for MPL to prevent diet-induced dyslipidemia 
and hepatic steatosis. Therefore, MPL extracts could be a useful source of dietary bioactives to 
potentially combat metabolic complications of obesity.   
Figure 7.1. Schematic of dietary sphingomyelin’s effects on metabolic dysfunction. Bolded effects represent 
findings from this work. Lined effects are well-established within the literature. Italicized effects are future directions 
based off of findings in this work. Solid lines represent known connections between effects, while dashed lined are 
potential connections.   
7.2. Future Directions 
7.2.1. Understanding the Impact of Food Matrix on Dietary SM 
Although this dissertation has contributed to the literature that supports a role for dietary SM to 
limit lipid absorption and influence lipid metabolism, we still do not completely understand the 
mechanism. Sphingomyelin’s effect on inhibiting lipid absorption has been attributed partly to an 
inhibition of pancreatic lipase activity [1, 2]. Despite pancreatic lipase having a sphingolipid-
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sensing domain, SM seemingly does not bind to a synthetic mimic of pancreatic lipase [3], and 
therefore, it is not likely to be a direct inhibition. Alternatively, SM inhibition of pancreatic lipase 
may be due in part to the displacement of colipase from pancreatic lipase [2]. The mechanism of 
this is not completely clear, but it could be a result from increased lipid ordering caused by 
SM:cholesterol interactions [4]. Order can be tested using a laurdan probe [5]. This could be tested 
by making micelles with varying concentrations of SM, cholesterol as well as saturated and 
unsaturated phosphatidylcholine to generate micelles of different rigidities measured by the 
laurdan probe. These micelles could be incubated with lipase and colipase and the association 
between them can be measured as a ratio, as previously reported [2]. Comparing degrees of 
ordering and colipase:lipase interactions would allow us to see if there is an effect of lipid ordering 
on lipase activity. Additionally, comparing micelles of similar rigidities containing different 
amounts of SM would elucidate if it is a specific interaction of SM or the consequence of lipid 
ordering. Another potential explanation of SM effects on lipid absorption is its potential for 
affecting proteins involved in cholesterol uptake by intestinal cells. Recently, exogenous SM was 
shown to reduce NPC1L1 protein expression in Caco-2 cells [6]. Although this runs counter to our 
in vivo mRNA findings of Aim 1 thought to be a consequence of cellular cholesterol reduction by 
dietary SM, it has been shown that increasing membrane rigidity through lysophosphatidylcholine 
acyltransferase 3 knockout, disrupts NPC1L1 protein expression in the intestine [7]. If the 
membrane is more rigid and prevents NPC1L1 to incorporation, it may be dislocated and degraded, 
a change that may not be captured by mRNA analysis. Therefore, quantifying \ the protein 
expression of NPC1L1 and other membrane proteins in the intestines of mice fed a long-term SM-
rich diet may be of interest to confirm these recent findings [6].   
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Overall, our understanding of the interactions of the food matrix and SM’s efficacy is 
sparse. This is highlighted by the discrepancy in the findings between Aim 1, where milk-derived 
SM was more hypolipidemic, and Aim 2, where egg-derived SM was more effective. There are 
several differences in these studies, including diet composition, SM dosage, and diet duration. 
Since the hypolipidemic effects are thought to be due to the inhibition of lipid absorption, these 
discrepancies are likely due to differences among dietary-derived SM structures. Therefore, the 
likely important variables are the dosage or diet composition. This work started under the 
assumption that milk-derived SM more strongly inhibits lipid absorption than egg-derived SM [8]. 
However, this direct comparison may not have been fully explored. A major difference between 
the diet that can be explored is the compositions in Aims 1 and 2. Aim 2 added a substantial amount 
of cholesterol. First, the ratio of SM to cholesterol can alter cholesterol absorption [9, 10], however, 
this is not necessarily in a linear fashion. Therefore, the relationship may be more complex than 
more SM leads to a greater inhibition of lipid absorption. If this is true, there may be different 
optimal ratios of cholesterol:SM for different structurally-distinct sources of SM. Current 
absorption studies, with the exception of one [8], have only used a single source of SM. Therefore, 
testing the effects of several ratios of egg- and milk-derived SM to cholesterol on lipid absorption 
using both cell culture and rodent models could help explain differential effects in Aim 1 and 2.  
Lastly, dietary phospholipids have been shown to increase the appearance of milk SM-
derived ceramide species [11]. This is possibly due to increased SM hydrolysis because there is 
little evidence of SM being absorbed whole. However, this would run counter to previous in vitro 
studies where phospholipids inhibited alkaline sphingomyelinase [12]. Therefore, this study could 
be repeated with intestine-specific alkaline sphingomyelinase knockout mice [13]. If milk 
184 
 
phospholipids are unable to increase lymphatic milk SM-derived ceramides in this model, the milk 
phospholipids are likely enhancing SM digestion.  
Using the dual-isotope method [9], it would be important to understand if administration 
of SM as a pure compound or as part of a mixture, such as in beta-serum, has differential effects 
on cholesterol and lipid absorption. This was suggested by the finding that 1% MPLs (wt:wt) had 
little effect on serum cholesterol in Aim 4, while purified SM at similar concentrations to lowered 
serum cholesterol in Aims 1 and 2, as well as in other studies [14]. However, direct comparison of 
these studies is insufficient to conclude that dietary phospholipids can alter SM’s effects on 
cholesterol absorption, because these studies use significantly different animal models and 
intestinal cholesterol absorption is not the only factor contributing to hypercholesterolemia. 
Therefore, directly comparing purified milk-derived SM and beta-serum would provide evidence 
of how the phospholipids alter SM’s efficacy.  
7.2.2 Further Elucidating the Molecular Mechanism of SM’s Anti-inflammatory Effects 
The effects of exogenous and endogenous sphingolipids on inflammation are contradictory. In 
general, research has found most exogenous sphingolipids to be anti-inflammatory [15-17], but 
the mechanism is poorly understood. In Aim 3, we managed to determine that the hydrolysis of 
SM is necessary for the anti-inflammatory effects. Replicating this finding in bone marrow-derived 
macrophages would further strengthen these findings. 
One aspect that remains unclear is if ceramide digestion is required for the anti-
inflammatory effects observed. Sphingosine’s capacity to inhibit inflammation certainly suggests 
ceramide digestion is necessary. To test this, we will need to repeat the SM experiments while 
inhibiting acid ceramidase, which is also secreted from RAW 264.7 macrophages [18]. We could 
make use of the newly synthesized ceramidase inhibitor, LCL521, which targets the lysosome, to 
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hopefully avoid off target effects [19]. This would inform us if ceramide hydrolysis is required for 
the anti-inflammatory effects of SM and further resolve which metabolite are responsible for the 
effects found in Aim 3.  
 Assuming sphingosine is the causal agent, it would be important to use radiolabeled 
sphingosine to examine the fate of sphingosine within the cell in both inflammatory and non-
inflammatory conditions. To do this, we could simply repeat the experiment from Aim 3 with 
radiolabeled sphingosine and separate the lipids of cell lysates using thin layer chromatography. 
This would provide insight to whether it is sphingosine or a metabolite of exogenous sphingosine 
that is formed and provide a target for further research. Finally, to address the dynamic nature of 
sphingolipid metabolism within a cell, these lysates should be analyzed for total sphingolipids and 
each sphingolipid class using lipidomics [20]. This would help to determine if there are any 
increases in more complex sphingolipid species that could be missed with the radiolabeled tracer 
method mentioned above. 
 Additionally, some in vivo experiments demonstrate anti-colitic effects of dietary SM [21, 
22]. Due to dietary SM’s incomplete digestion, it is possible some of the anti-inflammatory effects 
are at the level of the intestine. One putative mechanism is inhibiting LPS translocation. Aim 1 
and 3 demonstrate reductions in serum LPS activity by dietary milk-derived SM. Ghoshal et al. 
has reported that formation of chylomicrons is required for LPS translocation into the lymph [23]. 
Thus, SM inhibition of lipid absorption could potentially lower LPS translocation. In support of 
this, dietary gangliosides have been shown to improve gut barrier function in response to LPS 
challenge [24]. Dietary SM helps promote the maturation of the gut in infant rats [25]. Bovine milk 
phospholipids have been shown to improved Caco-2 cell barrier function in response to LPS [26]. 
Therefore, our lab is currently aiming to explore SM’s potential to reduce LPS translocation using 
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a Caco-2 cell transwell model. In this model, we will measure transepithelial electrical resistance, 
LPS activity of the basal lateral compartment, and triglyceride accumulation. These experiments 
will allow us to determine if emulsions containing milk-derived SM can improve barrier function 
and/or reduce LPS translocation, and if they are associated with inhibition of lipid absorption.   
7.2.3. Interactions between Dietary SM and Gut Microbiota 
Sphingosine has been shown to be bactericidal against a variety of enteropathogens [27]. 
Conversely, some microbes have been identified to possess sphingolipid metabolic capacity [28]. 
Our results show an increase in Firmicutes, Actinobacterium, and Bifidobacterium with higher 
dosages of dietary milk SM (0.25% w/w of diet) in mice. In addition to our results, there are only 
a few studies that examine dietary SM and gut microbiota [29, 30]. However, at this point these 
studies are difficult to compare, as wild-type mice can have vastly different gut microbiotas 
between litters [31]. Additionally, contamination from non-sterile bedding or supplies can be a 
factor [31]. Therefore, using gnotobiotics [32], conditions of well-controlled sterility, or mice 
inoculated with a known culture [33] could help control for these factors. These types of studies 
would offer more clarity in the effects of both background diet and dietary SM on the gut 
microbiota.  
Another aspect of sphingolipids that has gone unexplored is their impact on the gut 
microbiome, or the collective genome of gut microbiota. As mentioned above, there are species of 
bacteria that can metabolize sphingolipids. Combined with the broad-spectrum bactericidal effects 
of sphingosine, it is fair to hypothesize these bacteria may have a survival advantage in the context 
of a sphingolipid-enriched diet. Therefore, bulk genomic sequencing of the microbiome in addition 
to 16S ribosomal RNA sequencing of gut microbiota may help further elucidate the effects of 
dietary sphingolipids on gut bacteria. I would expect the genes associated with sphingolipid 
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metabolism to be increased in the mice fed sphingolipids. This idea has been illustrated by 
measuring the gut bacteria-dependent trimethylamine production from choline and carnitine. 
Particularly, in response to carnitine challenge, omnivorous humans produced more 
trimethylamine N-oxide compared to strict vegans [34]. This suggests that the chronic 
consumption of meat increased the host gut microbiota capacity to produce trimethylamine N-
oxide’s precursor.   
Lastly, while Sprong et al. [27] provided proof-of-concept for the bactericidal effects of 
sphingosine, much more work could be done with this concept. Dietary SM and ceramide reach 
the distal intestines [35]. Therefore, studying their interactions with common gut bacteria in simple 
in vitro models, similar to the Sprong et al. publication, could provide useful information. 
Additionally, more species of bacteria should be tested for sphingolipid toxicity. Some members 
of the phyla Bacteroidetes can synthesize sphingolipids [36, 37], which are essential for their 
survival in the intestines. Additionally, Bifidobacterium, part of the Actinobacteria phyla, can 
metabolize sphingolipids [28]. Therefore, it would be interesting to see if exogenous sphingolipids 
are less toxic to Bacteroidetes or Bifidobacterium. The results of Aim 1 would suggest 
Bifidobacterium are less affected by dietary sphingolipids. Aim 1 revealed a decrease in 
Bacteroidetes with milk-derived SM treatment. This may be a result of increased dietary fat 
reaching the colon because chronic HFD decreases Bacteroidetes in mice [38].  
7.2.4. Dietary SM and Prevention of Chronic Disease 
Currently, there is little work on dietary SM and the development of late-stage chronic metabolic 
diseases. The work in this dissertation lays the foundation for the investigation into the progression 
of non-alcoholic steatohepatitis, cardiovascular disease, and type 2 diabetes mellitus. Currently, 
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our laboratory has two studies investigating the impact of dietary SM on atherosclerosis 
development in hyperlipidemic mouse models.  
 A natural progression of Aim 4 would be to induce non-alcoholic steatohepatitis (NASH) 
in LDLr-/- mice while feeding beta serum. It is likely the signs of improvement with the higher 
dose observed in Aim 4 would result in reductions in disease severity. In this study, comparing the 
efficacy of an equal dose of milk-derived SM would help understand if the excess phospholipids 
are improving or reducing the beneficial effects of SM.  
 Another important distinction that needs to be made is if the effects of dietary SM are 
exclusively due to effects on lipid absorption. The anti-inflammatory data, effects on gut 
microbiota, and the fact that some milk-derived ceramides appear in the lymph suggest otherwise. 
Inhibiting diet-induced inflammation may be a secondary effect of SM. A simple comparison study 
with ezetimibe could help deduce if there are additional anti-inflammatory effects. First, a dual-
isotope study could be conducted in mice to determine equivalent hypolipidemic dosages for milk-
derived SM and ezetimibe on a Western-type diet. These doses could then be used in a diet-induced 
obesity mouse model to see if there are significant differences on inflammation outcomes.  
 The gut microbiota is another important factor in metabolic dysfunction. As demonstrated 
in Aims 1 and 3, SM can significantly alter the gut microbiota. Whether this impacts SM’s effects 
on metabolic dysfunction remains to be seen. It has been recently shown that egg-derived SM had 
anti-atherosclerotic effects in apoE-/- mice, and these effects were attenuated when co-administered 
with broad-spectrum antibiotics to deplete gut microbiota [29]. The gut microbiota has 
implications in metabolic dysfunction as reviewed in Chapter 2. Therefore, testing the effects of 
dietary SM on an obesogenic diet with and without broad spectrum antibiotics would demonstrate 
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if there are implications of the SM and gut microbiota interactions on metabolic dysfunction. 
Another interesting discovery made recently is the deposition of serine dipeptide lipids in human 
atherosclerotic plaques derived from bacteria of the Bacteroidetes phylum, namely lipid 654 and 
lipid 430 (L654 and L430) [39]. This association has highlighted another potential bacterial 
byproduct that may accumulate in tissue. Due to the hydrophobic nature and sphingolipids’ effects 
on microbiota it would be interesting to see if L654 and L430 levels in the liver are modulated by 
dietary sphingolipids. More research is needed into the characteristics of these bacterial lipids, as 
their transport and metabolism in tissues is not well understood.    
7.2.5. Clinical Trials to Measure the Efficacy of SM to Inhibit Cholesterol Absorption in Humans 
Although one study did measure phytosterols as a measure of sterol absorption when feeding a 
phospholipid mixture, it would be advantageous to directly measure cholesterol absorption in 
humans, using stable isotope tracers [40]. The additional alkaline sphingomyelinase in human bile 
[41] and the minute gastric lipase activity in rodents [42] could result in differences in dietary SM 
effects between rodents and humans.  Gastric lipase reduces SM’s inhibitory effect on pancreatic 
lipase activity [43]. These tracer studies need to be done with both purified SM and a phospholipid 
fraction, such as beta-serum. This type of work should precede any further dietary interventions to 
ensure efficacy in humans.  
7.2.6. Does Dietary SM Correlate with Disease Outcomes?    
An epidemiological study could be conducted to determine if there is an association between 
dietary SM intake and serum cholesterol, metabolic syndrome, cardiovascular events, or liver 
disease. The intakes could be estimated using the National Health and Nutrition Examination 
Survey (NHANES) data in combination with multiple sources citing the abundance of SM in 
foods. This study would need to control for the intake of plant-based foods, fats, sugars, and 
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cholesterol, as these are some of the possible confounders that could influence the findings. 
Hypothetically, if there was an association it would strengthen the hypolipidemic effects observed 
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Appendix A. Primer List
195 
 
Gene Protein* 5'-Forward Primer-3' 5'-Reverse Primer-3' 
Acaca ACC GTCCCGGCCACATAACTGAT CGCTCAGGTCACCAAAAAGAAT 
Abcg5 ABCG5 GCGTAGGTCTCCTTTACCAGTTTG GGAAACAGATTCACAGCGTTCA 
Acad ACAD1 AGAGCAAGTCCCCACCAATG GGCTTGCTTGGCATCAACA 
Acox1 ACOX1 CCCAAGACCCAAGAGTTCATTC CAGGCCACCACTTGATGGA 
Actb β-actin TCCTTCTTGGGTATGGAATCCT CAGCACTGTGTTGGCATAGA 
Adgre1 F4/80 GAGTGGAATGTCAAGATGTTA CAGTGGAAGAAGAGAAGC 
Adipoq Adiponectin CAACCAACAGAATCATTATG GGTAAGAGAAGTAGTAGAGT 
Apoa4 ApoA-IV TTCCTGAAGGCTGCGGTGCTG CTGCTGAGTGACATCCGTCTTCTG 
Ccl2 MCP-1 TTCCTCCACCACCATGCAG CCAGCCGGCAACTGTGA 
Cd36 CD36 CTTACACATACAGAGTTCGTTATC TCCAACAGACAGTGAAGG 
Cd68 CD68 TGTCTGATCTTGCTAGGACCG GAGAGTAACGGCCTTTTTGTGA 
Cebpa C/EBPα CAAGAGCCGAGATAAAGC TCATTGTCACTGGTCAAC 
Cpt1a CPT1α GAACCCCAACATCCCCAAAC TCCTGGCATTCTCCTGGAAT 
Cpt1b CPT1β GCTCTGAGACACATCTACC CTAAGGATGCCATTCTTGATTC 
Dgat2 DGAT2 GGAATAAGTGGGAACCAGATCA CCGCAAAGGCTTTGTGAAG 
Fabp2 FABP2 GTCTAGCAGACGACGGAACGGA AGAAACCTCTCGGACAGCAA 
Fabp4 FABP4 CACCATCCGGTCAGAGAGTACTT CGGTGATTTCATCGAATTCCA 
Gapdh GAPDH TGTGTCCGTCGTGGATCTGA CCTGCTTCACCACCTTCTTGAT 
Hmgcr HMGCR GATGATTATGTCTTTAGGCTTG CAGAGAGAAACACTTGGT 
 Il1b IL-1β  GTCACAAGAAACCATGGCACAT GCCCATCAGAGGCAAGGA  
Il6 IL-6 GACTGATGCTGGTGACAA GCCATTGCACAACTCTTT 
Itgax Cd11c CTGGATAGCCTTTCTTCTGCTG GCACACTGTGTCCGAACTC 
Ldlr LDLr TTCCTGTCCATCTTCTTCC GACCATCTGTCTTGAGGG 
Lpl LPL AAGGTCATCTTCTGTGCTAGG CCAGTGTCAGCCAGACTT 
Mip1b  MIP-1β TCTGTGCAAACCTAACCCCG  GAGGGTCAGAGCCCATTGGT  
Mttp MTTP CTACCAGGCCCAACAAGAC CGCTCAATTTTGCATGTATCC 
Mylip IDOL AGGAGATCAACTCCACCTTCTG ATCTGCAGACCGGACAGG 
Npc1l1 NPC1L1 CGTCTGTCCCCGCCTATACA CTAATGACACCAGCTGCTTGGT 
Nr1h3 LXRα TTTAGGGATAGGGTTGGAGTCA GTGGACGAAGCTCTGTCG 
196 
 
Ocln OCLN CACCTATCACTTCAGATCAACAA CAGCAGCCATGTACTCTTC 
Pck1 PEPCK AACTGACAGACTCGCCCTATGTG TGCCCATCCGAGTCATGAT 
Pcsk9 PCSK9 AGGTGGAGGTGTATCTCTTAGA CACTTGCTCGCCTGTCTG 
Ppara PPARα CGGCAGTGCCCTGAACA TGGTACCCTGAGGCCTTGTC 
Pparg PPARγ CACAATGCCATCAGGTTTGG GCTGGTCGATATCACTGGAGATC 
Pparg2 PPARγ2 TTCGCTGATGCACTGCCTAT GCATCTCTGTGTCAACCATGGT 
Ppargc1a PGC-1α AAGCTGAAGCCCTCTTGCAA ACTGTACCGGGCCCTCTTG 
Rplp0 RPLP0 (36B4) CCTGAAGTGCTCGACATCAC CCACAGACAATGCCAGGAC 
Scd1 SCD1 CAGTGCCGCGCATCTCT CCCGGGATTGAATCTTCTTG 
Slc2a4 GLUT4 CATGGCTGTCGCTGGTTTC AAACCCATGCCGACAATGA 
Srebf1 SREBP-1c GGAGCCATGGATTGCACATT GGCCCGGGAAGTCACTGT 
Srebf2 SREBP-2 GTGTGCGGAGGAGAAAATCC CCCATGGCCGCTGTCA 
Tgfb1 TGFβ CGCAACAACGCCATCTAT TGCTTCCCGAATGTCTGA 
Tjp1 TJP1 AGAGGAAGAGCGAATGTC TTCGGTTCTGGAAGAGTG 
Tnfa TNFα GGCTGCCCCGACTACGT ACTTTCTCCTGGTATGAGATAGCAAAT 
 
